Notice of Meeting

UNIVERSITY OF HAWAI‘I
BOARD OF REGENTS

Board business not completed on this day will be taken up on another day and time announced at the conclusion of the meeting.

Date: Thursday, October 20, 2022
Time: 9:30 a.m.
Place: Leeward Community College
        Education Building
        ED-201
        96-045 Ala ‘Ike
        Pearl City, HI 96782

See the Board of Regents website to access the live broadcast of the meeting and related updates:  www.hawaii.edu/bor

AGENDA

I. Call Meeting to Order
II. Approval of the Minutes of the September 15, 2022 Meeting
III. Public Comment Period for Agenda Items:

Individuals who are unable to provide testimony at this time will be allowed an opportunity to provide testimony before each agenda item.

All written testimony on agenda items received after posting of this agenda and up to 24 hours in advance of the meeting will be distributed to the board. Late testimony on agenda items will be distributed to the board within 24 hours of receipt. Written testimony may be submitted via the board’s website through the testimony link provided on the Meeting Agendas, Minutes and Materials page. Testimony may also be submitted via email at bor.testimony@hawaii.edu, U.S. mail at 2444 Dole Street, Bachman 209, Honolulu, HI 96822, or facsimile at (808) 956-5156.

Those wishing to provide oral testimony virtually may register here. Given the constraints with the format of hybrid meetings, individuals wishing to orally testify virtually must register no later than 8:00 a.m. on the day of the meeting in order to be accommodated. Registration for in-person oral testimony on agenda items will also be provided at the meeting location 15 minutes prior to the meeting. It is highly recommended that written testimony be submitted in addition to registering to provide oral testimony. Oral testimony will be limited to three (3) minutes per testifier.

If you need an auxiliary aid/service or other accommodation due to a disability, contact the Board Office at (808) 956-8213 or bor@hawaii.edu as soon as possible. If a response is received less than five (5) days in advance of the meeting, we will try to obtain the auxiliary aid/service or accommodation, but we will not guarantee that the request will be fulfilled. Upon request, this notice is available in alternate formats such as large print, Braille, or electronic copy.
All written testimony submitted are public documents. Therefore, any testimony that is submitted orally or in writing, electronically or in person, for use in the public meeting process is public information and will be posted on the board’s website.

IV. Report of the President
A. SCR201 Task Force Next Steps Progress Report
B. Strategic Plan Progress
C. Enrollment Update
D. Extramural Funding Update
E. Stadium Update
F. Other
G. Leeward Community College Campus Presentation

V. Committee and Affiliate Reports
A. Report from the Committee on Academic and Student Affairs
B. Report from the Committee on Intercollegiate Athletics
C. Report from the Committee on Research and Innovation
D. Affiliate Reports
   1. University of Hawai‘i Student Caucus

VI. Agenda Items
A. Consent Agenda
   1. Approval of Provisional Status for the Master of Education in School Counseling at the University of Hawai‘i at Mānoa
B. Information and Discussion: Honolulu Authority for Rapid Transportation (HART) Presentation
C. Approval of the Establishment of the Indigenous Innovation and Health Equity Endowed Chair at the University of Hawai‘i Center for Indigenous Innovation and Health Equity
D. Approval of the Establishment and Naming of the Tang Wee Loke Distinguished Professorship at the School of Travel Industry Management at the University of Hawai‘i at Mānoa Shidler College of Business
E. Approval of Emerita Title for Gail Makuakāne-Lundin
F. Review of Proposed Tuition Schedule

VII. Executive Session (closed to the public):

If you need an auxiliary aid/service or other accommodation due to a disability, contact the Board Office at (808) 956-8213 or bor@hawaii.edu as soon as possible. If a response is received less than five (5) days in advance of the meeting, we will try to obtain the auxiliary aid/service or accommodation, but we will not guarantee that the request will be fulfilled. Upon request, this notice is available in alternate formats such as large print, Braille, or electronic copy.
A. Personnel: (To consider the hire, evaluation, dismissal, or discipline of an officer or employee, where consideration of matters affecting privacy will be involved, pursuant to Section 92-5(a)(2), Hawai‘i Revised Statutes (HRS))
   1. Discussion of Personnel Actions (A-1 for approval)

B. Legal Matters: (To consult with the board’s attorneys on questions and issues pertaining to the board’s powers, duties, privileges, immunities, and liabilities, pursuant to Section 92-5(a)(4), HRS)
   1. Quarterly Status Report on Legal Matters

VIII. Agenda Items (continued)
   A. Personnel Actions (A-1 for approval)

IX. Announcements
   A. Next Meeting: November 17, 2022, at University of Hawai‘i Hilo

X. Adjournment

ATTACHMENTS

Attachment A1 – Personnel actions posted for approval
Attachment A2 – Personnel actions posted for information only, pursuant to Section 89C-4, HRS. These actions are not subject to approval by the Board of Regents.
Attachment A-i: Personnel Action for BOR approval. Pursuant to §89C-4, HRS, the following proposed compensation actions for excluded Executive/Managerial are disclosed for purposes of public comment.

<table>
<thead>
<tr>
<th>Campus</th>
<th>First Name &amp; Middle Initial</th>
<th>Proposed Title</th>
<th>Unit</th>
<th>Nature of Action</th>
<th>Monthly Salary</th>
<th>Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>UH System</td>
<td>Rose Jennifer</td>
<td>Executive Director</td>
<td>Office of Equity Assurance</td>
<td>Appointment</td>
<td>$15,834</td>
<td>October 21, 2022</td>
</tr>
<tr>
<td>UH Mānoa</td>
<td>Ueno Naoto</td>
<td>Director of Research Institute</td>
<td>University of Hawai‘i Cancer Center</td>
<td>Appointment</td>
<td>$35,417</td>
<td>December 12, 2022</td>
</tr>
</tbody>
</table>

Recommendation: That the Board approve the personnel action as recommended.

David Lassner
President
Pursuant to §89C-4, Hawai'i Revised Statutes, the following proposed compensation actions for excluded Executive/Managerial are disclosed for purposes of public comment.

<table>
<thead>
<tr>
<th>Campus</th>
<th>Last Name</th>
<th>First Name &amp; Middle Initial</th>
<th>Proposed Title</th>
<th>Unit</th>
<th>Nature of Action</th>
<th>Monthly Salary</th>
<th>Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>UH System</td>
<td>Schatz</td>
<td>Stephen</td>
<td>Director of Hawaii P-20 Partnerships</td>
<td>Hawaii P-20</td>
<td>Special Salary Adjustment</td>
<td>$1,508 Additional Salary for a total of $16,584/month</td>
<td>October 21, 2022</td>
</tr>
<tr>
<td>UH System</td>
<td>Suzuki</td>
<td>Darren</td>
<td>Director of Risk Management</td>
<td>Office of Risk Management</td>
<td>Appointment</td>
<td>$11,418</td>
<td>October 21, 2022</td>
</tr>
<tr>
<td>UH Mānoa</td>
<td>Quinn</td>
<td>April</td>
<td>University Academic Affairs Program Officer</td>
<td>Office of the Vice Provost for Academic Excellence</td>
<td>Special Salary Adjustment</td>
<td>$963 Additional Salary for a total of $10,598/month</td>
<td>October 21, 2022</td>
</tr>
<tr>
<td>UH Hilo</td>
<td>Holland</td>
<td>Christopher</td>
<td>Interim Vice Chancellor</td>
<td>Student Affairs</td>
<td>Appointment</td>
<td>$13,167</td>
<td>October 21, 2022 - October 20, 2023</td>
</tr>
<tr>
<td>CC System</td>
<td>Loo</td>
<td>Tiana</td>
<td>Interim Academic &amp; Student Affairs Program Officer</td>
<td>Office of the Vice President for Community Colleges</td>
<td>Appointment</td>
<td>$10,000</td>
<td>October 21, 2022 - October 20, 2023</td>
</tr>
<tr>
<td>Hawai'i CC</td>
<td>Quintana</td>
<td>Christine</td>
<td>Vice Chancellor</td>
<td>Student Affairs</td>
<td>Appointment</td>
<td>$10,556</td>
<td>October 21, 2022</td>
</tr>
<tr>
<td>Maui College</td>
<td>Dukelow</td>
<td>Kaheleolani</td>
<td>Vice Chancellor</td>
<td>Academic Affairs</td>
<td>Reassignment</td>
<td>$10,520</td>
<td>October 21, 2022</td>
</tr>
</tbody>
</table>
Chair Moore called the meeting to order at 10:03 a.m. on Thursday, September 15, 2022, at Windward Community College, Hale Akoakoa 101-103, 45-720 Kea'ahala Road, Kāne‘ohe, HI 96744, with regents participating from various locations.

Quorum (10): Chair Randy Moore; Vice-Chair Alapaki Nahale-a; Vice-Chair Ernest Wilson; Regent Kelli Acopan; Regent Eugene Bal; Regent Wayne Higaki; Regent Gabriel Lee; Regent Diane Paloma; Regent Laurie Tochiki; and Regent Robert Westerman.

Excused (1): Regent William Haning.

Others in attendance: President David Lassner; Vice President (VP) for Administration Jan Gouveia; VP for University of Hawai‘i (UH) Community Colleges (UHCC) Erika Lacro; VP for Legal Affairs/University General Counsel Carrie Okinaga; VP for Budget and Finance/Chief Financial Officer Kalbert Young; VP for Advancement/UH Foundation (UHF) Chief Executive Officer (CEO) Tim Dolan; UH Mānoa (UHM) Provost Michael Bruno; UH Hilo Chancellor Bonnie Irwin; UH West O‘ahu (UHWO) Chancellor Maenette Benham; Windward Community College (WinCC) Chancellor Ardis Eschenberg; Executive Administrator and Secretary of the Board of Regents (Board Secretary) Kendra Oishi; and others as noted.

II. APPROVAL OF THE MINUTES

Chair Moore inquired if there were any corrections to the minutes of the August 18, 2022, meeting which had been distributed. Hearing none, the minutes were approved.

III. PUBLIC COMMENT PERIOD

Board Secretary Oishi announced that the Board Office received written comments from Amanda Patrick regarding the availability of in-person or face-to-face course options at UHWO for persons with learning disabilities, and that no individuals signed up to provide oral testimony.

Written testimony may be viewed at the of the Board of Regents website as follows:

Written Testimony Comment Received

IV. REPORT OF THE PRESIDENT

A. COVID-19 Update
President Lassner provided the rationale for the lifting of the remaining face mask requirements on all university campuses as of September 16, 2022, stating that this decision was based upon recommendations from the university’s health and wellness experts and is in accord with State Department of Health and Centers for Disease Control and Prevention guidelines. However, as a matter of public health policy, he stated that the wearing of masks is still required for individuals who have been exposed to someone with COVID-19 or who are recovering after having contracted the virus. Additionally, individual campuses will retain the ability to require mask-wearing for certain events and within specific venues. The administration continues to encourage the wearing of masks indoors and at crowded events, requests that individuals be respectful of the mask wearing choices of others, and urges everyone to obtain applicable vaccinations.

Given that the pervasiveness of the COVID-19 pandemic is lessening, President Lassner stated that, going forward, he would only provide reports on this issue if the situation changes.

B. SCR 201 Task Force (Task Force) Next Steps Progress Report

While policies addressing most of the recommendations contained within the Task Force’s report have been drafted and are currently being prepared for appropriate consultation in the fall, discussions are still ongoing with respect to determining criteria for a new class corresponding to specialist and non-instructional faculty at the community colleges. Although it is a daunting task, the working group formed to provide input on this matter continues to deliberate. President Lassner stated that recommendations for changes in response to the charge are expected to be prepared for presentation to the board by the end of the calendar year.

C. Strategic Plan Progress Report

The initial draft framework for the university’s six-year strategic plan has been published and made available for public review and comment. President Lassner stated that internal and external feedback on the four imperatives identified within the draft strategic plan is currently being solicited and encouraged all stakeholders to recommend specific actions that can be taken to achieve the strategic plan’s objectives. He also noted that several town halls will be conducted to give the community opportunities to learn more about the strategic plan and share their ideas, insights, and concerns, and that meetings regarding the strategic plan will be held with systemwide campus governance groups. Additionally, the administration is concomitantly refining proposed metrics to monitor the success of the imperatives. The team is also formulating action plans to achieve the goals and objectives of the strategic plan, taking the approach that specific action plans should be more agile and better suited to adapt to changing situations over time as opposed to the longer-term vision and imperatives of the strategic plan.

D. Other
Eleven days prior to the official census date when enrollment numbers are frozen, systemwide registered credit headcount enrollment for the fall semester is down approximately 2.8 percent, although UHM is expecting to welcome its largest-ever entering freshman class exceeding 3,000 students for the first time in the history of the campus. Early college programs experienced their highest enrollments recorded to date with over 3,300 enrollees this fall, a nearly 20 percent increase over last year. The downward trend in the number of transfer students registering at the university continues, although it was underscored that institutions of higher education across the country are encountering similar declines. President Lassner noted that interest in online course instruction continues to grow with larger numbers of enrolled students at many of the university’s campuses choosing online course sections over in-person course sections, particularly at Leeward Community College and UHWO. He also stressed that enrollment figures do not factor in the large number of individuals taking non-credit workforce training courses at the community colleges. The administration is presently assessing the entirety of available enrollment information on a more granular level and will provide a detailed report on fall enrollment to the board in November.

The university has received $132 million in extramural funding to date as compared to $127 million received at the same point-in-time last year which represents a 3.7 percent increase. President Lassner spoke about the beneficial community impacts that can arise from university-led research related projects financed by extramural research funding. He shared information on four such endeavors currently underway that are addressing the Red Hill drinking water crisis by focusing on several issues including water quality, water security preparedness and resilience, the effective management and protection of water resources in Hawai‘i and the United States Affiliated Pacific Islands, improvements to underground fuel storage facilities and delivery systems that will lead to safer operations and mitigate groundwater contamination risks, and enhanced laboratory capabilities and capacity at the university to meet future water quality research needs. He also announced that the university will be hosting a one-day conference in October that emphasizes the importance of water to island communities through a cultural and historical context, as well as the current challenges facing our state, including the situation with the Red Hill bulk fuel storage facility.

President Lassner highlighted an anonymous philanthropic cash donation of $4.6 million that was made to the university’s new Center for Indigenous Innovation and Health Equity, $3 million of which will be used to fund an endowed chair and $1.6 million of which will be used to support programs and activities. He also referenced two recent events that involved the university including the inauguration of the Daniel K. Inouye Solar Telescope on Haleakalā and the Pacific Island Conference of Leaders meeting that took place at the East-West Center for which he hosted a reception at College Hill.

E. WinCC Campus Presentation

Vice-Chair Nahale-a, who participated remotely, arrived at 11:00 a.m. and noted that two family members were intermittently present in the same room.

Chancellor Eschenberg provided an overview of enrollment statistics and noted relevant data trends over the last five years. While WinCC was successful in sustaining
matriculation for several student populations, economic and social challenges continue to impede the pursuit of higher education among certain demographic groups which impacts overall enrollment numbers. She recapped some of the work initiated by WinCC to address the immediate needs of its students and talked about longer-term initiatives undertaken to assist in-need populations including the Hoʻolei Scholarship Program (Hoʻolei) and the Hānaikaiaulu College Friendly Workplace Initiative (Hānaikaiaulu), a program that identifies, promotes, and collaborates with employers in the community that commit to being supportive of college-going student employees, stating that early data on the success of these interventions is promising.

In addition to the provision of direct financial support, WinCC has embarked on several endeavors to remove barriers to a post-secondary education, reduce perceptions that college is unattainable, and strategically increase enrollment. Chancellor Eschenberg reviewed some of the actions being taken to tackle these issues including ventures to increase engagement with potential early college students, particularly those of Native Hawaiian ancestry, by using programs such as Hoʻolei and Hānaikaiaulu as leverage; address male student enrollment gaps; and develop and promote pathways to a college education that are conducive to student time constraints, particularly those faced by working adults. She also noted that WinCC is the first campus in the university system to offer several certificate and degree granting programs to incarcerated individuals, as well as to implement the Second Chance Pell Experimental Sites Initiative which provides need-based Pell grants to individuals incarcerated in state and federal penitentiaries thereby allowing these individuals to receive quality higher education both in prison and post release.

Chancellor Eschenberg went over some of the degrees and certificates that are awarded by WinCC and provided statistics on declared majors over the past five academic years highlighting a large drop in liberal arts majors but noting increases in other majors such as Hawaiian Studies and Veterinary Technician and Assistant. She also reviewed data trends related to several of UHCC’s performance measures, including fall-to-fall persistence rates, certificates of achievement and associate degrees awarded, graduation rates, transfer rates, and success rates for first-time, full-time students. While fall-to-fall persistence and transfer rates have remained relatively constant, there have been incremental increases in both three- and six-year graduation rates, as well as first-time, full-time student success rates, and parity has almost been achieved between degrees and certificates earned by Native Hawaiian students as compared to non-Native Hawaiian students. However, the overall number of degrees and certificates awarded has declined. Chancellor Eschenberg stated that WinCC is actively pursuing a number of approaches to address flagging numbers and spoke about some of the strategies currently being undertaken.

Referencing anecdotal evidence regarding struggles faced by the LGBTQ+ community on the WinCC campus, particularly among transgender students, Chancellor Eschenberg stated that a decision was made to conduct an LGBTQ+-specific campus climate survey to measure attitudes and perceptions among the campus community. She shared the results of the survey, which indicated a need for improvement, and stated that WinCC is actively engaged in efforts to cultivate a safe and supportive
campus environment so that all students can achieve academic success and experience personal growth.

Chancellor Eschenberg noted several events that will be held to mark the 50th anniversary of WinCC and stated that one of the goals for its anniversary year is to raise $1 million in scholarship monies to assist students in overcoming financial barriers to a college education.

**Faculty Report**

Noe Tupou, WinCC Faculty Senate Presiding Chair, spoke about the work and accomplishments of the WinCC faculty, highlighting its efforts in developing, improving, increasing, and managing five innovative academic programs that have been launched since 2020. She talked about the benefits of these academic programs, noting that consideration was given to adult learner best practices in their development; provided an overview of each of these fully online programs which include the Hawai‘iloa Hawaiian Studies Associate of Arts Degree Program (Hawai‘iloa Program), the Kaʻōhekani Hawaiian Music Certificate Program (Kaʻōhekani Program), Business Core, the Entrepreneurship Associate of Arts Degree Program, and the Mental Health Technician Program; discussed program content and enrollment data; explained some of the rationale for the popularity of these programs; and highlighted program successes. A short video about the Kaʻōhekani Program was also shown.

**Student Report**

Roger Cardenas, President of the Associated Students of the University of Hawai‘i at WinCC (ASUH-WinCC) and Ciera Adversalo-Clarke, Vice-President of ASUH-WinCC provided a report on ASUH-WinCC’s post-pandemic attempts to re-engage and reconnect with students both through in-person interactions and the maintenance of a social media presence. Mr. Cardenas spoke about some of the on-campus and online activities that ASUH-WinCC has coordinated to increase interpersonal and campus connections including an Easter egg hunt and ice cream social, as well as podcasts and video game tournaments. A video highlighting these efforts and other ASUH-WinCC student activities held throughout 2022 was shown.

Ms. Adversalo-Clarke and Mr. Cardenas provided information on ASUH-WinCC sponsored events to address the personal and mental well-being of students including food drives and yoga workshops. They also spoke about actions being taken, as well as events hosted by ASUH-WinCC, to improve support for Native Hawaiian students.

**Staff Report**

Christy Lawes, Staff Senate Chair, gave an overview of the type of work performed by WinCC staff, stating that their mission is to ensure both student and faculty success through the delivery of efficient on-campus services, as well as the effective provision of brick-and-mortar and online operational support. Although WinCC staff have a strong campus connection, she noted that the COVID-19 pandemic impacted the staff’s sense of belonging and reported on several staff-organized activities that were designed to maintain campus and interpersonal connections. She also reviewed some of the staff’s
undertakings to support the basic needs of students, such as the offering of free meals, and coordinate proactive community building events.

**Ke Kumu Pali Hawai‘ian Council (Ke Kumu Pali)**

Ha’aheo Pagan, Chair of Ke Kumu Pali, provided an overview of the mission of Ke Kumu Pali and reviewed some of the cross-disciplinary actions it is taking to promote the access and educational needs of Native Hawaiians including the holding of cultural enriching workshops for faculty, students, and staff, and supporting Hawaiian-centric productions at WinCC’s award-winning Paliku Theater.

Mr. Pagan presented data on Native Hawaiian student success at WinCC highlighting enrollment parity, fall-to-spring persistence rates, online course completion rates, and semester credit hours taken as compared to non-Native Hawaiian students, and expressed Ke Kumu Pali’s belief that these statistics are critical to the decision-making process regarding the education of Native Hawaiians at WinCC. He also spoke about a unique program offered at WinCC for students interested in ‘āina based work which was made possible through a collaborative partnership with the nonprofit organization Hoʻokuaʻaaina. The Hoʻokuaʻaaina - Ahupua’a Apprenticeship Program includes two years of paid tuition, allows students to gain hands-on experience in carrying on cultural practices and traditions and creating sustainable ahupua’a systems in Hawai‘i, and leads to the awarding of an Academic Subject Certificate in addition to an Associate of Arts or an Associate of Science degree upon completion.

Regents commended the students, faculty, staff, and administrators at WinCC for their thoughtful efforts to give back to the community, praised the work being done to reduce economic and social barriers to higher education, as well as to increase cultural awareness and expand Native Hawaiian educational programming, and lauded their ability to effectively garner external support for the campus.

Referencing the success of the Hawai‘i‘aloa Program, Chair Moore asked whether the actions responsible for this success would be transferrable to other degree programs. Chancellor Eschenberg responded in the affirmative noting that WinCC has been actively working to incorporate the targeted marketing concepts used for the Hawai‘i‘aloa Program to advance other online degree programs such as Business Core and the Mental Health Technician Certificate Program.

Noting the large number of students enrolled in the program that reside out-of-state, Chair Moore inquired about the means used to market this program. Ms. Tupou replied that the majority of marketing for the Hawai‘i‘aloa Program took place via word-of-mouth through Hawaiian civic clubs, halau, and other Hawaiian organizations on the continent. Mr. Pagan added that WinCC strategically contacted halau and other Native Hawaiian community groups on the continent and utilized the social networks of these organizations to share information about, and generate interest in, the program.

Chair Moore expressed his dismay at the precipitous decline in Pell Grant recipients at WinCC given the amount of federal COVID-19 pandemic relief funds that were made available to students, as well as the student financial aid provided by the Harold K.L.
Castle Foundation. Chancellor Eschenberg stated that data for the current academic year will not be available until later in the fall but hypothesized that there would be an increase in the number of students receiving Pell Grants.

V. REPORT OF THE UNIVERSITY OF HAWAII FOUNDATION (UHF)

VP/UHF CEO Dolan reported that UHF’s fundraising efforts resulted in the receipt of approximately $165 million in contributions for Fiscal Year (FY) 2021-2022, which surpassed the record-setting previous fiscal year by $64.75 million and was nearly double the amount raised two years ago. He also pointed out the large amount of cash donations made stating that this accounted for just over $100 million of the total amount of funds received; discussed some of the community impacts of donations being made to the university; reviewed the various purposes for which funds were being donated, as well as a breakdown of the amounts received; and spoke about the sources from which funds were raised. It was also noted that UHF has been experiencing a rising trend in the receipt of major gifts which, while beneficial to the university, presents a new set of fundraising challenges including the lack of a sufficient number of major gifts officers to foster long-term relationships with current and prospective donors.

Although UHF has raised just over $20 million to date for the current fiscal year, VP Dolan stated that donations were running behind same-day figures from last year but explained that this lag could be attributed to the receipt of a $50 million gift from the Chan Zuckerberg Initiative (CZI) that was made in early FY 2021-2022.

John Han, Chief Operating Officer for UHF, reviewed UHF’s operating revenues and expenditures for FY 2021-2022 stating that the significant increase in total revenues realized, which amounted to approximately $16.8 million, was due to the selling off of high yield bonds from UHF’s endowment fund, a 36 percent increase in endowment fund returns on investment, and a surge in service fees due to the large number of donations made to the university. UHF saw a roughly 14.7 percent increase in operating expenditures which was mainly attributed to an increase in program activities, as well as the ramping up of marketing efforts. Overall, UHF’s total net revenues amounted to slightly more than $3.3 million.

Projections for UHF’s FY 2022-2023 operating revenues and expenditures were also presented. Mr. Han stated that UHF believes it will see a drop in the total number of gifts received during the fiscal year which will result in the diminution of proceeds from service fees and lead to a slight decline in operating revenues. UHF also expects to continue its aggressive fundraising and marketing campaigns and hire additional personnel to assist in these efforts thereby increasing its operating expenditures.

Regent Lee asked whether the monies raised to date by UHF for the current fiscal year were comparable to the same time period last fiscal year with the exclusion of the CZI gift. VP Dolan replied that the same-day point-in-time monies raised in both fiscal years are fairly comparable when the CZI gift is removed from consideration. However, the CZI gift will cause a large disparity to be reflected on the balance sheets as the year progresses.
VI. REPORT OF THE UNIVERSITY OF HAWAI'I ALL CAMPUS COUNCIL OF FACULTY SENATE CHAIRS (ACCFSC)

Regent Wilson, the board’s liaison to the ACCFSC, introduced Truc Nguyen and Rosie Vierra, the ACCFSC four-year and two-year campus co-chairs for 2021-2022. Dr. Nguyen and Ms. Vierra introduced current ACCFSC four-year campus chair Dr. Brent Sipes, who was unable to join the meeting due to a scheduling conflict, and current two-year campus chair Dr. Richard Halverson, who would be providing the presentation.

Dr. Halverson, spoke about the purpose, functions, composition, and meeting schedule of the ACCFSC noting that it serves as an arena for university faculty to participate in the development and interpretation of system-wide policy and fosters communication and understanding among the faculty, students, administration, board, and community. He also presented the findings of a quality of faculty work life survey conducted by the ACCFSC which measures faculty satisfaction and morale at each of the university campuses, and reviewed data on time spent by faculty on teaching activities as compared to research and scholarly activities, highlighting that all professors spend more time teaching than on research.

Chair Moore inquired about ACCFSC’s use of the information it obtains. Dr. Halverson replied that the information obtained is shared with the faculty senates at each of the campuses and is a helpful tool in duplicating successful efforts occurring at a particular campus as well as generating new ideas about campus improvements that will benefit the entire campus community.

Regent Acopan expressed her belief that students face similar challenges to those faced by faculty which were noted in the quality of work life survey and suggested that a similar survey be conducted among students to better gauge and understand their situation.

VII. COMMITTEE AND AFFILIATE REPORTS

A. Report from the Committee on Budget and Finance

B. Report from the Committee on Personnel Affairs and Board Governance

C. Report from the Committee on Planning and Facilities

Chair Moore stated that the committees noted above met on September 1, 2022, and referred regents to their respective committee reports contained in the materials packet.

VIII. AGENDA ITEMS

A. Consent Agenda

1. Approval of Fiscal Year (FY) 2022-2023 Operating Budget

   University Operating Budget for FY 2022-2023 Presentation

   Link to FY 2022-2023 Operating Budget Presentation
B. Regents’ perspectives on what it means for UH to be a Hawaiian-serving institution and UH’s role in reconciliation

Chair Moore summarized the primary goal, actions, and metrics of an imperative contained within the initial draft of the university’s strategic plan for 2023-2029 (Strategic Plan), which was to embrace kuleana to Hawaiians and Hawai‘i. He noted prior board discussions on this matter and explained that today’s conversation was intended to garner regents’ personal perspectives on what it means to be a Hawaiian serving institution, as well as whether the university has a broader role to play in the reconciliation of Native Hawaiian issues. He noted that he does not see the university’s role as fixing the problem, but should consider what role it plays in helping to get the problem fixed.

Regents were asked for their thoughts on these matters.
Vice-Chair Wilson provided background information on past attempts to tackle this issue, as well as discussions about this matter that have been, and continue to be held among members of the Native Hawaiian community. He stated that this information should be reviewed and used as a blueprint to facilitate further development of the Strategic Plan.

Regent Tochiki expressed her belief that WinCC exemplified the role and action steps toward being a leader and modeling reconciliation.

Discussions ensued on the extent of the university’s internal and external roles in the reconciliation of Native Hawaiian issues; whether members of the Native Hawaiian community were or should be consulted on this subject given that this matter primarily impacts their constituency; individual campus successes in addressing issues impacting Native Hawaiians that have exemplified the university’s role in reconciliation and whether the action steps created through these endeavors can be duplicated systemwide; and the necessity of achieving consensus on this issue.

Regents also expressed their beliefs that the university’s role with respect to Native Hawaiian issues is not to solve the problem but rather is to serve as a leader in facilitating the discussion on this subject; that this issue is not limited to the Native Hawaiian community but impacts all of the people of Hawai’i; that the university is poised to be a leader in the matter of reconciliation and should serve as a venue for conversations on this topic; and that discussions dealing with the long-standing and deep-seated issues regarding this topic must wholeheartedly involve the university.

Regent Paloma suggested that the board be apprised of the specific goals created with respect to past attempts to establish the university as a Native Hawaiian place of learning, as well as the status of these goals and whether questions surrounding this matter have been answered, and proposed that the university’s Native Hawaiian work committee, Hawai‘i Papa O Ke Ao, be asked to give a presentation at a future board meeting in order to provide greater context to this discussion. Chair Moore concurred with this proposal and asked President Lassner whether it would be possible for Hawai‘i Papa O Ke Ao to provide a presentation as to their thoughts and observations on this matter to the board at an upcoming meeting. President Lassner responded in the affirmative.

Vice-Chair Nahale-a opined that the university is the only entity in Hawai‘i that can deal with the complexity surrounding Native Hawaiian reconciliation and address the historic injustices the Native Hawaiian population has faced for generations. He also spoke about the frustrations felt among the Native Hawaiian population, as well as those that consider themselves to be Hawaiian nationals and others, with respect to the current State governance system’s failure to address these matters. As such, he feels that the university has an obligation to serve all the people of Hawai‘i, including the Native Hawaiian population and other marginalized groups, so as to ensure that every individual is provided with an opportunity to succeed on a systemic level. Vice-Chair Nahale-a stated his desire for the university to announce its intentions to be the strongest ally for Native Hawaiian self-governance going forward and discuss its rationale for its decision to not advocate for this position should it so choose.
President Lassner stated that the university has historically been focused on addressing this issue from a student and faculty standpoint. A new challenge is identifying the university’s role in broader Hawaiian issues such as the future of self-governance, the Hawaiian Homes program, and ceded lands issues.

Regent Westerman suggested that the drafters of the strategic plan reconsider the use of the phrase “Native Hawaiians across the islands” that is currently contained within the third imperative of the Strategic Plan given the large number of individuals of Native Hawaiian ancestry who are living in various parts of the world.

Chair Moore thanked regents for the robust conversation stating that a tremendous amount of information about the perspectives of regents on this particular matter has been provided to the individuals within the administration who are working on the Strategic Plan.

Chair Moore and President Lassner agreed that a follow up presentation would be scheduled for the November 2022 board meeting.

IX. ANNOUNCEMENTS

Chair Moore announced that the next board meeting was scheduled for October 20, 2022, at Leeward Community College.

X. ADJOURNMENT

There being no further business, Chair Moore adjourned the meeting at 12:42 p.m.

Respectfully Submitted,

Kendra Oishi
Executive Administrator and Secretary
of the Board of Regents
Item IV.
Report of the President
A-F

NO MATERIALS
ORAL REPORT
Item IV.G

Report of the President

LeeCC Campus Report

MATERIALS
Our Students

60% Female
37% Male
3% Non-Binary/Other

First Time 15%
Returning 7%
Continuing 50%
Transfer 12%
Other 16%

27% Full-Time
73% Part-Time

2022
0%
10%
20%
30%

26% 23%

• Native Hawaiian
• Filipino
Fall Enrollment

- UHCC System
- Leeward CC

<table>
<thead>
<tr>
<th>Year</th>
<th>UHCC System</th>
<th>Leeward CC</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>30,000</td>
<td>6,709</td>
</tr>
<tr>
<td>2019</td>
<td>29,700</td>
<td>6,568</td>
</tr>
<tr>
<td>2020</td>
<td>29,424</td>
<td>6,363</td>
</tr>
<tr>
<td>2021</td>
<td>29,057</td>
<td>6,413</td>
</tr>
<tr>
<td>2022</td>
<td>28,689</td>
<td>6,221</td>
</tr>
</tbody>
</table>
# SSH (Credit) Comparison

<table>
<thead>
<tr>
<th>Year</th>
<th>UHCC System</th>
<th>Leeward CC</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>229,423</td>
<td>58,397</td>
</tr>
<tr>
<td>2019</td>
<td>221,136</td>
<td>56,510</td>
</tr>
<tr>
<td>2020</td>
<td>208,070</td>
<td>53,631</td>
</tr>
<tr>
<td>2021</td>
<td>189,506</td>
<td>50,427</td>
</tr>
<tr>
<td>2022*</td>
<td>180,924</td>
<td>47,936</td>
</tr>
</tbody>
</table>

- % Change:
  - UHCC System: -3.6%, -5.9%, -8.9%, -4.5%
  - Leeward CC: -3.2%, -5.1%, -6.0%, -4.9%
**Fall Enrollment (Fall 2022)**

**Student Type:**
- **New (First-Time & Transfer)**
- **Continuing/Returning**
- **Early Admit**

<table>
<thead>
<tr>
<th>Year</th>
<th>New (First-Time &amp; Transfer)</th>
<th>Continuing/Returning</th>
<th>Early Admit</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>9%</td>
<td>58%</td>
<td>9%</td>
</tr>
<tr>
<td>2019</td>
<td>9%</td>
<td>57%</td>
<td>9%</td>
</tr>
<tr>
<td>2020</td>
<td>7%</td>
<td>56%</td>
<td>10%</td>
</tr>
<tr>
<td>2021</td>
<td>10%</td>
<td>56%</td>
<td>44%</td>
</tr>
<tr>
<td>2022</td>
<td>14%</td>
<td>57%</td>
<td>43%</td>
</tr>
</tbody>
</table>
Our Students (Fall 2022)

- Liberal Arts: 36%
- Career & Technical: 23%
- *Unclassified: 18%
- **Not Leeward: 24%

*"Unclassified" includes Early College.
**"Not Leeward" are home-based at another campus.
Student Outcomes

Retention
At the beginning of the third Fall

Graduation
By the end of year three

Transfer
By the end of year three

First-time, Full-time Students (all graphs are percentages)

- Leeward
- UHCC
Student Outcomes (Native Hawaiian)

Retention
At the beginning of the third Fall

Graduation
By the end of year three

Transfer
By the end of year three

First-time, Full-time Students:  • Native Hawaiian  • Non-Native Hawaiian
Student Outcomes (Filipino)

Retention
At the beginning of the third Fall

Graduation
By the end of year three

Transfer
By the end of year three

First-time, Full-time Students:  • Filipino  • Non-Filipino
College Enrollment after High School Graduation

- Enrolled at UH same year as HS grad
- Enrolled at LEE same year as HS grad

Total Number
- 2018: 100
- 2019: 200
- 2020: 300
- 2021: 400
- 2022: 500

Percentage
- 2018: 0%
- 2019: 10%
- 2020: 20%
- 2021: 30%
- 2022: 40%
Continuing Education & Workforce Development (Non-Credit)

<table>
<thead>
<tr>
<th>Year</th>
<th>Overall Enrollment</th>
<th>Overall Headcount (unduplicated)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY 2019-20</td>
<td>2,382</td>
<td>1,918</td>
</tr>
<tr>
<td>FY 2020-21</td>
<td>3,145</td>
<td>2,881</td>
</tr>
<tr>
<td>FY 2021-22</td>
<td>2,620</td>
<td>2,421</td>
</tr>
</tbody>
</table>
HICARES: Hawaii Career and Resiliency Education Support, an initiative to support Hawaii’s job seekers and small businesses during the Covid-19 crisis and through the recovery efforts.

**Transportation program includes Commercial Driver’s License and other transportation classes.**

*HICARES: Hawaii Career and Resiliency Education Support, an initiative to support Hawaii’s job seekers and small businesses during the Covid-19 crisis and through the recovery efforts.

**Transportation program includes Commercial Driver’s License and other transportation classes.**

Continuing Education & Workforce Development (Non-Credit)

<table>
<thead>
<tr>
<th>Field</th>
<th>FY 2019-20</th>
<th>FY 2020-21</th>
<th>FY 2021-22</th>
</tr>
</thead>
<tbody>
<tr>
<td>HICARES*</td>
<td>1,500</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transportation**</td>
<td>1,000</td>
<td>500</td>
<td>0</td>
</tr>
<tr>
<td>Business</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Industry and Trades</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Healthcare</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Computers</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Supporting our Students

- Summer Bridge program and college orientation
- Weekly student success seminars
- Huaka'i (site visits) to important cultural and historical sites
- Reserved anchor cohort courses
- Assistance through kua'ana (peer mentor) and program counselor
- Career exploration

- Financial support for first-year students
- Weekly student success seminars – in-person or online
- Huaka'i (site visits) to important cultural and historical sites
- Assigned kua'ana (peer mentor) for weekly check-in meetings
- Career assessment, exploration, practice, “job ready” skills
- Program activities that nurture resilience, achievement, and wellness
Ke Ala ʻIke Scholars Program
A culture-based “Excellence Program” designed to incentivize a commitment to cultural growth and academic achievement. Scholars are granted the privilege of wearing a kīhei at Leeward CC’s Commencement.

- Research Moʻokūʻauhau (genealogy)
- Interview Hawaiian Kupuna
- Learn College Oli (chant)
- Engage in Mālama ʻĀina activity
- Develop Transfer and Career Plan

Ke Ala ʻAnuʻu
Leeward CC and the UH West O'ahu partnered to expand and enhance the STEM learning experiences and improve the educational outcomes of Native Hawaiians through this collaborative project.

A key strategy is the implementation of Hawaiian Culture-Based Education Bridging Programs with institutional STEM pathways to ease transition and matriculation between Leeward and UHWO.
Pūkoʻa no nā ʻEwa
Native Hawaiian Council, Chair
Genai Uʻilani Keliʻikulī
Associate Professor, Hawaiian Studies
CAMPUS CHANTS

- Hālau Puʻuloa
- Hālau Waiʻanae

HOʻŌIA ʻĀINA STATEMENT

GRADUATION KĪHEI
Ka Waimanomano Program

*Ka Waimanomano (the many waters) is a 10-week professional development cohort program designed to support Leeward employees who are interested in learning more about Hawaiian culture, values, history, and language in order to improve their work at our college.*
Cross-Campus Endeavors

INOA HAWAIʻI - BUILDINGS AND ROOMS
RESTRUCTURING HAWAIIAN UNIT
STRATEGIC PLAN
MAKAHIKI GAMES
WAʻA
Staff Senate

Tiffany Kasoga
Chair – Administrative Support Group

Kalekona Kingsbury
Representative - APT Staff Group
Staff Engagement at Leeward CC!

- Kawaimanomano Cohorts
- Hui Hoʻola
- Innovation Awards
- Summer “Reconnecting” Classes
- Leadership Development Programs
- Faculty & Staff Book Club
Staff Senate: Upcoming Plans

- Get the Word Out!
- Gather Input
- Formation & Recruitment
To help the staff of Leeward CC to:

• Share responsibility
• Develop a unified voice
• Exchange and coordinate information
• Stay informed
• Provide input / Lend expertise
• Participate and serve
• Foster a culture of respect and community
Faculty Senate

Michael Oishi
Associate Professor, Literature
Chair, Faculty Senate
Focus on Improving Student Success and Collaborative Engagement: Major Areas

- Creating a culture of assessment to improve student success.
- Improvement of instructional design and delivery of online courses.
- Updates to policies and procedures that benefit students.
- Improvements to the college’s Integrated Planning and Budgeting Process.
Faculty Senate Assessment Committee

- Identified and contacted faculty who had not assessed their course learning outcomes (CLOs) in the last five years.
- Efforts resulted in an assessment completion rate of 86% (426 of 494) through August 24, 2022.
- Led multiple training sessions on the use of Anthology, the college’s new Assessment Management System.
- Created a Course Assessment Worksheet to inform instructors of assessment data that needs to be collected from courses and how to enter it into Anthology.
- Assessment of CLOs assists instructional faculty in reflecting objectively, and with data, on the effectiveness of their instructional design and delivery to improve student success in courses.
Faculty Senate Distance Education Committee

• Revised the campus’ DE Guidelines to ensure DE courses are accessible to a wide range of student learners and to provide a more specific and rigorous definition of "regular and substantive interaction."

• Will offer, beginning Fall 2022, new professional development and peer coaching for online course support.

• Will review its DE processes to ensure compliance with new federal guidelines and Accrediting Commission for Community and Junior Colleges policies.
Faculty Senate Student Affairs Committee

• Amended Leeward Policy L7.201 (Policy on Graduation).
• Amended Leeward Policy L7.210 (Unsatisfactory Academic Progress).
• Revised Student Conduct Code procedures.
• Updates to policies and procedures are intended to uphold the rigor of our academic programs and to ensure transparency and consistency in our guidance to students.
Faculty Senate Faculty Committee

• Changed the Participation Verification syllabus notification from an optional notification to a required notification.

• Amended the College’s Student Complaint Process document to make transparent to students their rights to due process and quality instruction.

• Changes help ensure students are aware of their responsibilities and their rights if they have questions or concerns about instructional practices.
Goals:

• Propose revisions to the current campus budget and planning process.
• Host campus forums, and review and advise, on the UH General Education Design Team’s proposal for a new UH General Education curriculum.
• Review and vote on the campus’ revised mission, vision, and Strategic Plan.
• Recommend amendments to the college’s Academic Grievance Policy and Procedures.
Student Government's kuleana for 2022-2023 is to kōkua and mālama Leeward CC by encouraging our community to share their needs and to provide innovative solutions.

‘O ke kuleana o Ke ‘aha haumāna no ka makahiki 2022-2023, ‘o ia ke kōkua a me ka mālama iā Leeward CC i ka ho‘opaipai ‘ana i ko kākou kaiaulu e kūkākūkā e pili ana i nā nele a hana pū i ke alahele pono me nā ka‘ina hou.
What We’ve Done...

- Student Government is highly active on [Instagram](https://www.instagram.com) and launched a [Podcast](https://example.com)!
  - Financial Literacy Podcast Series
  - Community Podcast Series
  - Over 100 listeners
  - Created a discord to engage in conversations with students
- In-Person Events on both campuses: Student Involvement Fair and Grab, Go, Get to Know
- **Educating Students:** [Participation Verification Video](https://example.com)
- **Campus Engagement:** Contributed to updates on the Student Conduct Code Policy, Graduation Policy, Student Fee Policy, etc.
- **System Engagement:** Only student voice on the Strategic Plan(s) and the Gen Ed Redesign, active in Student Caucus, and engaged in various Town Halls.
Mahalo
Agenda Items:

A. University of Hawai‘i System Academic Priorities and Policy Overview

   Debora Halbert, Vice President (VP) for Academic Strategy, provided an overview of the program proposal process emphasizing that each proposal is scrutinized to ensure appropriate placement and determine whether the program aligns with the academic interests and system-level strategies of the university. She also provided a synopsis of several broad initiatives being undertaken to improve academic effectiveness and efficiency, discussed ongoing efforts to develop some of these initiatives, and went over policies associated with the various proposals that may require revisions.

   Farrah-Marie Gomes, Associate Vice President for Student Affairs, reported on efforts to address basic student needs such as food security, housing, and mental health, on a systemwide level that builds upon successful endeavors already in existence at the campus level, stressing that addressing these issues is critical to improving academic performance, as well as persistence and graduation rates.

B. Recommend Board Approval of Provisional Status for the Master of Education (MEd) in School Counseling at the University of Hawai‘i at Mānoa (UHM)

   Michael Bruno, UHM Provost, provided an overview of the request to grant provisional status for the MEd in School Counseling degree program within the Department of Kinesiology and Rehabilitation Science at UHM, stating that this program will address Hawai‘i’s immediate and continuous school counselor workforce needs and will fill the gap in preparing school counselors statewide to support P-12 students in academics, personal well-being, social and emotional development, and mental health. He spoke about program requirements and anticipated enrollment, highlighting that this graduate degree program is completely online.

   **Action:** The committee voted to recommend board approval to grant provisional status to the MEd in School Counseling degree program.

C. General Education (Gen Ed) Redesign Update

   VP Halbert provided an update on efforts to examine and revamp the Gen Ed curriculum, stating that feedback received on the initial draft of the redesign plan was used to develop a new proposal that will be presented to the campus faculty senates for approval during the current academic year. She reviewed some of the guiding principles used to craft the current proposal, went over its components noting that it is a competencies-based program, and discussed some of the advantages of the current proposal as well as the timeline for finalization and implementation.

   Discussions ensued on transferability of requirements between campuses and the lengthy timeframe for its full implementation.
Agenda Items:

A. Coaches Corner: Michael Stephens, University of Hawai‘i at Mānoa (UHM)
   Swimming and Diving Head Coach

UHM Head Swimming and Diving Coach Michael Stephens spoke about his coaching
career at Boston College where he served a four-year stint as the swimming and diving
team’s assistant coach before being named its head coach, a position he held for five
years. He cited some of the factors taken into account when he applied for and
accepted the head coaching position at UHM including Hawai‘i’s unique lifestyle and
rich swimming history; discussed his coaching philosophy; and expressed his
excitement to be coaching at UHM noting the team’s potential success for the upcoming
season and beyond.

Discussions occurred on the mental-health needs of student-athletes in the swimming
and diving program.

B. Student-Athlete Corner: Darren Williams, University of Hawai‘i at Hilo (UHH),
   Men’s Basketball Student-Athlete

UHH senior men’s basketball standout Darren Williams, who has received both
academic and athletic accolades, shared information on his personal background,
including his early basketball career; spoke about his journey to playing basketball at
UHH; and offered insights into his experiences as both a student and athlete since
arriving on the UHH campus in 2020 stating that the sense of community he has felt at
UHH will be one of his most cherished memories.

When asked about the need for any facility improvements at UHH, Mr. Williams
suggested fixing the gym floor which is impacted when it rains.

C. Athletic Facilities Update

UHH Athletic Director Pat Guillen reviewed several recently completed athletic facilities
projects at UHH including the soccer field/softball field/multipurpose building project, as
well as renovations to the outdoor tennis courts and the athletic training room. He also
spoke about future priority projects for UHH Athletics which consist of improvements to
the on-campus gymnasium, the baseball field, and the weight room/fitness facility.

UHM Associate Athletic Director (AAD) Lois Manin provided an update on completed,
as well as ongoing, athletic facility improvement projects, noting the benefits of well-
designed and maintained amenities. She discussed the reasoning behind the recent
expansion of the Clarence T.C. Ching Athletics Complex; reviewed plans for further
expansion of the Complex which will provide several added benefits to UHM Athletics;
talked about the uncertainty surrounding the Aloha Stadium project; noted facility
improvements that will be needed in the near future; and discussed UHM Athletics’
aspirations to develop a high performance center that would serve as a multi-purpose
athletic facility to provide more efficient and impactful services to student-athletes.
Agenda Items:

A. Research Project Briefing: “University of Hawai‘i Center for Indigenous Innovation and Health Equity (CIIHE)” Presentation by Kamuela Enos, Director, Office of Indigenous Innovation, and Dr. Aimee Grace, Director, Office of Strategic Health Initiatives

Director Enos presented on behalf of himself and Dr. Aimee Grace who was unable to attend due to a conflict. He provided background information on the establishment of CIIHE, including the rationale for and roots of its genesis; recognized the core collaborators and community partners involved with CIIHE; reviewed the key premise of CIIHE which posits that the contemporary application of ancestral knowledge and systems is a means of addressing the current healthcare and poverty inequities facing indigenous populations and frames equity as an exit strategy from this disparity; noted several activities undertaken by CIIHE during the first year of its existence; and discussed CIIHE’s second year plans. He also recognized the work of CIIHE team members. Each individual team member introduced themselves, spoke about their backgrounds and the projects they are working on, and extolled the beneficial impacts CIIHE can have on indigenous communities across the globe.

B. Research and Innovation Fiscal Year (FY) 2022 Year-in-Review and FY 2023 Outlook

VP Syrmos reported on the extramural awards received for FY 2022; provided a breakdown of trends, significant awards, and award amounts by campus; and summarized data pertaining to various research and innovation metrics. He highlighted that the university received a record $505 million in extramural awards for FY 2022 and noted that extramural funding obtained for the first quarter of FY 2023 is approximately 10 percent higher than the same period last fiscal year. He also reviewed the number of invention disclosures made, the number of patents applied for, and the number of licenses/options awarded for research projects for FY 2022. VP Syrmos stated that the administration remains cautiously optimistic that the university’s extramural funding efforts will continue to experience success in FY 2023.

Discussions occurred about the impacts of inflation on extramural research funding requests.

C. Strategic Directions: Extramural Awards Targets vs. Actuals FYs 2015 – 2022

VP Syrmos provided historical trend data of annual targets versus the actual amount of extramural awards received since 1975, noting that information of both research and non-research extramural award targets versus actuals for each of the major units of the university during the last five years was provided in the meeting materials.

D. Committee Work Plan

Chair Bal reviewed the Committee Work Plan stating that it would be used as an outline to guide the work of the committee during the coming year and noting a modification in the presentation of extramural award reports from quarterly to semiannually.
University of Hawai‘i Student Caucus (UHSC)
Affiliate Report for the October 20, 2022, Board of Regents Meeting

Date of Affiliate Meeting:  N/A

Topics Covered:  N/A

Summary of Discussions:  N/A

Actions Taken:  N/A

Future Meetings:

The UHSC is currently in the process of determining its meeting schedule for the current academic year under the guidance of Farrah-Marie Gomes, who was recently appointed to the position of Associate Vice President for Student Affairs.
MEMORANDUM

TO: Randoph G. Moore  
   Chair, Board of Regents  
   Ernest Wilson  
   Chair, BOR Academic and Student Affairs Committee

VIA: David Lassner  
     President

VIA: Michael Bruno  
     Provost

VIA: Laura E. Lyons  
     Interim Vice Provost for Academic Excellence

VIA: Krystyna Aune  
     Dean, Graduate Division

VIA: Nathan M. Murata  
     Dean, College of Education

FROM: Christopher Stickley  
     Department of Kinesiology and Rehabilitation Science

SUBJECT: REQUEST FOR PROVISIONAL STATUS FOR THE MED IN SCHOOL COUNSELING AT THE UNIVERSITY OF HAWAI'I AT MĀNOA

SPECIFIC ACTION REQUESTED:
It is respectfully requested that the Board of Regents grant provisional status to the Master of Education (MEd) in School Counseling in the Department of Kinesiology and Rehabilitation Science (KRS) at the University of Hawai'i at Mānoa. The ATP was approved on April 29, 2021.
RECOMMENDED EFFECTIVE TERM/YEAR:
Fall 2023.

ADDITIONAL COST:
This program will not require new funding and is expected to use existing College of Education (COE) resources. Additional cost savings and revenues will be generated from offering the program through Outreach College.

PURPOSE:
The MEd in School Counseling is a priority for the COE because it will directly address the workforce needs in Hawai‘i and will help to fill the gap in preparing School Counselors statewide to support P-12 students in academics, personal well-being and social and emotional health. There exists no program in the UH system that prepares candidates for licensure in School Counseling.

BACKGROUND:
School counselors provide a unique and important role in the healthy development of school-aged children. They are considered important and contributing members of the education team at all levels, from pre-K to post-secondary transition; and are in positions at the school, district, and state levels. School counselors plan and deliver a comprehensive counseling program that addresses all students; and are adept at helping students in areas of academic achievement, personal well-being, career and college readiness, and social and emotional development. They are able to gather and provide data-driven services aligned with the unique needs of their students, schools, and families. This includes planning and delivering guidance lessons in the classrooms and small group sessions, assisting in assessments, and collaborating with families. School counselors not only provide direct counseling services to students, but also act as a consultant to teachers, administration, and family members. Their positive contribution in the K-12 school systems depends greatly on effective graduate level preparation and opportunity.

The Hawai‘i Teacher Standards Board (HTSB) School Counseling Workgroup Report, 2020-2021, found that of 631 current school counselors in the Hawai‘i Department of Education (DOE), 586 have a Hawai‘i School Counselor license, the remainder of whom were either licensed in another field or unlicensed. This indicates a need to provide 40-50 more licensed school counselors for the State annually. The HTSB now requires that in order for an individual to be awarded a Hawai‘i license in school counseling they must complete a state approved school counseling preparation program at the master’s degree level.
A steady pipeline into the profession is needed so the DOE is not left with uncertified counselors in counseling positions providing critical services and care to the students. Additionally, school counselors will play an essential role in helping students re-adjust to school and life regarding the trauma of COVID impacting schools, families, and students.

The attached documents provide further background, significance/contribution for the degree, demand projections, accreditation details, program plans/courses/syllabi, and program resources and efficiency.

**ACTION RECOMMENDED:**
It is respectfully recommended that the Board of Regents grant provisional status to the Master of Education (MEd) in School Counseling in the Department of Kinesiology and Rehabilitation Science (KRS) at the University of Hawai‘i at Mānoa. The ATP was approved on April 29, 2021.

**ATTACHMENTS:**
1. Proposal for Master of Education in School Counseling
2. ATP MEd in School Counseling
3. MFS Resolution of Support
4. Letters of Support

cc: Executive Administrator and Secretary of the Board Kendra Oishi
MEMORANDUM

TO: David Lassner
   President

FROM: Debora J. Halbert
      Vice President for Academic Strategy

SUBJECT: Delegation of Authority

This is to inform you that I will be on vacation from September 7, 2022, through September 20, 2022. I will be back in the office on Wednesday, September 21, 2022.

In my absence, Pearl Iboshi, Director, Institutional Analysis, Research and Planning Office, will act on my behalf and having signing authority.

c: Officers
   OVPAS Managers
   Board of Regents Office
   Blanche Fountain
Guidelines for Proposals for New Academic Programs  
(15-Page Limit)  
Proposal: Master of Education in School Counseling

The program proposal for provisional status should follow the guidelines below. Programs are provisional for 150% of the proposed degree length. Once the college-level review has been completed, please submit the proposal and cover memo to April Goodwin at agoodwin@hawaii.edu.

I. Executive Summary
The University of Hawaiʻi at Mānoa, College of Education, Department of Kinesiology and Rehabilitation Science (KRS) is proposing a Master of Education in School Counseling, further known as the MEd in School Counseling. Once approved, the program will be submitted to the Hawaiʻi Teacher Standards Board (HTSB) for licensure approval in the specialty area of School Counseling (K-12). The University of Hawaiʻi System does not currently offer a school counseling licensure program. The MEd in School Counseling will be offered as an online graduate program and fills the need to provide a cost-efficient, quality education to students statewide. This program will also help to fill school counseling positions with licensed school counselors in the Hawaiʻi Department of Education; and will address the growing social and emotional needs of K-12 students. This 6-semester, 48-credit program closely aligns with the KRS Rehabilitation Counseling in Education Program (RCEP) and utilizes shared resources. More than half of the courses in the School Counseling program are also required courses in the RCEP. The program plan outlines online coursework along with supervised practicum and internships to provide real life experiences. Starting in the Fall of 2023, the program will admit a cohort of between 10-15 students each year. In years 3+, it is expected the program will have an enrollment between 30-45 students and a retention rate of 82%, consistent with the KRS RCEP retention rate. All graduating students will be recommended for licensure through the Hawaiʻi Teacher Standards Board (HTSB). The proposed MEd in School Counseling will not require new funding and is expected to use existing COE resources. Additional cost savings and revenue will be generated from offering the program though Outreach College.

II. Program Purpose and Outcomes
A. Why is this program a priority for the unit? Describe how the program will meet the needs of students, the local community, and the state. Include a market analysis detailing how the program will respond to the social, economic and workforce needs of the nation and state.

The MEd in School Counseling is a priority for the COE because it will fill the gap in preparing School Counselors statewide to support K-12 students in academics, personal well-being, and social and emotional health. The objectives of the MEd in School Counseling are to

1. Provide a graduate level education in school counseling, which is currently not offered in the University of Hawaiʻi system.
2. Address a State of Hawaiʻi workforce and community need by providing a new entry point for prospective school counselors to obtain HTSB licensure.
3. Assist the State of Hawaiʻi by providing another option for residents to obtain a high quality and cost-efficient graduate level degree in School Counseling.
4. Deliver an online graduate program statewide to allow students on Oʻahu as well as the neighbor islands to enroll in the program.

School counselors provide a unique and important role in the healthy development of school aged children. They are considered important and contributing members of the education
team at all levels, from pre-K to post-secondary transition; and are in positions at the school, district, and state levels. School counselors plan and deliver a comprehensive counseling program that addresses all students; and are adept at helping students in areas of academic achievement, personal well-being, career and college readiness, and social and emotional development. They gather and provide data-driven services aligned with the unique needs of their students, schools, and families. This includes planning and delivering guidance lessons in the classrooms and small group sessions, assisting in assessments, and collaborating with families. School counselors not only provide direct counseling services to students, but also act as a consultant to teachers, administration, and family members. Their positive contribution in the K-12 school systems depends greatly on effective graduate level preparation and opportunity.

There are no school counseling programs within the state that are totally online and serve the outer islands and rural areas. In Hawai‘i, the HTSB School Counseling Workgroup Report 2020-2021 indicated that approximately 45 practicing counselors were unlicensed in the field of School Counseling and indicated a need to offer a high-quality school counseling program statewide. Recruitment of this identified group will be pursued. The proposed program will seek approval from the Hawai‘i Teacher Standards Board to fully license graduates in the specialty area of School Counselor, K-12 (see section C, page 4, that provides further evidence of the need for the program).

While UH Mānoa provided a School Counseling and Guidance (EDCG) program in the past, due to personnel issues, accreditation was withdrawn, and the School Counseling program was subsequently stopped out. Past personnel issues were resolved, and current accreditation is addressed in Section V of this proposal. At present, The COE is undergoing a re-envisioning of the unit, and engaged in possible re-organization of existing departments, because of the new COE Strategic Plan. The COE is prepared to reinstate and is positioned to house the program. The proposed program also addresses one of the stated critical gaps identified as a community priority, Health and Wellness, as school counseling is commonly described under the umbrella or aligned with the profession of counseling. A steady pipeline into the profession is needed so the DOE is not left with non-certified counselors in counseling positions providing critical counseling services and mental health care to the students.

B. Describe how the program aligns with the UH academic master plan and strategic priorities.

The proposed graduate program aligns with the UH Strategic Directions (2015-2021) in the following areas:

Hawai‘i Graduation Initiative (HGI)
1. **HGI Action Strategy 2: Implement structural improvements that promote persistence to attain a degree and timely completion.**

The proposed program provides an online format which will expand opportunities statewide for Native Hawaiian students, under-represented populations, military/veterans and their families, returning adults, and online students. Summer sessions are incorporated in the design to best support student success.

2. **HGI Action Strategy 3: Anticipate and align curricula with community and workforce needs.**
This proposed program will **address the workforce and community needs** in the Hawai‘i DOE in the area of school counseling and in the community priority and identified critical gap areas of Health and Wellness (see below in Sections d, 3, and 4).

3. **HGI Action Strategy 4:** Increase delivery of online courses and degrees, while maintaining other distance delivery modes (interactive TV, cable TV, and off-campus face-to-face instruction.)

The proposed program will be **designed to deliver online courses targeting graduate students statewide through Outreach College.** Professional development and distance teaching support, if needed, for faculty in the COE will be provided to deliver quality and effective courses and services. Additionally, online student services will be provided to support academic success in various forms from application to program completion.

Hawai‘i Innovation Initiative (HII)

4. **HII Action Strategy 3:** Invest internal resources and seek external resources for strategic infrastructure requirements and hires that leverage our location and strength as well as address critical gaps.

   - **Health and Wellness**

The program addresses one of the stated critical gaps identified as a **community priority,** Health and Wellness, as school counseling is commonly described under the umbrella or aligned with the profession of counseling. The program will seek approval from the Hawai‘i Teacher Standards Board to fully license graduates in the specialty area of School Counseling, K-12.

High Performing System (HPS)

5. **HPS Action Strategy 1:** Employ best practices in management, administration and operations.

The proposed program supports best practices in management, administration, and operations by utilizing current structures in place. It is modeled after the successful graduate level KRS RCEP offered through Outreach College. The online format provides students statewide access to gain school counselor licensure and opportunities for education, training, and employment in rural and neighbor islands. The proposed MEd in School Counseling program is implementing common core and elective classes with the current KRS RCEP program and will therefore save the University on some instructor and overhead costs, as well as maintaining a robust student class size. Currently, there are no competing, existing, or duplicate programs for the specialty area of School Counseling in the University of Hawai‘i system.

C. **Provide evidence of the need for the program including projected number of students and graduates, career and graduate education opportunities, etc.**

According to the U.S. Bureau of Labor Statistics, school counseling as a profession has a national employment projected growth rate of 11% between 2020-2030, faster than the average of all other occupations with a projection of about 35,000 openings each year on average, over the next 10 years. Nationally, most colleges of education within public universities offer a graduate school counseling program as part of their service commitment to K-12 schools. Currently, there are no
programs that provide licensure for the specialty area of School Counseling in the University of Hawaiʻi System. The only program in the state of Hawaiʻi providing licensure for School Counselors approved by the Hawaiʻi Teacher Standards Board is Chaminade University, which under normal circumstances (pre-COVID) offers an in-person based program only to serve the island of Oʻahu. Based on the 2018 Hawaiʻi Teacher Standards Board report, in 2016-2017 21 students graduated from the Chaminade school counseling program, and 18 completed the program in 2017-2018. ANNUAL STATE APPROVED TEACHER EDUCATION PROGRAM REPORT 2018 Section I. – EPP Profile

The proposed program will seek approval from the Hawaiʻi Teacher Standards Board to fully license graduates in the specialty area of School Counseling K-12 to address the constant need for school counselors in the DOE. Although it has not been deemed a shortage area, vacancies in school counseling continue to go unfilled. According to Hawaiʻi DOE Assistant Superintendent Cindy Covell (personal communication 8/10/20), as of August 10, 2020, the DOE had 571 school counselor positions statewide and 18 existing vacancies. Additional information found in the HTSB School Counseling Workgroup Report, 2020-2021 indicated that approximately 45 practicing counselors were unlicensed in the field of School Counseling and indicates a need to offer a high quality School Counseling program statewide. The Report stated:

- Qualifications of current practicing, licensed school counselors are inconsistent regarding program completion, assessments, and clinical experience, especially those who were either trained out of state or added the field of school counseling utilizing a licensure test and experience.
- The one state approved school counseling preparation program in Hawaii cannot prepare enough school counselors to meet the state’s needs, especially for Neighbor Islands.
- The issues that students and families are facing now are more complex than ever and require specialized knowledge and clinical experience.
- School counselors need high-quality training prior to becoming a school counselor as well as appropriate mentoring and placement.
- Counselors also need on-going training to support continuing professional growth and development.
- There is a need to have specialized knowledge for the counselor position in counselor theory and social emotional learning to support student achievement.
- Staff reductions are resulting in counselors being placed in classrooms, potentially without pedagogy training, creating the same dilemma as non-trained individuals in school counseling positions (pages 1-2).
- Approximately 45 current school counselors are not licensed in the field of school counseling.

The Report recommended that for an individual to be awarded a Hawaiʻi license in school counseling they must complete a state approved school counseling preparation program at the master’s degree level. A steady pipeline into the profession is needed so the DOE is not left with unlicensed counselors in counseling positions providing critical services and care to the students. Additionally, school counselors will play an essential role in helping students re-adjust to school and life regarding the trauma of COVID impacting schools, families, and students.

The proposed MEd in School Counseling responds to the national and local need to better address a growing population of culturally and linguistically diverse students and their families and speaks directly to the COE’s Strategic Planning Framework Principle: Native Hawaiian Place of Learning
and Teaching (college-wide presentation by Dr. Murata, 8-20-20). The unique quality of the University of Hawai‘i at Mānoa is the ability to provide graduate students with an education immersed in Native Hawaiian culture and diversity. The demographic make-up of the student population in KRS includes a culturally-diverse student body, faculty, and staff. The outcome of this type of experience is graduates who are better equipped to work in schools with students representing diverse backgrounds and beliefs. By offering the program online through Outreach College, we offer the opportunity for those living and working in the outer islands and rural areas to become licensed school counselors.

Additionally, the program will utilize local public and charter schools for school counseling internships, which allow for authentic experiences in a culturally diverse school setting and grounds the COE’s commitment to actualize a Native Hawaiian place of learning and teaching. The School Counseling internship embeds collaboration and instruction between the DOE faculty, UH faculty, and students. This addresses the COE’s 2nd Strategic Planning Principle of Collaboration, Partnerships and Community. The internship collaboration with the DOE and online format prepares students from all geographic areas, including outer islands and rural areas, to train and eventually work and serve in the communities they live in. This provides the state DOE with licensed counselors who live in hard to fill areas.

The proposed MEd in School Counseling also responds to the local and national need of identifying and addressing student mental health and wellness and this is reflected in the COE’s 3rd Strategic Planning Principle of Innovate and Inspire. According to the CDC (Data and Statistics on Children’s Mental Health), youth behavioral and mental health issues are on the rise, including depression and anxiety. According to recent data (Mental Health in America - Youth Data), 59% of youth with major depression do not receive mental health treatment across the nation. In Hawai‘i, 58% or about 6,000 youth with major depression do not receive any mental health services. The 2017 Youth Risk Behavior Survey indicates 10% of the high school youth surveyed in Hawai‘i attempted suicide, 16% seriously considered attempting suicide, and 29.5% of high school youth felt sad or hopeless for almost every day for 2 weeks or more that they stopped doing some normal activities (Youth Online: High School YRBS - United States 2017 Results | DASH). School counselors are considered a vital part in recognizing and addressing youth mental health and wellness appropriately in the K-12 setting and are needed more than ever. The pandemic’s impact on youth has taken a huge toll, and includes increased anxiety and depression among school aged children. As stated by Courtney, D., Watson, P., Battaglia, M., Mulsant, B. H., & Szatmari, P. (2020), “Children and youth are highly vulnerable to the impact of sustained stressors during developmentally sensitive times, and thus, their mental health during and after the pandemic warrants special consideration.” Researchers also point to the underfunding of youth mental health services as a problem and is exacerbated during the pandemic as resources get diverted and identification, assessment, and providing services become more challenging (Courtney et al., 2020). Key findings from the Institute of Education Sciences study released in April 2022 (2022 School Pulse Panel) indicate 70% of public schools are seeing an increase in students seeking counseling services since the start of the pandemic; 76% of public school faculty and staff expressed concerns about depression, anxiety and trauma in students; and only 56% of public schools reported that their school is able to effectively provide counseling services to students in need. Locally, Hawai‘i public schools continue to struggle with the lack of resources to address rising behavioral and mental health issues among school children. Civil Beat recently reported the increase of K-12 behavior incidents and mental health needs post-pandemic indicate a need for more mental health and trauma counseling at the school level. (Fights At Hawaii Schools Highlight The Need For More Mental Health Support - Honolulu Civil Beat). According to Dean Murata’s College-wide address, the COE is committed to providing novel and new
ways to inspire and provide constructive change towards a more just and equitable society. The university and specifically the COE is in a unique position to provide a much-needed graduate level degree to address this urgent national and local need.

The School Counseling program will accept 10-15 students to start the program in the Fall of 2023. We expect to have our first graduates in the Spring of 2026. Based on the closely aligned and successful MS in KRS for Rehabilitation Counselor Education Program (RCEP), we expect a retention rate of 82% or higher (the average retention rate from 2009-2016 for the MS KRS in RCEP), which amounts to 8-12 students graduating in 2026. The typical length of time spent obtaining the RCEP degree is 36 months and is the expected amount of time for the MEd in School Counseling. Based on the RCEP data, we also expect a 94% or higher employment rate within 6 months of graduating from the program. This addresses the COE’s 4th Strategic Planning Principle - Research to Improve Educational Outcomes and demonstrates the COE’s commitment to innovate, improve, or influence the knowledge base of diverse learners who can contribute to a just society. Additionally, the COE’s School Counseling program provides the opportunity to obtain an MEd in a financially feasible, online format that appeals to non-traditional students who may be returning to school, changing careers, and balancing family and work responsibilities.

D. Describe the profile of students who will likely enroll in the program and provide evidence of student demand (i.e., needs assessment).

Currently, there are approximately 45 current practicing school counselors who are not licensed in the field of school counseling. Recruitment of this identified group will be pursued. In addition, the proposed program will likely attract primarily in-state and some out-of-state students from the Pacific Rim and West Coast wishing to obtain a graduate level degree in the field of School Counseling, and who are interested in flexible online learning environments. This format is appealing for both working professionals and recent graduates who want to continue their education. In upholding the University of Hawai’i’s academic mission, prospective students will gain a quality graduate education rich in diverse knowledge and experiences. Additionally, the proposed program provides an opportunity for students to gain a graduate degree in School Counseling at a competitive cost. Since this is a new program, it will attract students to the Mānoa campus that would have chosen either Chaminade or other universities on the continent to acquire a degree in school counseling. We expect to see Hawai’i residents make up the majority of the student population in this degree.

According to the licensing entity for the Hawai’i DOE, the Hawai’i Teacher Standards Board, the only other graduate level program that offers this specialty area located in Hawai’i is at Chaminade University. According to the 2021-2022 Chaminade Graduate Catalog (https://catalog.chaminade.edu), Chaminade offers a Master of Science in Counseling Psychology in a campus-based format. Their School Counseling specialty area is a 60-credit degree at a cost of $1,030 per credit. This amounts to approximately $61,800 for degree completion at Chaminade. The proposed MEd in School Counseling will be 48 credits. The cost is approximately $650 per credit via Outreach College (Tuition and Fees | University of Hawai’i at Mānoa Outreach College) and will amount to about $31,200 plus fees. This cost savings will make this graduate degree affordable and attractive to residents and non-residents alike. The program will seek approval from the Hawai’i Teachers Standards Board for licensure in School Counseling.

E. Includes enrollment and completion estimates with an explanation on how
As presented in the Program Outcomes earlier, we estimate the number of this graduate level program will accept 10-15 students to start the program in the Fall of 2023. We expect to have our first graduates in the Spring of 2026. Based on the closely aligned KRS RCEP program, we expect a retention rate of at least 82% (the average retention rate from 2009-2016 in RCEP), which amounts to 8-12 students graduating in 2026.

F. Please complete tables 1 and 2 below.

Table 1. Enrollment Projects: Provisional Years

<table>
<thead>
<tr>
<th>Projected Enrollment</th>
<th>Year 1¹</th>
<th>Year 2²</th>
<th>Year 3³</th>
<th>Year 4</th>
<th>Year 5</th>
<th>Year 6</th>
<th>Current Year</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>10-15</td>
<td>20-30</td>
<td>30-45</td>
<td>30-45</td>
<td>30-45</td>
<td>30-45</td>
<td></td>
</tr>
</tbody>
</table>

Notes: ¹In Year 1, one cohort of 10-15 students will be admitted in each track; ²In Year 2, a second cohort of 10-15 students will be admitted. Two cohorts of 20-30 students will run concurrently in Year 2; ³In Year 3, a third cohort will be admitted; three cohorts of 30-45 students will run concurrently from Year 3 forward.

Table 2. Program Completion Projection

<table>
<thead>
<tr>
<th>Projected Program Completion (annual)</th>
<th>Year 1¹</th>
<th>Year 2²</th>
<th>Year 3²</th>
<th>Year 4</th>
<th>Year 5</th>
<th>Year 6</th>
<th>Current Year</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
<td>0</td>
<td>8-12</td>
<td>8-12</td>
<td>8-12</td>
<td>8-12</td>
<td></td>
</tr>
</tbody>
</table>

Notes: ¹The MEd in School Counseling is a three-year program and will not have any graduates at the end of Years 1 and 2; ²Beginning in Year 3, one cohort will graduate every year. A retention rate of 82% or higher (the average retention rate from 2009-2016 for the MS KRS in RCEP) is expected.

III. Program Organization

A. Provide a description of curriculum organization, total credits to complete the program including all prerequisites requirements, admission policies, advising, and other aspects of the program, with reference to its goals/outcomes. Provide additional justification if the program is more than 120 credits (bachelor’s).

The proposed graduate level degree is a distance education program leading to a Master of Education in School Counseling. Nationally, school counseling programs range from 48-60 credits and include Master of Arts in Education, Master of Science in Education, Master of Education, Master of Arts, and Master of Science degrees. A Master of Education degree often includes the following majors: curriculum and instruction, counseling, school psychology, and administration. The Master of Arts degree is a degree option that is focused on areas such as the humanities. The Master of Science degree option is usually for programs that are more focused on scientific and mathematical subjects.
This School Counseling (SC) program will share core requirements with the graduate level KRS RCEP (see appendix). Sharing core requirements across different counseling specialty areas is a common practice for graduate level counseling programs nationally. This SC program will share 9 core courses with RCEP that include common curricular areas in counseling: Professional counseling and ethical practice, social and cultural diversity, human growth and development, career development, counseling and helping relationships, group counseling and group work, practicum, crisis intervention, and research and program evaluation. In alignment with the KRS department, the mission of the program is to offer graduate level training that is designed to promote practical implementation of essential knowledge, skills, and attitudes necessary to produce knowledgeable and skillful practitioners in the field of school counseling. The RCEP and SC programs differ in the areas of specialty and target population and will offer courses to address these specialty requirements. RCEP produces graduates who are prepared to work as a Rehabilitation Counselor in the community as part of state or federal vocational rehabilitation agencies, private or non-profit support agencies, substance abuse treatment agencies, mental health agencies, correctional facilities and in post-secondary settings, such as disability services on college campuses. Rehabilitation Counselors work with adults. By contrast, School Counselors work with the K-12 school population including students with disabilities, students from military families, and linguistically diverse students and their families. A strong theoretical foundation as well as a hands-on, in-depth practicum and internship will provide the framework for the proposed program. We propose a high-quality graduate school counseling education program that meets the ethical, curriculum, and performance Standards of the Hawai‘i Teacher Standards Board (HTSB), the American School Counselor Association (ASCA), and the Association for Advancing Quality in Educator Preparation (AAQEP) national standards. The ASCA national standards are also embodied in the program outcomes as outlined:

- To prepare students with knowledge and techniques in school counseling;
- To prepare students with knowledge of research and development in counseling and with skills for applying, conducting, and evaluating school counseling programs;
- To provide opportunities for students to develop understanding of ethical practices in school counseling through demonstration, research, program development, faculty consultation, and in-service practicum in education;
- To increase student’s level of multicultural and linguistic diversity awareness, knowledge, and skills, especially as applied to school counseling.

Overview:
The proposed 48-credit distance education program leads to a Master of Education in School Counseling. The program consists of 16 3-credit courses, nine of which are already offered in the Rehabilitation Counselor Education Program (RCEP), and seven 3-credit courses that are not currently being offered. The suggested course sequence shows students will take 3 years to complete the program. In practice, this means full-time attendance or 6 credits in 6 regular semesters and 2 summer sessions and includes both online courses and fieldwork (see attached 3-Year Program Plan). A new cohort of students (10-15) will be admitted each fall. Therefore, from the 3rd year forward, three cohorts of students (30-45) will be enrolled in the program.

Licensure:
The curriculum in the MEd in School Counseling is proposed to meet licensure requirements of the Hawai‘i Teacher Standards Board (HTSB). The HTSB “school counselor performance standards align with the American School Counselor Association (ASCA) National Model and contain basic standards of practice expected from counselors” (htsb.org NBI 11-53). The HTSB has approved a Letter of
Intent to Plan a School Counseling program at UHM (see NBI 20-15 in attachments). Once the program is approved at UHM, a proposal will be submitted to HTSB for approval. Once approved, graduates of the program will be eligible to apply to HTSB for a license as a School Counselor, K-12.

Delivery Options:
The program will be delivered entirely online in both synchronous (typically meeting once a week) and asynchronous formats. Synchronous graduate classes in the COE often begin at 4:30 pm HST to accommodate working students; however, other time slots will be considered. In addition, students will participate in 3 semesters of field experiences in a K-12 school.

Alternate Time Frames:
The program offers various electives synchronously and/or asynchronously during the summer for students to complete course requirements.

Program Components:
In alignment with the framework of the American School Counseling Association (ASCA) and the Hawai’i Teacher Standards Board (HTSB), the proposed program will include graduate level courses on the following topics, as well as additional departmental requirements:

- Foundational knowledge and competency in the professional specialty of school counseling, including: (a) normal and abnormal developments in physical, cognitive, emotional, social, and personality areas; (b) theories of counseling; (c) individual and group counseling methods; (d) career development, career guidance, and vocational counseling; (e) differences related to ethnicity, culture, sex-membership, and lifestyle; (f) professional literature and research; (g) theories and procedures in assessment and evaluation; and (h) ethical and legal principles of counseling.

- In-service learning requirements:
The program must include significant supervised experiences, a minimum of 600 hours across at least two semesters. At least 40 percent of the supervised experiences should be direct contact hours. Students who fail to attain a grade of B or better in practicum/internship will not be allowed to continue in the program. Supervisors must be appropriately credentialed (commensurate with program goals and relevant state requirements). Faculty supervisor to student ratio must allow for sufficient oversight and meet accreditation requirements (if any). The accrediting body AAQEP does not specify any student to faculty ratio for supervision. It is left to the institution to justify that they have adequate faculty (see section V. B. Page 17 for further accreditation information).

  Supervised practicum/internship include:
  • 100 hours of supervised practicum over 1 semester
  • 600 hours of supervised internship over 2 semesters

- Candidates may elect to follow either Plan A (Thesis) or Plan B (Portfolio) to complete their program of studies.

- Admissions Requirements
The proposed MEd in School Counseling admission is based on previous preparation and background, intellectual and affective potential for graduate study, and personal qualifications that contribute to success as a school counselor. As defined by UH Mānoa’s Graduate Division, “To be eligible, an applicant must hold or expect to hold prior to
matriculation a bachelor’s degree from a regionally accredited U.S. college or university, or an equivalent degree from a recognized non-U.S. institution of higher education. At minimum, the applicant needs to demonstrate above average academic performance (B average, usually a 3.0 on a 1.0-4.0 scale) for undergraduate course work and for any post-baccalaureate or graduate course work. Because the number of qualified applicants exceeds the number of spaces available, admission is competitive. Meeting minimum admissions standards does not guarantee admission.” If applicable, specific exams or other options approved by the HTSB must be passed prior to the application deadline to meet license requirements and national accreditation requirements.

- Required documents should show evidence that an applicant’s personal qualifications, motivation, and academic preparation indicate competence and potential success in school counseling. These include: Three letters of recommendation relating to the candidate’s personal qualifications and/or professional background; one official transcript for each institution of higher education attended; statement of objectives; writing sample; and interview.

- Upon acceptance, all practicum and internship students are required to submit proof of liability insurance prior to their prospective course start dates. In addition, each student must go through the Hawaiʻi DOE screening and fingerprinting process prior to all field-based classes where graduate students are in a DOE school setting.

For a full list of required courses, practicum/internship courses, and possible elective courses see: School Counseling List of Courses for a complete description of the courses and alignment with ILOs and Standards). All course syllabi have been updated to reflect current research and best practices.

Courses Required in School Counseling and offered in Rehabilitation Counseling (9 of 16)

KRS 605 Human Growth and Development—Life Span (3)
KRS 606 Counseling: Theory and Practice (3)
KRS 626 Introduction to Practicum (3)
KRS 627 Career Development and Vocational Counseling (3)
KRS 628 Research and Evaluation in Rehabilitation (3) (UHM Form 2 submitted to reflect focus on school counseling and rehabilitation counseling)
KRS 629 Counseling: Group Theory and Practice (3)
KRS 633 Crisis Intervention (3)
KRS 637 Cross-Cultural Counseling (3)
KRS 685 Ethical Issues for the Helping Profession (3)

Courses Required in School Counseling Only (6 of 16)

KRS 600 Counseling in the Schools (3)
KRS 630 Tests and Inventories in Guidance (3)
KRS 703 (Alpha) Practicum in Counseling (V) Supervised clinical experience
KRS 733 (Alpha) Internship I (V) Supervised post-practicum experience in counseling and guidance
KRS 734 (Alpha) Internship II (V) Supervised post-internship I experience in counseling and guidance KRS 741 Seminar in School Counseling (3)
One Elective Course Required (3): Examples include:

KRS 631 Problems of School Adjustment (3)
KRS 632 Theory and Assessment of Intelligence (3)
KRS 684 Psychopathology in Counseling (3) (UHM Form 2 submitted to accurately reflect the school counseling program and to remove the prerequisite)

B. Describe provisions for articulation with UHCCS.
Articulation agreements with community colleges in Hawai‘i will not be needed as this is a graduate program.

C. Relevant program/academic plans
   - 3-Year Academic Plan
   - School Counseling List of Courses
   - Courses with ILOs and Standards
   - NBI 20-15: HTSB Approval of Intent to Plan a Program in School Counseling
   - Course Syllabi

CII. Please complete Table 3 below.
Table 3 displays the number of new courses that will be offered, the number of new sections, and the annual SSH for the program. New courses were identified if they are not currently being offered in any program. At present, 9 of the 16 courses in the School Counseling program are being offered to students in the Rehabilitation Counseling program; therefore, not considered new. Therefore, seven new courses will be offered over the three years of the program; multiple sections of the practicum and internship courses will be offered. Section numbers exceed the number of new courses offered.

<table>
<thead>
<tr>
<th>Year 1</th>
<th>Year 2</th>
<th>Year 3</th>
<th>Year 4</th>
<th>Year 5</th>
<th>Year 6</th>
<th>Current Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of new courses offered</td>
<td>2</td>
<td>4</td>
<td>7</td>
<td>7</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Number of new sections offered</td>
<td>2</td>
<td>7</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Annual SSH (Total cr taken by Ss x # Ss)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>216 (18 cr. x 12 Ss)</td>
<td>432 (18 cr. x 24 Ss)</td>
<td>648 (18 cr. x 36 Ss)</td>
<td>648 (18 cr. x 36 Ss)</td>
<td>648 (18 cr. x 36 Ss)</td>
<td>648 (18 cr. x 36 Ss)</td>
<td></td>
</tr>
</tbody>
</table>

(Projected 10-15 students admitted yearly; average of 12 students per cohort used for this chart)
Yr. 3 and all subsequent years, 36 students x 48 cr. = 648 SS

IV. Program Resources and Efficiency
A. What operating and instructional resources will the program need and where will they come from? What are the program’s facilities needs?
The proposed MEd in School Counseling will not require new funding and is expected to use existing COE resources. Additional cost savings and revenue will be generated from offering the
program through Outreach College. It is aligned closely with the KRS RCEP program and differs in specialization. The opportunity to utilize elements of the successful KRS RCEP program allows for the best use of resources and creates a wealth of knowledge for the students to tap into. There are 9 courses that overlap between the two programs. Current tenured faculty can teach these shared courses in both programs utilizing this format, which is common practice in most other counseling programs, including national and benchmark institutions. Examples of accredited Rehabilitation and School Counseling programs using shared courses are Northeastern Illinois University, Kent State University, and Wright State University. This format maximizes student enrollment and faculty utilization. Additionally, using Outreach College as the venue for this program provides consistency between both online programs, allows for statewide access, and offers low overhead costs to operate the program.

Two additional faculty will eventually be needed to support the MEd in School Counseling, particularly the specialized courses. The College plans to provide them incrementally in the time frame required through internal reallocation based on current and expected retirements and through funds generated by program enrollment. We will need the campus to approve these hiring actions within existing COE resources. These faculty will contribute to both the SC and the RCEP master’s programs.

The proposed program is an online program that does not require the use of classrooms or other facilities, thus saving the University on operating costs. New faculty hires can be accommodated through existing office spaces.

B. What are the risks associated with this program?
The College of Education is experienced in implementing successful teacher preparation programs. Potential risks are routinely reviewed and include practices such as requiring practicum and internship students to obtain liability insurance and requiring all faculty who supervise counseling candidates to pass a background check. In addition, the Hawai‘i DOE institutes screening and fingerprinting of graduate students completing internship hours in a DOE school setting. As illustrated by personnel and operating costs in Tables 4 and 5 (below), the MEd in School Counseling is a resource-generating program. If enrollment numbers are not as anticipated, there is a risk that personnel costs will exceed revenue. No additional risks are anticipated. Given the shortage of school counselors in Hawai‘i, and the lack of a statewide program at present, there is little to no risk that there will be employment difficulties for program graduates.

C. What impact will developing this program have on resource (re)allocation in the unit?
There will be minimal impact on resources in developing this program. Current faculty will teach shared courses between the proposed program and KRS RCEP. The two additional positions needed for this program will be reallocated from current and expected retirements in alignment with the COE’s reorganization plans. As previously stated, we will need the campus to approve these hiring actions within existing COE resources. These faculty members will contribute to both the School Counseling and the Rehabilitation Counselor Education master’s programs. These positions are needed to teach shared courses between School Counseling and KRS RCEP, as well as specialized courses in School Counseling. Additionally, funds generated through Outreach College are projected to exceed the costs of the program from Year 3 forward to support unanticipated expenses.

D. List similar programs that currently exist in the UH system. Describe how this program
compares and provide a justification for a new program in this field.

There are no programs available in the University of Hawai‘i system that offer the specialty area of school counseling. UH Hilo offers a Master of Arts in Counseling Psychology with a specialization in clinical mental health counseling, which differs from a school counseling program. School counselors focus on the academic, emotional, social, and behavioral issues that impact learning in schools. They provide career and college, individual, group, and classroom guidance and counseling sessions. A school counseling program focuses on these school specific interventions and strategies in a K-12 educational setting. The UH Hilo MA in Counseling Psychology program provides graduate training in clinical mental health counseling and not in school counseling. Their program is designed to train students to become therapists who will be able to help those in need of therapy and clinical counseling services, which is not aligned with school counseling. Additionally, the UH Hilo MA in Counseling Psychology is not approved by the Hawai‘i Teachers Standards Board; therefore, graduates are not eligible for licensure as a School Counselor in Hawai‘i.

The HTSB website lists the preparation programs approved in Hawai‘i: Preparation Programs. For School Counseling, the only program approved by HTSB is with Chaminade University: Behavioral Sciences Division in the field of School Counselor (K-6, 6-12, K-12).

The need for this program is evidenced by the limited opportunities for prospective students to attend a graduate level program in the specialized area of School Counseling located in Hawai‘i and approved by the Hawai‘i Teachers Standards Board. The cost to attend the school counseling program will also fill a need to offer a financially feasible program for Hawai‘i resident students to attend since it will cost half of what it costs to obtain the Chaminade degree in school counseling.

E. Has there been consultation at the program level between campuses and within the originating campus? Please provide documentation of who was consulted, in what capacity, and when? Provide a summary of the results of the consultation.

The school counseling proposal emerged from conversations with the UH Mānoa administration to address the statewide need for licensed school counselors. Prior to February 2020, VP Don Straney approached the Dean of the College of Education and inquired about the COE’s ability and willingness to offer a graduate level School Counseling program. Since School Counseling was previously offered in the COE, it was reasonable to consider reviving the program with current resources. It was discussed that UH West O‘ahu also was interested in offering a School Counseling program and was in conversation with the UH system. Since Mānoa is already a graduate degree granting institution and previously offered School Counseling as a graduate level program, the UHM COE was asked to consider reviving the program.

Between February and September 2020, the Dean initiated and held ongoing conversations within the COE with the chairs of all departments, at the Dean’s Council meetings, and in KRS with the chair and faculty. After receiving feedback and support from the COE [i.e., COE Faculty Senate, Committee on Curriculum and Program Planning (CCPP)], the ATP was submitted in September 2020 and approved in April 2021. Based on the feedback of the Council of Chief Academic Officers (CCAO), Dr. Murata consulted with UH Hilo to discuss the possibility of shared resources between the UH Hilo MA in Counseling Psychology program and the proposed School Counseling (SC) program. Due to programming challenges, cost sharing was not feasible at that time. Furthermore, the faculty at the UH Hilo Counseling Psychology program are licensed and trained in a different focus (clinical) and have limited or no experience in school counseling. This may impact accreditation for both
In February 2022, based on the recommendation of the Graduate Council, additional consultation and letters of support were received by Dr. Murata from Dr. Bryan Kim, the former Director of the UH Hilo MA in Counseling Psychology program and current Chair of the Division of Social Sciences in the College of Arts and Sciences at UH Hilo, and Nicole Colello, President of the Hawai‘i Association of School Counselors (see attached). Both outlined support for the COE’s proposed SC program to address the need for licensed school counselors. Also, on January 31, 2022, Dr. Jessica Miranda from the COE consulted with AAQEP staff to determine necessary steps for accreditation (see more in Section V below).

F. Please complete tables 4-6 below.

A cohort of 10-15 students will be admitted yearly; an average of 12 students per cohort was used to generate data for Table 4. As a new cohort is admitted, across their first year (Fall, Spring, and Summer semesters) the students will enroll in a total of 18 credits. With an Outreach College graduate tuition rate of $650/credit and a total of 12 students, this will generate $140,400 in tuition in Year 1. In Year 2, a second cohort will begin, yielding 24 new students. Students in the two cohorts will enroll in 18 credits each for Year 2 of the program. With two cohorts running, 24 students x 18 credits x $650/cr = $280,000 will be generated as tuition revenues in Year 2. In Year 3 we will reach capacity with three concurrent cohorts, from that year forward. In Year 3, 36 students will enroll in 18 credits each, and $421,200 in tuition revenues will be generated yearly from that point forward. If a maximum of 15 students per cohort are admitted, the revenues will exceed those listed in Table 4. At present, Outreach College retains 27% of the revenues, returning 73% to the College of Education. From Year 3 forward, this would result in revenue of approximately $113,724 for Outreach College and $307,476 for the College of Education annually. These program revenues will exceed the costs to fund this new program.

Table 4. Existing Resources and Funding (Funding Generated through Outreach College)

<table>
<thead>
<tr>
<th>Year 1</th>
<th>Year 2</th>
<th>Year 3</th>
<th>Year 4</th>
<th>Year 5</th>
<th>Year 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Existing Resources</td>
<td>1 tenure track full professor - RCEP and SC</td>
<td>1 tenure track full professor - RCEP and SC</td>
<td>1 tenure track full professor - RCEP and SC</td>
<td>1 tenure track full professor - RCEP and SC</td>
<td>1 tenure track full professor - RCEP and SC</td>
</tr>
<tr>
<td>Combined Tuition/Summer/Course Fees</td>
<td>12 students x 18 cr x $650 = $140,400 COE: $102,492</td>
<td>24 students x 18 cr x $650 = $280,800 COE: $204,400</td>
<td>36 students x 18 cr x $650 = $421,200 COE: $307,476</td>
<td>36 students x 18 cr x $650 = $421,200 COE: $307,476</td>
<td>36 students x 18 cr x $650 = $421,200 COE: $307,476</td>
</tr>
<tr>
<td>Other Allocation (Grants)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Outreach College tuition = $650/cr. resident
As previously mentioned, two additional faculty will be needed to support the MEd in School Counseling. The College plans to provide them incrementally in the time frame required through internal reallocation based on current and expected retirements and expected revenue through Outreach College. The first faculty position will be through internal reallocation. The College expects funds generated through Outreach College from Year 3 on out to be applied towards the second faculty position (see Table 4 and 5). These faculty will contribute to both SC and RCEP programs.

Table 5. Anticipated NEW Personnel (supported by funds generated through Outreach College and by internal reallocation of positions in the COE)

<table>
<thead>
<tr>
<th>Personnel</th>
<th>Year 1</th>
<th>Year 2</th>
<th>Year 3</th>
<th>Year 4</th>
<th>Year 5</th>
<th>Year 6</th>
<th>Current Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Tenure Track Faculty</td>
<td>1 new</td>
<td>1 new &amp; 1 continuing</td>
<td>2 continuing</td>
<td>2 cont.</td>
<td>2 cont.</td>
<td>2 cont.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$65,000</td>
<td>$130,000</td>
<td>$130,000</td>
<td>$130,000</td>
<td>$130,000</td>
<td>$130,000</td>
<td></td>
</tr>
<tr>
<td>Total Cost</td>
<td>$65,000</td>
<td>$130,000</td>
<td>$130,000</td>
<td>$130,000</td>
<td>$130,000</td>
<td>$130,000</td>
<td></td>
</tr>
</tbody>
</table>

Other program costs: Instructional and office supplies are minimal and can be absorbed by the College. There will not be new library costs associated with the MEd in SC. Most of these resources are electronic and can be used by multiple students concurrently. Because the MEd in SC is to be delivered primarily online, classroom space is not required. There will be additional costs for mileage and travel expenses to conduct practicum supervision, which will be covered by funds generated through Outreach College. Virtual observation tools, such as GoReact, will also be considered to supplement face-to-face supervision, and lower travel/mileage costs.

Table 6. Anticipated NEW Operating Costs (funds available generated through Outreach College)

<table>
<thead>
<tr>
<th>New Operating Costs- mileage &amp; travel for practicum supervision</th>
<th>Year 1</th>
<th>Year 2</th>
<th>Year 3</th>
<th>Year 4</th>
<th>Year 5</th>
<th>Year 6</th>
<th>Current Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>$5000</td>
<td>$7500</td>
<td>$10,000</td>
<td>$10,000</td>
<td>$10,000</td>
<td>$10,000</td>
<td>$10,000</td>
<td></td>
</tr>
</tbody>
</table>

V. Program Effectiveness

A. Briefly describe (one paragraph or less) the plan for assessing the quality of student learning.

The proposed program will adhere to the guidelines of the KRS department in assessing student learning, including embedded student assessments in each course, end-of-course evaluations for all courses, and required end-of-semester student reflection activities. Student learning will also be assessed through field work observation evaluations from site supervisors and instructors. Internship site supervisors and instructors will have the opportunity to provide feedback and guidance to students on a regular basis. To gather additional feedback about student learning and program responsiveness, we plan to assess students via an online survey after their first year of the program. We also hope to conduct a follow up survey upon graduation to understand the impact of the graduate degree on their professional and personal life. The data will be analyzed, and the findings will be presented to faculty, students, and other stakeholders. The findings of the data will help shape future direction of course development and program implementation to support a high-quality education and experience for the students. The assessment plan will include multiple assessment measures from program entry to post-completion, including both direct measures of student performance through course and clinical observation assessments, as well as indirect measures through
end-of-course evaluations and surveys administered during the program, at the time of completion, and post-graduation.

B. Identify relevant program accreditation and plans to meet accreditation requirements.

The program will seek national accreditation through the Association for Advancing Quality in Educator Preparation (AAQEP). The program is being designed to align with AAQEP's standards to ensure that the program meets all accreditation requirements set forth by AAQEP. In June 2021, sixteen of the College of Education’s (COE) academic programs were awarded full national 7-year accreditation (through June 30, 2028) by AAQEP with no conditions or concerns cited. The COE was the first institution to be awarded national AAQEP accreditation of doctoral programs. AAQEP was founded by educators in 2017 to promote the preparation of effective educators and other school professionals in innovative, outcome-focused programs that engage education’s toughest challenges directly and in context. AAQEP’s comprehensive standards for educator preparation specify aspects of completer performance and program practice that identify effective programs and that qualify those programs for AAQEP accreditation. AAQEP currently has awarded accreditation to two school counseling programs: Utah State University and Northwest Missouri State University. In addition, the University of the Virgin Islands has a school counseling program in the pipeline for AAQEP accreditation review.

Once approved by the University, the program will seek approval from the Hawai‘i Teacher Standards Board to fully license graduates in the specialty area of School Counseling. The School Counseling program faculty and the COE’s Director of Assessment, Accreditation, and Accountability, Jessica Miranda, met with AAQEP staff on January 31, 2022, to determine the necessary steps to pursue AAQEP accreditation for a new program when the institution currently holds AAQEP accreditation for other programs. They informed us that once the School Counseling program is approved both by the university and by the HTSB, then we can submit the AAQEP Substantive Change Request Form, which will officially notify them of our new program and initiate the process of determining when full accreditation review of the new program will take place. Faculty hired for the SC and RCEP Program will have met minimum requirements in specialty areas. There were no issues surrounding a minimum number of qualified faculty required for accreditation.


MEMORANDUM

TO: David Lassner
   President

VIA: Michael Bruno
    Provost

VIA: Laura Lyons
    Interim Associate Vice Chancellor for Academic Affairs

VIA: Krystyna Aune
    Dean, Graduate Division

FROM: Nathan M. Murata
      Dean

SUBJECT: Request Approval of ATP for a Master of Education in School Counseling

SPECIFIC ACTION REQUESTED:
It is requested that the President approve the Authorization to Plan (ATP) for a Master of Education in School Counseling, College of Education, Department of Kinesiology and Rehabilitation Science (KRS), University of Hawai‘i at Mānoa.

RECOMMENDED EFFECTIVE DATE:
Upon approval, first cohort to enter Fall 2024.

ADDITIONAL COST:
Two additional faculty positions will be needed. The College plans to provide them in the time frame required through internal reallocation based on current and expected retirements. We will need the campus to approve these hiring actions within existing COE resources.
PURPOSE:
The College of Education proposes to offer a Master of Education in School Counseling further known as MEd in School Counseling. The mission of the program is to offer graduate level training that is designed to promote practical implementation of essential knowledge, skills, and attitudes necessary to produce knowledgeable and skillful practitioners in the field of school counseling.

BACKGROUND:
School counselors are considered a vital part in recognizing and addressing youth mental health and wellness appropriately in the K-12 setting. The University is in a position to provide much needed graduate level specialization to address this urgent national and local need. There are no programs available in the University of Hawai‘i system that offers the specialty area of School Counseling. The opportunity to utilize elements of the successful KRS program allows for the best use of resources and creates a wealth of knowledge for the students to tap into.

ACTION RECOMMENDED:
It is recommended that the President approve the Authorization to Plan (ATP) for a Master of Education in School Counseling, College of Education, Department of Kinesiology and Rehabilitation Science (KRS), University of Hawai‘i at Mānoa.

UPDATED: Officers (meeting date): 04/19/2021
CCAO (meeting date): 04/21/2021


David Lassner
President

April 29, 2021

Date

Attachments:
1. ATP – MEd in School Counseling
ATTACHMENT

Authorization to Plan MEd in School Counseling

1. **Campus, school/college and department/division proposing the new program**
   The University of Hawai‘i at Mānoa, College of Education, is proposing a Master of Education in School Counseling.

2. **Degree proposed and program objectives**
   We propose a Master of Education in School Counseling, a specialized field of study. Once approved, the program will be submitted to the Hawaii Teacher Standards Board (HTSB) for approval in School Counseling (K-12). The objectives of the proposed program are to:
   - Provide a graduate level education in school counseling, which is currently not offered in the University of Hawaii system.
   - Assist the State of Hawaii by providing a new entry point for prospective school counselors to obtain HTSB licensure.
   - Assist the State of Hawaii by providing another option for residents to obtain a high quality and cost-efficient graduate level degree in School Counseling.
   - Deliver an online graduate program statewide to allow students on Oahu as well as the neighbor islands to enroll in the program.

   The proposed graduate level degree is a distance education program leading to a Master of Education in School Counseling. Nationally, school counseling programs range from 48-60 credits and include MEd, MS, and MA degrees. A Master of Education degree often includes the following majors: curriculum and instruction, counseling, school psychology, and administration. The Master of Arts degree is a degree option that is focused on areas such as the humanities. The Master of Science degree option is usually for programs that are more focused on scientific and mathematical subjects. School counseling programs vary across IHEs; including Master of Arts in Education, Master of Science in Education, Master of Education, Master of Arts, and Master of Science.

   This School Counseling program will share core requirements with the graduate level KRS Rehabilitation Counselor Education Program (RCEP). In alignment with the KRS department, the mission of the program is to offer graduate level training that is designed to promote practical implementation of essential knowledge, skills, and attitudes necessary to produce knowledgeable and skillful practitioners in the field of school counseling. Our graduates will be prepared to effectively work with a diverse K-12 student population, including students with disabilities, students from military families, and linguistically diverse students and their families. A strong theoretical foundation as well as a hands-on, in-depth practicum and internship will provide the framework for the proposed program. We propose a high-quality graduate school counseling education program that meets the ethical, curriculum, and performance Standards of the Hawaii Teacher Standards Board (HTSB), and the American School Counselor Association (ASCA) and the Association for Advancing Quality in Educator Preparation (AAQEP) national standards. The ASCA national standards are also embodied in the program outcomes as outlined:
   - To prepare students with knowledge and techniques in school counseling;
   - To prepare students with knowledge of research and development in counseling and with skills for applying, conducting, and evaluating school counseling programs;
• To provide opportunities for students to develop understanding of ethical practices in school counseling through demonstration, research, program development, faculty consultation, and in-service practicum education;
• To increase student’s level of multicultural and linguistic diversity awareness, knowledge, and skills, especially as applied to school counseling.

3. Alignment with the Campus and UH system mission, strategic plan and the Integrated Academic and Facilities Plan (https://www.hawaii.edu/offices/aa/IAFP_BOR_Approved_April17.pdf).
The proposed graduate program aligns with the UH Strategic Directions (2015-2021) in the following areas:

Hawai'i Graduation Initiative (HGI)

a. **HGI Action Strategy 2: Implement structural improvements that promote persistence to attain a degree and timely completion.**

The proposed program provides an online format which will expand opportunities statewide for Native Hawaiian students, under-represented populations, military/veterans and their families, returning adults, and online students. Summer sessions are incorporated in the design to best support student success.

b. **HGI Action Strategy 3: Anticipate and align curricula with community and workforce needs.**

This proposed program will address the workforce and community needs in the Hawai'i DOE in the area of school counseling and in the community priority and identified critical gap area of Health and Wellness (see below).

c. **HGI Action Strategy 4: Increase delivery of online courses and degrees, while maintaining other distance delivery modes (interactive TV, cable TV, and off-campus face-to-face instruction.)**

The proposed program will be designed to deliver online courses targeting graduate students statewide. Professional development and distance teaching support for faculty from the COE will be provided to deliver quality and effective courses and services. Additionally, online student services will be provided to support academic success in various forms from application to program completion.

Hawai'i Innovation Initiative (HII)

d. **HII Action Strategy 3: Invest internal resources and seek external resources for strategic infrastructure requirements and hires that leverage our location and strength as well as address critical gaps.**

• **Health and Wellness**

The proposed program addresses one of the stated critical gaps identified as a community priority, Health and Wellness, as school counseling is commonly described under the umbrella or aligned with the profession of counseling. The proposed program will seek approval from the Hawai'i Teacher Standards Board to fully license graduates in the specialty area of School Counseling (K-12).
e. **HPS Action Strategy 1: Employ best practices in management, administration and operations.**

Currently, there are no competing, existing, or duplicate programs for the specialty area of School Counseling in the University of Hawai‘i system. Additionally, the proposed program supports best practices in management, administration, and operations by utilizing current structures in place to provide students with a new opportunity. The proposed MEd in School Counseling program is implementing common core and elective classes with the current KRS Rehabilitation Counseling program and will therefore save the University on some instructor and overhead costs, as well as maintaining a robust student class size.

4. **Justification of need** that includes a clear rationale for the new program with as much direct evidence as possible. If justification is not tied to employment or industry need, the rationale should include evidence that the proposed program is linked with high priority initiatives of the campus or system.

According to the U.S. Bureau of Labor Statistics, school counseling as a profession has a national employment projected growth rate of 8% between 2018-2028, faster than the average of all other occupations. Nationally, most colleges of education within public universities offer a graduate school counseling program as part of their service commitment to P-12 schools. Currently, there are no programs that provide licensure for the specialty area of School Counseling in the University of Hawai‘i System. The proposed program will seek approval from the Hawai‘i Teacher Standards Board to fully license graduates in the specialty area of School Counseling K-12 to address the constant need for school counselors in the DOE. Although it has not been deemed a shortage area, vacancies in school counseling continue to go unfilled. According to Hawai‘i DOE Assistant Superintendent Cindy Covell (personal communication 8/10/20), as of August 10, 2020, the DOE has **571 school counselor positions statewide** and **18 existing vacancies**. The only program in the state of Hawaii providing licensure for School Counselors approved by the Hawaii Teacher Standards Board is Chaminade University, which under normal circumstances (pre-COVID) offers an in-person based program only to serve the island of O‘ahu. Based on the 2018 Hawaii Teacher’s Standards Board report, in 2016-2017 21 students graduated from the Chaminade school counseling program, and 18 completed the program in 2017-2018. **ANNUAL STATE APPROVED TEACHER EDUCATION PROGRAM REPORT 2018 Section I.**

– EPP Profile

The proposed program also addresses one of the stated critical gaps identified as a community priority, Health and Wellness, as school counseling is commonly described under the umbrella or aligned with the profession of counseling. A steady pipeline into the profession is needed so the DOE is not left with uncertified counselors in counseling positions providing critical services and care to the students. Additionally, school counselors will play an essential role in helping students re-adjust to school and life regarding the trauma of COVID impacting schools, families, and students.

The MEd in School Counseling responds to the national and local need to better address a growing population of culturally and linguistically diverse students and their families and speaks directly to the COE’s Strategic Planning Framework Principle: Native Hawaiian Place of Learning
and Teaching (college-wide presentation by Dr. Murata, 8-20-20). The unique quality of the University of Hawai‘i at Mānoa is the ability to provide graduate students with an education immersed in Native Hawaiian culture and diversity. The demographic make-up of the student population in KRS includes a culturally-diverse student body, faculty, and staff. The outcome of this type of experience is graduates who are better equipped to work in schools with students representing diverse backgrounds and beliefs. By offering the program online, we offer the opportunity for those living and working in the outer islands and rural areas to become licensed school counselors. Additionally, the program will be utilizing local public and charter schools for school counseling internships, which allow for authentic experiences in a culturally diverse school setting and grounds the COE’s principle to commit to actualize a Native Hawaiian place of learning and teaching. The School Counseling internship embeds collaboration and instruction between the DOE faculty, UH faculty, and students. This addresses the COE’s 2nd Strategic Planning Principle of Collaboration, Partnerships and Community. The internship collaboration with the DOE and online format prepares students from all geographic areas, including outer islands and rural areas, to train and eventually work and serve in the communities they live in. This provides the state DOE with certified counselors who live in hard to fill areas.

The proposed MEd in School Counseling also responds to the local and national need of identifying and addressing student mental health and wellness and this is reflected in the COE’s 3rd Strategic Planning Principle of innovate and Inspire. According to the CDC (Data and Statistics on Children’s Mental Health), youth behavioral and mental health issues are on the rise, including depression and anxiety. According to recent data (Mental Health in America - Youth Data), 59% of youth with major depression do not receive mental health treatment across the nation. In Hawai‘i, 58% or about 6,000 youth with major depression do not receive any mental health services. The 2017 Youth Risk Behavior Survey indicates 10% of the high school youth surveyed in Hawai‘i attempted suicide, 16% seriously considered attempting suicide, and 29.5% of high school youth felt sad or hopeless for almost every day for 2 weeks or more that they stopped doing some normal activities (Youth Online: High School YRBS - United States 2017 Results | DASH). School counselors are considered a vital part in recognizing and addressing youth mental health and wellness appropriately in the K-12 setting and are needed more than ever. While too early to determine with certainty, one can predict the pandemic’s impact on youth include increased anxiety and depression among school aged children. As stated by Courtney, D., Watson, P., Battaglia, M., Mulsant, B. H., & Szatmari, P. (2020), “Children and youth are highly vulnerable to the impact of sustained stressors during developmentally sensitive times, and thus, their mental health during and after the pandemic warrants special consideration.” Researchers also point to the underfunding of youth mental health services as a problem and is exacerbated during the pandemic as resources get diverted and identification, assessment, and providing services become more challenging (Coutney et al, 2020). According to Dean Murata’s College-wide address, the COE is committed to providing novel and new ways to inspire and provide constructive change towards a more just and equitable society. The university and specifically the COE is in a unique position to provide a much needed graduate level specialization to address this urgent national and local need.

The School Counseling program will accept 10-15 students to start the program in the Fall of 2024. We expect to have our first graduates in the Spring of 2027. Based on the closely aligned and successful MS in KRS for Rehabilitation Counselor Education Program (RCEP), we expect a retention rate of 82% or higher (the average retention rate from 2009-2016 for the MS KRS in RCEP), which amounts to 8-12 students graduating in 2027. The typical length of time spent obtaining the RCEP
degree was 36 months, and is the expected amount of time for the MEd in School Counseling. Based on the RCEP data, we also expect a 94% or higher employment rate within 6 months of graduating from the program. This addresses the COE’s 4th Strategic Planning Principle - Research to Improve Educational Outcomes and demonstrates the COE’s commitment to innovate, improve, or influence the knowledge base of diverse learners who can contribute to a just society. Additionally, the COE’s School Counseling program provides the opportunity to obtain an MEd in a financially feasible, online format that appeals to non-traditional students who may be returning to school, changing careers, and balancing family and work responsibilities.

5. **Demand for the program** provides data/evidence that there is sufficient unmet demand in one or more of the following areas: student demand, demand for services or intellectual property of the program and/or employer demand.

As stated previously, there are no programs available in the University of Hawai’i system that offer the specialty area of School Counseling. UH Hilo offers a Master of Arts in Counseling Psychology with a specialization in clinical mental health counseling.

According to the licensing entity for the Hawai’i DOE, the Hawaii Teacher Standards Board, the only other graduate level program that offers this specialty area located in Hawai’i is at Chaminade University. According to the 2019-2020 Chaminade Graduate Catalog (pp. 72-86), Chaminade offers a Master of Science in Counseling Psychology in a campus-based format. Their School Counseling specialty area is a 60-credit degree at a cost of $1,000 per credit. This amounts to approximately $60,000 for degree completion at Chaminade. The proposed MEd in School Counseling will be 48 credits. The cost is approximately $663 per credit via Outreach College and will amount to about $31,824 plus fees. This cost savings will make college affordable and attractive to local and non-residents alike. Chaminade University under normal circumstances (pre-COVID) offers an in-person based program only to serve the island of O’ahu. Based on the 2018 Hawaii Teacher Standards Board report, in 2016-2017 21 students graduated from the Chaminade school counseling program, and 18 completed the program in 2017-2018. **ANNUAL STATE APPROVED TEACHER EDUCATION PROGRAM REPORT 2018 Section I. – EPP Profile**

The proposed program will seek approval from the Hawaii Teachers Standard Board (HTSB) for licensure in the specialty area of School Counseling K-12 to address the constant need for school counselors in the DOE. Although it has not been deemed a shortage area, vacancies in school counseling continue to go unfilled. According to Hawai’i DOE Assistant Superintendent Cindy Covell (personal communication 8/10/20), as of August 10, 2020, the DOE has **571 school counselor positions statewide and 18 existing vacancies**. A steady pipeline into the profession is needed so the DOE is not left with uncertified counselors in counseling positions providing critical services and care to the students. Additionally, school counselors will play an essential role in helping students re-adjust to school and life regarding the trauma of COVID impacting schools, families, and students.

School Counseling programs can be regionally or nationally accredited from various bodies. The nationally accredited bodies include AAQEP, the Council for Accreditation of Counseling and Related Educational Programs (CACREP), and Masters in Psychology and Counseling Accreditation Council (MPCAC), all of which currently require a minimum of 48 credits. Our proposed program adequately addresses the minimum requirements to seek national accreditation. The School
Counseling curriculum is also aligned with the KRS Rehabilitation Counselor Education Program (RCEP) curriculum, which is currently accredited by CACREP. In order to continue CACREP accreditation, the COE must have three fulltime faculty devoted to counseling programs. Once there are sufficient faculty and support staff resources for the counseling programs, the COE will reassess accreditation. In addition, CACREP is changing the minimum number of credits from 48 to 60. This School Counseling program will initially be a 48-credit program; not all accreditation bodies require 60 credits (AAQEP). The credit requirements will be reconsidered when national accreditation is pursued.

List of Accredited School Counseling Programs (2020):
AAQEP:
Accredited Programs
CACREP:
Directory
MPCAC:
Accredited Programs

6. **Non-duplication of programs** is addressed by listing all programs with the same degree level offered at other UH institutions.

There are currently no programs offering the specialty area of School Counseling in the UH system and the proposed program will seek approval from the Hawai‘i Teacher Standards Board to fully license graduates in the specialty area of School Counseling.

As previously mentioned, UH Hilo offers a Master of Arts in Counseling Psychology, however that program is not comparable to the proposed program. UH Hilo’s program specializes in mental health counseling for licensure as a Licensed Mental Health Counselor. This is not the same as a School Counseling program, which focuses on knowledge and practical skills in the field of School Counseling and seeks licensure with the HTSB.

According to the HTSB website, these are the approved preparation programs for hire in the HIDOE:  
https://hawaiiteacherstandardsboard.org/content/preparation-programs-2/

For School Counseling, the only approved HTSB program approved is:
Chaminade University: Behavioral Sciences Division

<table>
<thead>
<tr>
<th>Preparation Program Level</th>
<th>License Fields and Grade Levels</th>
</tr>
</thead>
<tbody>
<tr>
<td>Master’s Degree with Licensure</td>
<td>School Counselor (K-6, 6-12, K-12)</td>
</tr>
</tbody>
</table>

The proposed MEd in School Counseling shares many of the core requirements and select elective courses of the KRS RCEP program. The opportunity to utilize elements of the successful KRS program allows for the best use of resources and creates a wealth of knowledge for the students to tap into.

Consultation with both KRS and Dr. Nathan Murata, Dean of the COE, occurred on or before February 25, 2020 regarding this ATP application.

7. **List potential risks** (e.g., insurance, vendor contracts, off-site management) associated with the new program. These potential risks will be fully assessed in the new program proposal.
The College of Education is experienced in implementing successful teacher preparation programs. Potential risks are routinely reviewed and includes practices such as requiring practicum and internship students to obtain liability insurance and requiring all faculty who supervise counseling candidates to pass a background check. In addition, the Hawaii DOE institutes screening and fingerprinting of graduate students completing internship hours in a DOE school setting.

8. **New Resources.** If new resources will be necessary, please identify from where those resources will come.
   Two additional faculty positions will be needed. The College plans to provide them in the time frame required through internal reallocation based on current and expected retirements. We will need the campus to approve these hiring actions within existing COE resources.

9. **Timeline for submission of new program proposal.**
   
   Pending expedited review and approval of the proposal, the timeline is as follows:

   - **Spring 2023**  Advertise the program and recruit
   - **Fall 2023**    Student application period open
   - **Spring 2024**  Acceptance into the program
   - **Fall 2024**    Program starts
Signature Page

Signature indicates that the person has reviewed the ATP and supports the proposed program. Signature page is to be completed prior to submission to the VPAPP.

Nathan Murata  
October 30, 2020
Dean/Department/Division Chair  
Print Name  
Date

Krystyna S. Aune  
October 30, 2020
Dean, Graduate Division (grad only)  
Print Name  
Date

Michael Bruno  
Print Name  
Date

David Lassner  
04/29/2021
President  
Print Name  
Date
Presented to the Mānoa Faculty Senate by the Graduate Council for a vote of the full senate on April 20th, 2022, a resolution supporting the proposal for provisional status for the Master of Education degree in School Counseling. Approved by the Mānoa Faculty Senate on April 20, 2022 with 48 votes (97.96%) in support; 1 vote (2.04%) opposed; and 4 abstentions.

RESOLUTION SUPPORTING THE PROPOSAL FOR PROVISIONAL STATUS FOR THE MASTER OF EDUCATION (MEd) IN SCHOOL COUNSELING

WHEREAS, the Department of Kinesiology and Rehabilitation Science (KRS) in the College of Education has proposed to establish a Master of Education (MEd) in School Counseling to better meet the needs of students who seek to become school counselors licensed by the Hawai‘i Teacher Standards Board (HTSB); and

WHEREAS, the Department of KRS currently offers a MS degree in KRS with a concentration in Rehabilitation Counseling in Education (RCE), and the proposed MEd in School Counseling is designed to share resources by requiring most of the same courses as for the degree in RCE; and

WHEREAS, until 2008 the College of Education offered a 60-credit MEd degree in School Counseling and Guidance; and

WHEREAS, the newly proposed MEd would offer a 48-credit path in School Counseling, and by offering the degree in an online format through Outreach College, KRS aims to make the degree more available to students living and working away from the Mānoa campus and to provide funding for additional positions needed to support the program in the long term; and

WHEREAS, most colleges of education in public universities in the U.S. offer a graduate school counseling degree as part of their service commitment to K-12 schools, at this time the only other program in the state to offer a similar degree is at Chaminade University, while the University of Hawai‘i at Hilo offers an MA in Counseling Psychology with a clinical rather than a K-12 focus; and

WHEREAS, according to the U.S. Bureau of Labor Statistics, the profession of School Counseling has a national employment projected growth rate of 8% between 2018-2028, and the HTSB School Counseling Workgroup Report 2020-2021 found that approximately 45 practicing counselors in Hawai‘i schools were not licensed in the field of School Counseling; and

WHEREAS, the proposal has been reviewed and endorsed by the KRS faculty, the Faculty Senate of the College of Education, the dean of the College of Education, and the Graduate Council; therefore,
BE IT RESOLVED, that the Mānoa Faculty Senate approves the proposal to grant provisional status to the Master of Education degree in School Counseling in the Department of Kinesiology and Rehabilitation Science in the College of Education.

Supporting document:
Final Action Memo for the School Counseling (Revised March 24, 2022)
Final School Counseling Proposal (Revised March 24, 2022)
Dear Mr. Nathan M. Murata,

I am writing in support of the development of a school counseling program at the University of Hawaii, through the College of Education. I believe that the development of this counseling program will inspire future educators to continue to further their own education to help the keiki of Hawaii. School counselors at every level are beneficial in creating safe environments where students can thrive academically, behaviorally, socially and emotionally. We owe it to our keiki to provide them with licensed school counselors who can support their needs and let their voices be heard.

Living through the pandemic the past few years has shown how important school counselors are in listening to students and teaching them how to manage their emotions in a healthy and productive way. If they are not given the tools and opportunities to express themselves then we are not giving them the ability to succeed. The world has seen the value of us prioritizing our mental health and we need to start to prioritize our students’ mental health as well.

I am hoping that with the development of the school counseling program people on outer islands are given the opportunities to learn and grow on the islands that they call home. People who are part of the program would be able to support the keiki on their islands during their internships. There will be no need for students to travel to Oahu for their education and move their livelihoods. Connecting virtually with others the past few years has shown us that we are able to be together even though we are far apart.

I would love to see at least one licensed school counselor at every school who can dedicate their day to helping students achieve their highest potential. An even crazier idea would be to have a school counselor for every 250 students, as suggested by the American School Counselor Association. You can help us get there by allowing and supporting the creation of the...
school counselor program at the University of Hawaii. The decisions you make today will help the keiki of Hawaii tomorrow.

Sincerely,
Nicole Colello
President, Hawaii School Counselor Association
School Counselor, Sunset Beach Elementary
February 3, 2022

Nathan M. Murata, Professor & Dean  
College of Education  
University of Hawaii at Manoa 
1776 University Avenue, Everly Hall 128  
Honolulu, HI 96822

Dear Dean Murata:

My name is Bryan Kim, Ph.D., and I am writing to offer my strongest support for starting a master’s program in school counseling at the University of Hawaii at Manoa’s College of Education. I am a professor of psychology and the chairperson of the Division of Social Sciences at the University of Hawaii at Hilo. I am also a core faculty in the MA Program in Counseling Psychology (Specialization: Clinical Mental Health Counseling) and was its director for 12 years from 2008 to 2020. Given my experiences in our MA training program, I feel that I can speak knowledgeably about the need for a school counseling program at UH Manoa.

In our MA program, we train our students to become clinical mental health counselors and to eventually obtain the license in mental health counseling in the state of Hawaii. We typically admit 20 students each year and we have been receiving far more applications than we can accept; last year, we received over 150 applications. This demonstrates a great interest in the mental health counseling and more broadly in the field of counseling for which school counseling is one of the allied sub-disciplines.

More specific to school counseling, when I was the director of the program, I received numerous inquiries about whether our program offers training in school counseling. Unfortunately, given the different certification requirements for school counselors, compared to mental health counselors, I have had to turn away these potential students. In Hawaii, Chaminade University is the only entity that offers a school counseling program. However, the program is very small and it cannot meet the demand. If UH Manoa implemented a school counseling program, I would expect it to help meet this high-level demand from interested applicants.
From the service consumer side (i.e., K-12 students), given the ongoing pandemic and its negative effects on the students’ socio-emotional development, the need for services from school counselors has and will continue to increase. A school counseling program at UH Manoa would certainly help to meet this important need for our keiki.

To conclude, I hope you will start a school counseling program at UH Manoa’s College of Education. I believe the demand and need are such that the program will be a strong and vibrant one. Please do not hesitate to contact me at 808-238-4943 or bryankim@hawaii.edu if you have any questions about this letter.

Sincerely,

Bryan S. K. Kim, Ph.D.
Chair, Division of Social Sciences
Professor of Psychology and Core Faculty of the MA Program in Counseling Psychology
College of Arts and Sciences
University of Hawaii at Hilo
https://cms.uhh.hawaii.edu/faculty/kim/

Editor, The Counseling Psychologist (2020-2025)
Associate Editor, Measurement and Evaluation in Counseling and Development (2008-Present)
Past Associate Editor, The Counseling Psychologist (2007-2013)
Past Associate Editor, Cultural Diversity and Ethnic Minority Psychology (2007-2009)

Fellow, American Psychological Association (Divisions 17, 29, & 45)
Fellow, Asian American Psychological Association
Fellow, International Academy of Intercultural Research
Honolulu Rail Transit Project Update

UNIVERSITY OF HAWAIʻI BOARD OF REGENTS

OCTOBER 20, 2022

Hālaulani (Leeward Community College) Station
What is HART?

• The Honolulu Authority for Rapid Transportation is a semi-autonomous department of the City and County of Honolulu.

• Established by City Charter Amendment in 2010 to plan, construct, operate and maintain the City’s fixed-guideway rail system, similar to transit agencies in other cities.

• City Charter amended November 2016:
  • Transferred the operations and maintenance of the rail system to the City’s Department of Transportation Services (DTS).
    ➢ DTS also operates the City’s bus and para-transit services.
  • Accordingly, HART is responsible for the planning and construction of the rail system, and DTS is responsible for its operation.

• HART is 100% taxpayer funded.
Recovery Plan/FFGA

- HART’s 2022 Recovery Plan was submitted to FTA June 3, 2022 and accepted by the FTA, without changes, on September 30, 2022.
- The acceptance of the Recovery Plan will provide for the receipt of the remaining $744 million in federal funds, subject to the achievement of certain milestones.
- The accepted Recovery Plan includes:
  - A temporary terminus at the Civic Center Station (1.25 miles and 2 stations short of the original plan of reaching Ala Moana Transit Center), and
  - Deferral of the Pearl Highlands Parking Garage (estimated cost of $330 million, or $206,000 per stall for 1,600 stalls)
- Next step will be to amend the Full Funding Grant Agreement (FFGA) based upon the Recovery Plan scope and financial plan.
  - The completion of an amended FFGA will be the first funding-related milestone and will release $125 million in funds.
  - HART is working diligently with the FTA on an amended document.
Project Overview

- First driverless and fully automated commuter rail system in the United States
- Route is 18.75 miles from East Kapolei to Civic Center Station (corner of South Street and Halekauwila) with 19 stations
- Vehicle fleet: Twenty (20) four-car trains
- Rail Operations Center:
  - 43 acres near Leeward Community College
  - Includes maintenance and service facility and a train wash
  - Powered by electricity via a “third rail” that carries over 750 volts
Note that an extension from the Civic Center Station to the Ala Moana Transit Center and a parking facility will be completed in a separate project phase.
Forecast of Project Funding

HART is 100% Taxpayer Funded

<table>
<thead>
<tr>
<th>Funding Sources</th>
<th>$ in millions</th>
</tr>
</thead>
<tbody>
<tr>
<td>FTA FFGA</td>
<td>$1,550</td>
</tr>
<tr>
<td>FTA 2021 Grant</td>
<td>70</td>
</tr>
<tr>
<td>General Excise Tax (GET)</td>
<td>6,390</td>
</tr>
<tr>
<td>Transient Accommodations Tax (TAT)</td>
<td>1,101</td>
</tr>
<tr>
<td>Oahu TAT</td>
<td>488</td>
</tr>
<tr>
<td>City Subsidy</td>
<td>214</td>
</tr>
<tr>
<td><strong>Total Forecast Funding</strong></td>
<td><strong>$9,813</strong></td>
</tr>
</tbody>
</table>

- GET 66%
- State TAT 11%
- Oahu TAT 5%
- City Subsidy 2%
- FTA FY 2021 Grant 1%
- FTA FFGA 16%

83% Local Funds; 17% Federal Funds
Progress Toward Completion

**OPERATING SEGMENT 1**
East Kapolei to Aloha Stadium

- First 10 miles of guideway and 9 stations are complete
- 18 of 20 trains are on island
- Trial Running began on August 29, 2022
- Turn-over assets to City’s DTS expected in early 2023

*Keoneʻae (UH-West Oahu) Station*
Keone’ae (UH-West Oahu) Station

- New HECO easement to serve HART improvements
  - HECO reviewed and provided comments; HART is revising the property maps and metes/bounds description to address HECO’s comments.

- Abutilon Menziesii (Ko’oloa’ula/Red ‘Ilima) Habitat Conservation Plan
  - DHHL is pursuing the HCP as the lead agency and meeting with DLNR about next steps

- UH-West Oahu (UHWO)
  - Completed Road B and interim park and ride improvements at UHWO Station
  - Kualaka’i (East Kapolei) Station proposed “temporary” park and ride facility; UH Legal is working on an agreement draft to HART; expected in November 2022
Leeward Community College Parking Lot Repairs

- HART representatives provided plans for the parking lot repairs and met onsite with UH representatives
  - Paving activity is complete
  - Parking lot striping is underway
  - Completion scheduled end of October
  - Project Cost: $1.4M
CTAHR Pearl City Urban Garden (PCUG)

- UH HDOT Quitclaim Deed being reviewed by HART and HDOT
- Flooding/Drainage Issues at PCUG due to the Mauka sheet flow
- UH and HART to schedule an internal meeting to discuss concerns
Trial Running

• Began August 29, 2022 for Operating Segment 1
• Comprehensive series of tests of all aspects of the trains, stations, systems and operating personnel
• 24 hours a day, 7 days a week
• From Kualaka’i (East Kapolei) Station to the Hālawa (Aloha Stadium) Station
• Final series of testing before the rail system is ready to be in operation
• On October 22, 2022, an Emergency Exercise involving the City’s First Responders will be conducted near the UH-West Oahu station

TRIAL RUNNING SAFETY MESSAGES
• When driving, look ahead not overhead
• The “third rail” is electrified 24 hours a day, 7 days a week and carries 750 volts, which is deadly
Hammerhead Cracks

• “Hammerheads” are concrete structures that extend from the central column to support the station platform girders
• December 2018 - Cracks first observed
• January 2020 - Engineer of Record (EOR) concluded cracks due to shrinkage and structures are sound
• In June 2022, wider cracks observed
• Inspections conducted June/July 2022 by (4) four groups of structural engineers, including EOR
• Independent analyses underway. Expecting engineering reports late October
• EOR will determine what repair/remediation is required. The determinations will be independently validated
Progress Toward Completion

OPERATING SEGMENT 2
Aloha Stadium to Middle Street, including Airport

• 5.2 miles of guideway is 98% complete
  ➢ Completion of this guideway segment will represent 75% completion of the entire guideway
• The 4 stations in this segment range from 84% to 93% construction complete
• Core Systems work expected to begin in Fourth Quarter 2022
• Expected turn-over to DTS by early 2025

Final AGS Guideway Span Erected – Middle Street (Kahauiki) Station – April 2022
Progress Toward Completion

**OPERATING SEGMENT 3**
Middle Street to the Civic Center Station

- Downtown Utility Relocations–Iwilei Road to Cooke Street
  - Frank V. Coluccio Construction Company, Inc.
    - Roadway work began in August 2022; expected to be completed fourth quarter of 2024
- Dillingham Utility Relocations–Laumaka Street to Kaaahi Street
  - October 10, 2022–Notice to Proceed issued to Nan, Inc.
  - Construction work expected to begin November 28, 2022; and completed by first quarter of 2026.
- City Center Guideway and Stations – construction to be procured as Design/Build; award expected in 2023
- The current schedule projects a system completion date of 2031
Existing Dillingham Boulevard (looking East)

Niuhelewai (Honolulu Community College-Kapālama) Station
Example of Dillingham Underground Utilities
Mauka Guideway Shift
WAIAKAMILO ROAD TO KAAHII STREET

Honolulu Community College

Mauka Shift
2021 Design Refinements - Mauka Shift

- Mauka 138 kV line placed underground
- Trees removed
- Selected historic trees may remain
- Makai 138 kV line to remain

Honolulu Community College

Single 138 kV ductbank

Existing Right-of-Way

VIEW LOOKING KOKO HEAD (EAST)
City Center Utility Relocation Project Timeline: Overview Map

Dillingham Utility Relocations
(Areas 1A, 1B and 1C below)
38 Months - Anticipated
Completion Date January 2026

Downtown Utility Relocations
(Areas 2, 3 and 4 below)
28 Months - Anticipated
Completion Date September 2024

Ala Moana Utility Relocations
(Areas 5 and 6 below)
Procurement for this work will be in a later project phase
How to stay connected with HART

Join Monthly Business and Community Meetings

**Dillingham Utility Relocations**
Update Meetings will be held the fourth Thursday of every month
First meeting: October 27, 2022 | 12:00 pm

**Airport Guideway and Stations Construction**
Update Meetings are held the fourth Thursday of every month
Next meeting: October 27, 2022 | 5:00 pm

**Downtown Utility Relocations**
Update Meetings are held the second Wednesday of every month
Next meeting: November 9, 2022 | 6:00 pm

Sign up for our meetings and weekly eBlast notifications at [HonoluluTransit.org](http://HonoluluTransit.org).
Mahalo!
MEMORANDUM

TO: Randolph G. Moore  
Chairperson, Board of Regents  
University of Hawai‘i

VIA: David Lassner  
President  
University of Hawai‘i

FROM: Tim Dolan  
Chief Executive Officer  
University of Hawai‘i Foundation  

Vassilis L. Syromos  
Vice President for Research and Innovation  
University of Hawai‘i

SUBJECT: REQUEST FOR ACTION TO APPROVE THE ESTABLISHMENT OF THE INDIGENOUS INNOVATION AND HEALTH EQUITY ENDOWED CHAIR AT THE UNIVERSITY OF HAWAI‘I CENTER FOR INDIGENOUS INNOVATION AND HEALTH EQUITY

SPECIFIC ACTION REQUESTED:

It is requested that the University of Hawai‘i Board of Regents approve the establishment of the Indigenous Innovation and Health Equity Endowed Chair at the University of Hawai‘i Center for Indigenous Innovation and Health Equity in recognition of a private donation.

RECOMMENDED EFFECTIVE DATE:

Request that this be effective upon Board of Regents approval.

ADDITIONAL COST:

No additional costs are associated with this request.
PURPOSE:

The purpose of this Fund is to provide a chair in Indigenous Innovation and Health Equity at the University of Hawai‘i Center for Indigenous Innovation and Health Equity ("Center") to recruit and retain faculty of the highest caliber.

Funds may be used by the recipient at his/her discretion to enhance and support the goals and initiatives of the Center.

Examples of how funds may be used include, but are not limited to:

1. Salary support for the recipient based on the determination of the Director of the University of Hawai‘i System Office of Indigenous Innovation ("Director").
2. Program support as follows: Travel by the recipient and/or other members of the Center to other universities, government agencies, and industry visits.
3. Attendance at workshops, short or extended courses, and other educational opportunities on or off campus by the recipient and/or other members of the Center.
4. Support for faculty, junior faculty, fellows, graduate researchers, and other professionals in the Center.
5. Support for research, curriculum, and/or program development in the Center.

The recipient will consider input from the Director in determining priorities and activities for research, education, and community outreach initiatives. Funds may also be used to support the recruitment and relocation expenses of the endowed chair position.

The Director will appoint a committee to recommend candidates for the Chair. The Director will make the final decision in awarding the Chair after conferring with the Committee.

The recipient shall submit an annual budget to the Director for approval. The recipient is also required to submit an annual report on the previous year's related activities to the Director.

The criteria for the selection of the Chair are as follows:

1. Be a current faculty member or new recruit.
2. Hold a doctorate and be eligible for appointment to a tenure-track faculty position.
3. Have a documented record of research and strong knowledge in Indigenous Innovation and Health Equity.
4. Be able to provide program leadership and to make contributions to the education and research goals of the Center.
5. Have a strong interest in and substantial record of working with students.

The appointment will be reviewed for reassignment either to the current holder or for assignment to another individual at three (3) year intervals.

BACKGROUND:

This endowed chair shall be funded by a $3,000,000 gift from an anonymous donor. The donation will allow the Center for Indigenous Innovation to continue its work into perpetuity via creating an endowed chair. Allowing permanence in this position will ensure the generational, trust-based work of engaging our communities of practice is allowed to have the space, time, and resources it needs to build the "beloved community" it aspires to.

ACTION RECOMMENDED:

It is recommended that the University of Hawai‘i Board of Regents approve the establishment of the Indigenous Innovation and Health Equity Endowed Chair at the University of Hawai‘i Center for Indigenous Innovation and Health Equity in recognition of a private donation.

c: Kendra Oishi, Executive Administrator and Secretary to the Board of Regents
September 22, 2022

MEMORANDUM

TO: Randolph G. Moore  
   Chairperson, Board of Regents  
   University of Hawai‘i

VIA: David Lassner  
   President, University of Hawai‘i

VIA: Michael Bruno  
   Provost, University of Hawai‘i at Mānoa

FROM: Tim Dolan  
   Chief Executive Officer, University of Hawai‘i Foundation

V. Vance Roley  
   Dean, Shidler College of Business

SUBJECT: REQUEST FOR ACTION TO APPROVE THE ESTABLISHMENT AND NAMING OF THE TANG WEE LOKE DISTINGUISHED PROFESSORSHIP AT THE SCHOOL OF TRAVEL INDUSTRY MANAGEMENT AT THE UNIVERSITY OF HAWAI‘I AT MĀNOA SHIDLER COLLEGE OF BUSINESS

SPECIFIC ACTION REQUESTED:

It is requested that the University of Hawai‘i Board of Regents approve the establishment and naming of the Tang Wee Loke Distinguished Professorship ("the Professorship") at the School of Travel Industry Management ("TIM School") at the University of Hawai‘i at Mānoa Shidler College of Business ("Shidler College") in recognition of a private donation.

RECOMMENDED EFFECTIVE DATE:

Upon Board of Regent’s approval.

ADDITIONAL COST:

No additional costs are associated with this request.
PURPOSE:

The purpose of establishing this fund is to provide support for a distinguished professorship for the TIM School at Shidler College to recruit and retain faculty of the highest caliber.

The recipient will consider input from the Dean of the Shidler College of Business ("Dean") in determining priorities and activities for research and educational programs. Funds may be used for, but are not limited to:

1. A salary or supplement for the recipient; and/or
2. Any combination of costs as follows to support the recipient's research and education goals.
   a. Research and education program support as the recipient sees fit, including but not limited to, delivery of research and papers at conferences, manuscript preparation, library and equipment acquisition and other requirements of an active scholar and teacher.
   b. Travel by the recipient to other universities and research institutes, government agencies, and industry visits.
   c. Recipient's attendance at workshops, short courses, and other educational opportunities.
   d. Extended education programs by the recipient such as workshops, short courses, on or off campus programs for industry.
   e. Graduate student research assistants.
   f. Graduate and undergraduate student internships and travel.

The candidate must:
1. Be a current faculty member or new recruit.
2. Hold a doctorate, and be eligible for appointment to a tenure-track faculty position.
3. Have a documented record of research and strong knowledge in a hospitality and tourism-related field.
4. Be able to provide program leadership and to make contributions to the education and research goals of Shidler College.
5. Have a strong interest in and substantial record of working with students.

The Dean will appoint a committee to recommend candidates for the Professorship. The Dean will make the final decision in awarding the Professorship after conferring with the Committee.

The recipient shall submit an annual budget to the Dean for approval. The recipient is also required to submit an annual report on the previous year's related activities to the Dean.
Chairperson Randolph G. Moore  
September 22, 2022  
Page 3 of 3  

BACKGROUND:  

The University of Hawai'i Foundation has received a gift commitment of $250,000 pledged by Wee Loke Tang of Singapore, to establish an endowed, named distinguished professorship. The funds will be equally matched up to $250,000 with an unrestricted gift from Mr. Jay Harold Shidler, II.

Shidler College alumnus Wee Loke Tang (BBA '73) retired as deputy managing director of UOB Kay Hian Holdings Ltd, the parent of Singapore's largest stockbroking firm, in 2007. Tang joined Kay Hian in 1973 as an investment analyst and was instrumental in taking the former Kay Hian from a small family-owned firm to a global broking and corporate services group with offices in Southeast Asia, London, New York, Hong Kong, and Shanghai.

Following his retirement, he remained on the board of UOB Kay Hian as an executive director and is currently an independent director. Tang has also served on the boards of various UOB Kay Hian subsidiaries and led the formation of and served as founding chairman of the Securities Association of Singapore, which represents the interests of securities trading members in Singapore. He was inducted into the Shidler College of Business Hall of Honor in 2018.

ACTION RECOMMENDED:  

It is recommended that the University of Hawai'i Board of Regents approve the establishment and naming of the Tang Wee Loke Distinguished Professorship at the School of Travel Industry Management at the University of Hawai'i at Mānoa Shidler College of Business (“Shidler College”) in recognition of a private donation.

c: Kendra Oishi, Executive Administrator and Secretary to the BOR
MEMORANDUM

TO: Randolph Moore
    Chair, University of Hawaiʻi Board of Regents

VIA: David Lassner
     President, University of Hawaiʻi

VIA: Bonnie Irwin
     Chancellor, University of Hawaiʻi at Hilo

FROM: Farrah-Marle Gomes
      Vice Chancellor for Student Affairs, University of Hawaiʻi at Hilo

SUBJECT: APPROVAL OF EMERITA TITLE FOR GAIL MAKUKĀNE-LUNDIN

SPECIFIC ACTION REQUESTED:

It is requested that the Board of the Regents grant an exception to Board Policy and confer the title of Assistant Specialist Emerita in the Division of Student Affairs on Ms. Gail Makukāne-Lundin in recognition of the dedicated and honorable service she has provided to the University of Hawaiʻi at Hilo and the University of Hawaiʻi System.

RECOMMENDED EFFECTIVE DATE:

This action will take effect immediately, upon approval by the Board of Regents.

ADDITIONAL COST:

There are no additional costs associated with this request.

PURPOSE:

The purpose of this request is to honor a distinguished, respected, and admired University of Hawaiʻi employee, whose work and leadership is immeasurable. Emerita status serves three purposes: recognition of meritorious service by an individual, acknowledgment of continuing affiliation with the institution and enhancement of the reputation of the University. Emerita status for Ms. Makukāne-Lundin is fully justified in relation to all three purposes. Board approval is required as an exception to the Board of Regents Policy.
BACKGROUND:

Board of Regents Policy 5.219, Emeritus/Emerita Title, and Executive Policy 5.207, Awarding of Emeritus/Emerita Title, provides the policy and process for conferring the emeritus title to faculty retired or retiring at the highest rank after five years of dedicated and honorable service and to vice presidents and chancellors who have made exceptional contributions to the University. Under delegated authority, the policies also allow for the President to recommend to the Board consideration of individuals deserving of honor who do not meet the stated criteria.

There is precedent for granting exceptions for emerita recognition to both faculty at rank four and to administrators other than vice presidents. Ms. Makuakane-Lundin obtained tenure as Assistant Specialist but was not eligible to apply for promotion to Associate Specialist during the long term she served as both a faculty specialist and executive/managerial appointee. Ms. Makuakane-Lundin served with distinction for over 37 years at the University of Hawai‘i at Hilo and the University of Hawai‘i System as a tenured faculty member and administrator. She retired June 30, 2022.

Throughout her career, Ms. Makuakane-Lundin has been committed to advancing the educational opportunities and achievements for Native Hawaiian students and for the betterment of Native Hawaiians within Hawaiian and Pacific communities. She has achieved this over the years by maintaining active memberships with and providing valuable volunteer contributions to the American College Personnel Association (ACPA), Native Hawaiian Education Association (NHEA), National Indian Education Association (NiEA), and National Association of Student Personnel Administrators (NASPA). Ms. Makuakane-Lundin is a staunch advocate and effective change agent within the University, the community, and the profession. A summary of her curriculum vitae is attached. Above all else, Ms. Makuakane-Lundin’s tireless work ethic and exceptional track record for securing extramural funds sets her apart from other professionals in the field.

Utilizing her educational background in the sciences with her Bachelor’s degree in Biology from UH Hilo and a Master of Science degree in Public Health from University of Hawai‘i School of Public Health, in 1984, Ms. Makuakane-Lundin assisted the John A. Burns School of Medicine in developing the Health Careers Opportunity Program (HCOP), which provided opportunities for Native Hawaiian college students to enter the health field. Under her leadership and with support from programs like HCOP, the University of Hawai‘i at Hilo has increased the number of Native Hawaiian students interested in and graduating with STEM degrees. A few years later in 1987, Ms. Makuakane-Lundin was instrumental in implementation of UH Hilo’s first United States Department of Education TRiO grant that brought the Student Support Services Program (SSSP) to the campus. This program continues to thrive today serving hundreds of first-generation and low-income students each year. In total, Ms. Makuakane-Lundin has brought in more than $24 million through the United States Department of Education Title III, Native Hawaiian-Serving Institutions grants and another $2 million through grants from the United States Department of Labor Administration for Native Americans, United States Department of Health and Human Services, National Science Foundation, Office of Hawaiian Affairs, and Kamehameha Schools.
Ms. Makuakâne-Lundin has maintained an active program of scholarship that includes writing numerous internal reports, securing extramural funding, serving on search and steering committees, and presenting at Native Hawaiian Education Association Conventions, NASPA Annual Conferences, and Annual Pacific Education Conferences on topics such as Hawaiian Cultural Learning in Contemporary Hawai‘i; Native Hawaiian Student Services; Advancing API & Native Hawaiian Women as Leaders – Partnerships for Lifelong Empowerment; Inspiration and Sustenance, Native Hawaiian Experiences in Higher Education: Through the Voices of Student; Cultural Values and Learning Styles; and Promoting Success Through the University-Student Connection. Recognizing the value in providing professional development opportunities for students and employees, Ms. Makuakâne-Lundin volunteered as a planning committee member for programs and events like the World Hula Conference, World Indigenous Peoples’ Conference on Education (WIPCE), and NASPA Western Regional Conference that was held in Hawai‘i.

A common theme through each program that Ms. Makuakâne-Lundin has created is student leadership development. While this was at the core of the Hawaiian Leadership Development Program (HLDP) that Ms. Makuakâne-Lundin coordinated for over 20 years from 1993, she had a unique way of incorporating the importance of student leadership development into Title III Native Hawaiian-Serving Institution Grants that she was principal investigator and/or program director for more than 15 years after the HLDP ended. Ms. Makuakâne-Lundin also exemplified the characteristics of a leader herself where in her role as the Director for UH Hilo’s Kipuka Native Hawaiian Student Center, she promoted Native Hawaiian student success through the provision of culturally appropriate and responsive student support services and activities, supported the academic development and success of Native Hawaiians by promoting learning environments that were culturally responsive and appropriate, and implemented community and cultural programs to increase educational opportunities for Native Hawaiians within Hawaiian and Pacific communities.

Ms. Makuakâne-Lundin’s directorship with Kipuka was temporarily interrupted a few times when she was appointed to serve as Interim Vice Chancellor for Student Affairs twice and Interim Executive Assistant to the UH Hilo Chancellor twice. Through her interim appointments, Ms. Makuakâne-Lundin provided stability and continuity in services that allowed UH Hilo to stay focused on articulated goals without losing momentum with leadership changes. Ms. Makuakâne-Lundin undoubtedly brought a wealth of knowledge and institutional history to her various positions. Her most recent appointment extended beyond the UH Hilo campus when she was appointed as the UH System Hawaii Papa o Ke Ao Coordinator in 2019. In that role, Ms. Makuakâne-Lundin worked closely with all ten campuses to develop, implement and assess strategic actions to make the University of Hawai‘i a leader in indigenous education. As a result of much of the work led by Ms. Makuakâne-Lundin, the University’s next strategic plan that is currently being drafted includes reference to embracing kuleana to Hawaiians and Hawai‘i as one of four imperatives.

For over a decade, Ms. Makuakâne-Lundin was also an instructor at UH Hilo for various Hawaiian Studies, Interdisciplinary Studies, and University 101 courses. In her role as Interim Vice Chancellor for Student Affairs where one of the areas of responsibility included supporting military-connected
students, she was able to draw on her own military experience where she served as a Petty Officer Second Class, Yeoman in the United States Coast Guard for 18 years.

Ms. Makuakäne-Lundin is well respected among the Native Hawaiian community and the University system. For her many contributions spanning more than three decades, Ms. Makuakäne-Lundin has been recognized for numerous campus level awards:

- 2003 - University of Hawai‘i at Hilo Professional Staff Award presented to a faculty/professional staff member who has made major professional contributions to his/her unit and to the university as a whole, and has made a positive impact on the welfare of students and colleagues at the University of Hawai‘i at Hilo
- 2006 - University of Hawai‘i at Hilo Distinguished Service Award for Improving Student Life presented to an individual who has made outstanding contributions to student life beyond the boundaries of their official responsibilities at the University of Hawai‘i
- 2010 - University of Hawai‘i at Hilo Division of Student Affairs Leadership Award
- 2016 - University of Hawai‘i Hilo Pūlama ‘Ike Award presented to an individual who has made a significant contribution to developing and promoting the mission and spirit of the University of Hawai‘i at Hilo

Within the broader community, Ms. Makuakäne-Lundin has made a deep impact, as is evidenced by recognition for her multiple and meaningful contributions. In 2010, she was recognized as an honoree at the University of Hawai‘i at Hilo Na Pua No‘eau, Center for Gifted & Talented Native Hawaiian Children, Hawaiian Family affair. Three years later in 2013, Ms. Makuakäne-Lundin was recognized as a Native Hawaiian Education Association Educator of the Year Award Recipient. Many other organizations have also benefited from Ms. Makuakäne-Lundin’s involvement. A comprehensive list of community organizations that Ms. Makuakäne-Lundin regularly participated in is included in the attached curriculum vitae. Some of those participations include:

- Member, Hawai‘i Public Health Association, 1978 – present
- Member, Hilo Hawaiian Civic Club, 2005 – present
- Board of Directors, Hilo Hawaiian Civic Club 2012 – 2014
- Member Board of Directors, Ho‘oulu Lāhui Hawaiian Cultural Group, 1996 – 2007
- Lifetime Member, Kamehameha Schools Alumni Association, 1973 – present
- Member, Local School Board, Ka ‘Umeke Ka‘eo Public Charter School, 2005 – 2014
- Member, Ex-officio Community Advisory, Ka ‘Umeke Ka‘eo Public Charter School, 2014 – present.
- Treasurer, Native Hawaiian Education, Hawai‘i Island Council, 2014 – present

In 2015, Ms. Makuakäne-Lundin, along with her two sisters, made a pledge of $100,000 to establish the Daniel and Lydia Makuakäne Endowed Scholarship. The endowment honors their parents, Daniel and Lydia Makuakäne, for their contributions to the preservation and perpetuation of Hawaiian language and cultural practices. The scholarship is intended to help increase the number and proficiency of Hawaiian speakers. It supports eligible undergraduate and graduate students enrolled in the UH Hilo’s Ka Haka ‘Ula o Ke‘elikōlani College of Hawaiian Language.
Prior to retirement, Ms. Makuakāne-Lundin mentored Kipuka staff in co-authoring the last round of Title III grant proposals submitted, and all submitted proposals have since been funded. In this way, Ms. Makuakāne-Lundin’s legacy at UH Hilo continues on. In retirement, Ms. Makuakāne-Lundin has made herself available to UH colleagues and students as a trusted mentor and advisor. Emerita recognition is well deserved and justified. Such recognition will reflect positively upon the University of Hawai‘i.

**ACTION RECOMMENDED:**

It is recommended that the Board of Regents grant an exception to Board Policy and confer the title of Assistant Specialist Emerita in the Division of Student Affairs on Ms. Gail Makuakāne-Lundin.

**Attachments**

1. Curriculum Vitae
GAIL MILILANI MAKUAKÅNE-LUNDIN

Address: Hilo, HI. 96720
Phone: [Redacted]
E-Mail: gailml@hawaii.edu

FORMAL EDUCATION

2000 Ed.D. Candidate, Educational Leadership Rossier School of Education University of Southern California

1992 Certificate in Management, University of Hawai‘i College of Business

1978 Master of Science Public Health University of Hawai‘i School of Public Health

1978 Bachelor of Arts Biology University of Hawai‘i Hilo

PROFESSIONAL EXPERIENCE

July 2019-June 2022 Director Kipuka Native Hawaiian Student Center Division of Student Affairs University of Hawai‘i Hilo

January 2018-June 2022 Director Hawai‘i Papa O Ke Ao Office of the President University of Hawai‘i System

December 2016-July 2019 Interim Executive Assistant to the Chancellor Office of the Chancellor University of Hawai‘i Hilo

July 2014-June 2018 Director Kipuka Native Hawaiian Student Center Division of Student Affairs University of Hawai‘i Hilo
May 2014-November 2016  
Interim Vice Chancellor for Student Affairs  
Division of Student Affairs  
University of Hawai‘i Hilo

July 2011-May 2014  
Interim Executive Assistant to the Chancellor  
Office of the Chancellor  
University of Hawai‘i Hilo

April 2008-July 2011  
Executive Coordinator for Student Development Programs  
Division of Student Affairs  
University of Hawai‘i Hilo

October 2006-June 2022  
Principal Investigator and Program Director  
Title III Native Hawaiian-Serving Institution Grants  
University of Hawai‘i Hilo

October 2000-Sept 2006  
Program Director  
Title III Native Hawaiian-Serving Institution Grant  
University of Hawai‘i Hilo

August 2004 – July 2011  
Director  
Kīpuka Native Hawaiian Students Center  
Division of Student Affairs  
University of Hawai‘i Hilo

April 1997 – August 2000  
Interim Vice Chancellor for Student Affairs  
Office of Student Affairs  
University of Hawai‘i Hilo

June 1993 – August 2004  
Coordinator  
Hawaiian Leadership Development Program  
Office of Student Affairs  
University of Hawai‘i Hilo

September 1992 – May 1993  
Principal Investigator and Program Director  
Student Support Services Program  
Office of Student Affairs  
University of Hawai‘i Hilo

April 1991 – August 1992  
Director  
Native Hawaiian Health Professions Scholarship Program  
Kamehameha Schools  
Honolulu, HI
November 1987 – April 1991 Principal Investigator and Program Director,
Student Support Services Program
University Hawai‘i Hilo

December 1984 - Nov. 1987 Coordinator
Health Careers Opportunity Program
Office of Student Affairs
University of Hawai‘i Hilo

May 1984 – December 1984 Coordinator
Hawaiian Rehabilitation & Placement Specialist
Hilo, HI

December 1979 – May 1984 Director & Career Counselor
Employment and Training Program
Alu Like, Inc.,
Hilo, HI

TEACHING EXPERIENCE

June 1993 – 2005 Instructor, University of Hawai‘i Hilo
Hawaiian Studies 299 & 497 (Hawaiian Leadership)
Interdisciplinary Studies 298 (Hawaiian Leadership)
University 101 (Freshman Year Experience)

MILITARY EXPERIENCE

Aug. 1982 – 2000 Petty Officer Second Class, Yeoman
United States Coast Guard.

PROFESSIONAL AND COMMUNITY EXPERIENCES

Committees

University of Hawai‘i System
• Advisory Board, Hui Ho‘opili ‘Āina, University of Hawai‘i and Kamehameha Schools Partnership, 2014-2022
• Member, Underrepresented Minorities Committee, 2021-2022
• Member, Data Governance Committee, 2014-2017
• Member, Purge 2.0 Committee, 2015-2016
• Member, Title IX Committee, 2014-2017
• Member, Indigenous-Serving Task Force/Committee, 2011-2012; 2015-2018
- Member, Smithsonian Folklife Festival Steering Committee, 2012

University of Hawai‘i at Hilo
- Member, Chancellor’s Executive Council, 2011-2019
- Member, Council of Vice Chancellors, 2011-2019
- Member, Advisory Committee, Hawai‘i Community College-University of Hawai‘i Hilo
- Member, Kiapaepe Protocols Committee, 2016-2022
- Member, Advisory Committee, Academic Success Center (Kilohana), 2010-2011
- Member, Academic Policy Committee, 2009-2011
- Member, Assessment Committee, 2000-2005
- Member, Campus Beautification Committee, 2003-2005
- Member, Campus Crisis Management Team, 2015-2016
- Member, Faculty Congress, 2000-2009. Executive Board and Chair, Community Relations Committee and Admissions Committee
- Member, Hanakahi Council (formerly the Committee of Faculty of Hawaiian Ancestry), 1984-2022
- Member, EEO/AA Advisory Committee, 2010-2011
- Member, Enrollment Management Implementation Team, 2008-2009; Student Success Committee, 2014-2016
- Member, Chancellor’s Excellence in Diversity, Equity and Inclusion Committee, 2021-2022
- Member, Institutional Aid Task Force, 2021-2022
- Project Affiliate/Advisor, Kealohola/STEM Program, 2003-2011; 2020-2022
- Member, Chancellor’s Maunakea Advisory Committee, 2019-2022
- Member, Office of Student Affairs Professional Development Committee, 1992-1997 and 2003-2009
- Member, Student Affairs Leadership Council, 2019-2022
- Member, Student Services Professional Development Committee, 1992-1997
- Member, Service Learning Advisory Board, 2001-2010
- Member, Strategic Planning Committee, 2000-2002 and 2010-2011
- Member, Sustainability Committee, 2009-2011
- Member, Task Force on the Future of Higher Education on the Big Island, 2001-2002
- Chair, Advisory Board, University Canoe Club, 2001-2010
Ex-officio Member, Access Committee, 2012-2019
Ex-officio Member, Diversity Committee, 2016-2019
Ex-officio Member, Professional Development Committee, 2012-2019
Ex-officio Member, Strategic Planning Progress Review Team, 2012-2014
Ex-officio Member, Student Success Leadership Team, 2016-2019

Grant Experiences

2021-2022 Principal Investigator and Project Director, University of Hawai‘i at Hilo Title III Native Hawaiian-Serving Institutions Five Year Development Grants, Ho‘olana, E Halakau and Pā‘ie‘ie, U.S. Department of Education ($8.4 million)

2020-2022 Principal Investigator and Project Director, University of Hawai‘i at Hilo Title III Native Hawaiian-Serving Institutions Five-Year Development Grant, Kūkulu, U.S. Department of Education ($2.2 million)

2019-2022 Activity Lead, Hawai‘i Community College (lead), University of Hawai‘i at Hilo and University of Hawai‘i Maui College Title III Native Hawaiian Serving Institutions Five-Year Cooperative Grant, Mānai A Maui, U.S. Department of Education ($2.2 million)

2018-2022 Principal Investigator and Project Director, University of Hawai‘i at Hilo (lead), University of Hawai‘i Maui College, University of Hawai‘i Mānoa, University of Hawai‘i West O‘ahu and Kaua‘i Community College Nā Pua No‘eau-Ho‘olei Native Hawaiian Education Program, U.S. Department of Education ($1.9 million)

2015-2022 Program Director, University of Hawai‘i Hilo (lead) Hawai‘i Community College Title III Native Hawaiian Serving Institutions Five-Year Cooperative Grant, Mökaulele, U.S. Department of Education ($3.9 million)

2013-2017 Co-Principal Investigator, University of Hawai‘i Hilo Kupa ‘Āina Summer Bridge Program, Kamehameha Schools ($759,817)

2012-2014 Project Director, University of Hawai‘i Hilo Title III Native Hawaiian-Serving Institutions Two Year Development Grant, U.S. Department of Education ($3.2 million).

2010-2015 Principal Investigator and Project Director, University of Hawai‘i Hilo Title III Native Hawaiian-Serving Institutions Five-Year Development Grant, U.S. Department of Education ($3.6 million).
2010-2012 Principal Investigator and Project Director, University of Hawai‘i Hilo Title III Native Hawaiian-Serving Institutions Two-Year Renovation Grant, U.S. Department of Education ($3.9 million).

2010-2015 Co-Project Director, University of Hawai‘i Hilo and Hawai‘i Community College (lead) Title III Native Hawaiian Serving Institutions Five Year Cooperative Grant, U.S. Department of Education ($3.2 million).

2009-2010 Principal Investigator and Project Director, University of Hawai‘i Hilo Title III Native Hawaiian-Serving Institutions One-Year Renovation Grant, U.S. Department of Education ($1.7 million).


2006-2007 Project Director University of Hawai‘i Hilo Title III Native Hawaiian-Serving Institutions One-Year Renovation Grant, U.S. Department of Education ($348,000).

2005-2010 Project Director, University of Hawai‘i Hilo Title III Native Hawaiian-Serving Institutions Five Year Development Grant, United States Department of Education ($2.5 million).


2005-2006 Project Director, University of Hawai‘i Hilo Title III Native Hawaiian-Serving Institutions One Year Renovation Grant, United States Department of Education ($748,000).

2003-2007 Co-Principal Investigator, University of Hawai‘i Hilo Computer Science, Engineering and Math Scholarships. National Science Foundation ($284,000).


2001-2002 Principal Investigator and Director University of Hawai‘i Hilo Native Hawaiian Recruitment and Retention Program. Office of Hawaiian Affairs. ($11,500).

2000-2005 Project Director, University of Hawai‘i Hilo Title III, Native Hawaiian-Serving Institutions Five-Year Development Grant. U.S. Department of Education ($1.5 million).

1999-2002 Principal Investigator and Project Director, University of Hawai‘i Hilo Native Hawaiian Agriculture Curriculum Grant. U.S. Department of Labor Administration for Native Americans ($375,000).

1998 Co-Principal Investigator, National Cancer Institute, United States Department of Health and Human Services ($16,000).

Professional Organizations

- Member, American College Personnel Association (ACPA)
- Member, Native Hawaiian Education Association (NHEA)
- Member, National Indian Education Association (NIEA)
- Member, Student Affairs Administrators in Higher Education (NASPA)

Community Organizations

- Member, Board of Directors, Big Island AIDS Project, 1996 – 2005
- Member, Hale O Nā Ali‘i Halau Kalākaaua, 1995-present
- Member, Hawai‘i Public Health Association, 1978-present
- Member, Hilo Jaycees, 1992-present
- Member, Hilo Hawaiian Civic Club, 2005 – present, Board of Directors, 2012-2014; 2022
- Member Board of Directors, Ho‘oulu Lāhui Hawaiian Cultural Group, 1996 – 2007
- Lifetime Member, Kamehameha Schools Alumni Association, 1973 – present, President Mamalahoe Chapter, 1991-1992
- Advisory Board Member, Nā Pua Noe‘au Center for Gifted and Talented Native Hawaiian Children, 2009-2017
- Treasurer, Native Hawaiian Education, Hawai‘i Island Council, 2014-2016

Other Professional & Community Experiences

- Member, Planning Committee, World Hula Conference, Hilo, HI, 2001
- Member, Workshop Committee, World Indigenous Peoples’ Conference on Education, Cuzco, Peru 2011
- Member, Planning Committee, World Indigenous Peoples’ Conference on Education, Hilo, HI, 1999
- Member, Planning Committee, NASPA Western Regional Conference, Waikoloa, HI 2012
- Member, Strategic Planning Committee, Kamehameha Schools, Honolulu, HI, 1999-2000
• Member, Steering Committee, Hilo World Sprints, 2002-2004
• Reader, Gates Millennium Scholars Program, 2001 and 2003
• Researcher, Native Research Program, National Institutes of Health, 1997 and 1998

AWARDS AND RECOGNITION

• University of Hawai‘i Hilo Pūlama ‘Ike Award, 2016
• Native Hawaiian Education Association Educator of the Year Award Recipient, 2013
• University of Hawai‘i at Hilo Division of Student Affairs Leadership Award, 2010
• University of Hawai‘i at Hilo Na Pua No‘eau, Center for Gifted & Talented Native Hawaiian Children, Hawaiian Family Fair Honoree, 2010
• University of Hawai‘i at Hilo Student Support Service Award, 2006
• University of Hawai‘i at Hilo Professional Staff Award, 2003
• Outstanding University of Hawai‘i at Hilo Female Graduate in Science, 1992

SELECTED PUBLICATION AND PRESENTATIONS


Uluãkea: Inspiring Faculty to Indigenize the University of Hawai‘i at Hilo and Hawai‘i Community College. Panel Presentation at 21st Annual Native Hawaiian Association Convention. Virtual Presentation. July 2020.


Assisting Native and Non-Native Faculty in Becoming Advocates and Mentors for Native Students. Presentation at Mentoring Our Own Native Scientists (MOONS) Workshop, Haskell, KS. September 2018.

Student Engagement Through Living-Learning Communities at UH Hilo. Presentation at 16th Annual Native Hawaiian Association Convention, Kane‘ohe, O‘ahu, HI. March 2016.


Uluãkea, Inspiring Faculty to Transform the University of Hawai‘i at Hilo into a Hawaiian Place of Learning. Panel Presentation at the 2014 World Indigenous Peoples Conference: Education, Honolulu, HI. May 2014.
Hawaiian Cultural Learning in Contemporary Hawai`i. Panel Presentation at 14th Annual Native Hawaiian Education Association Convention, Hilo, HI. March 2013.


Demographics and Characteristics of University of Hawai`i at Hilo Students. Presentation at UH Hilo New Faculty Orientation, Hilo, HI. August 2006-August 2010.

Native Hawaiian Experiences in Higher Education: Through the Voices of Student. Presentation at UH Hilo Faculty Diversity Seminar, Hilo, HI. October 2005.


Promoting Success Through the University-Student Connection. Presentation at the Pacific Education Conference, Kapa`a, Kaua`i, HI. August 1998.
Review of Proposed Tuition Schedule: Academic Year 2023-2024 through 2026-2027

Submitted for Board of Regents Review

by

Pearl Iboshi, Director Institutional Research Analysis and Planning Office
David Lassner, President

October 20, 2022
Historic statutory context

• Until 1996, all UH tuition was deposited to the General fund and the State fully funded UH operations

• Act 161, SLH 1995 provided for UH to retain its tuition in recognition that the State could no longer afford to fully fund public higher education

• While contrary to statutory intent, General fund appropriations to UH decreased in times of recession and the share of UH operations paid for by tuition increased.
Tuition setting process

Act 251 (SLH 1996), approved by the Governor on 6/18/96, includes the following amendment to Chapter 304, HRS:

- When establishing tuition at UH, the BOR is exempt from the public notice, public hearing, and gubernatorial approval requirements of Chapter 91, HAR. The fees may be established at an open public meeting subject to the requirements of Chapter 92, provided that:
  - The open public meeting is held during or prior to the semester to which the fees apply; and
  - A copy of the tuition schedule is filed in the Office of the Lieutenant Governor prior to taking effect.
Tuition setting process
(Executive Policy 6.202)

1. UH administration develops proposed tuition schedule

2. The tuition proposal and request for comments is shared with the BOR and university community at least 15 days prior to public meetings

3. UH administration conducts open public meeting(s) on the tuition proposal on Hawaii, Maui, Kauai and Oahu. Meetings are announced on all campuses at least 15 days in advance via campus newspapers or other appropriate means. The meetings take place on campuses. The purpose of the meetings is to explain the proposal and provide an opportunity for testimony.

4. The administration provides the BOR with a summary of the positions stated at the public meetings and incorporates revisions as appropriate

5. A final tuition schedule is presented to the BOR for approval during or prior to the semester in which the tuition schedule applies

6. A copy of the approved schedule is filed in the Office of the Lieutenant Governor prior to the effective date
State appropriation share and tuition share of education revenue - UH System

Tuition share of education revenue has increased with recessions, and has since remained relatively stable with increases in general funds primarily supporting collective bargaining increases.

Source: IPEDS Finance Survey.
Board Policy 6.202 guides tuition decisions

Access
“...every qualified* Hawai‘i resident shall have an opportunity to pursue postsecondary education within the university system.”

Affordability
“... keep costs to resident students at the lowest practical level while maintaining a financial aid program that responds to the needs of students who cannot meet the costs of attendance.”

* The word “qualified” has been flagged to be removed in the next update

Regents Policy 6.202
Basic considerations outlined in University policy

1. Comparability of tuition charges with those at regional and national peer institutions
2. Differential tuition rates by unit missions, student level (undergraduate, graduate, professional), and residency
3. Accessibility and the mix of students (ethnic background, income levels, residents and non-residents, etc.)
4. Financial aid availability and use
5. The cost of education and the sharing of that cost between students and the general public

No one consideration overrides others; all are considered holistically

Regents Policy 6.202
Affordability: UH is comparable or better than peers when looking at tuition costs and household income together.

Source: U.S. Census Bureau; UH Executive Policy E6.201.
Tuition is not the major cost of attending UH for Hawai‘i residents

Tuition and Fees as a Percent of Cost of Attendance: AY 2022-23

Cost of attendance includes tuition and fees, books, supplies, room, board, misc. personal expenses, transportation, and electricity (for off-campus housing). Off campus is the same as living in the dorm. UHCC transportation cost is the average of the cost for O‘ahu, Hawai‘i, Maui, and Kaua‘i.
Recent BOR actions and current action required

• 2015 - Partial rollback of previously approved increases

• 2016 - Small increases, all dedicated to facilities improvements

• May 2019, the BOR approved a three-year tuition schedule that:
  
  • Kept tuition at the 2019-20 rate for undergraduate tuition at all campuses for 2020-21, 2021-22, and 2022-23, as well as for graduate tuition at UH Hilo and all professional programs at UH Mānoa.

  • Decreased the resident graduate tuition rate at UH Mānoa by $156 and the non-resident graduate tuition rate by $1,872 in 2020-21, and maintained those rates in 2021-22 and 2022-23

• 2022 – Setting new tuition schedule for AY 2023-24 and beyond
Historic summary of tuition levels relative to peers

• During the great recession, the decline in Hawai‘i state investment in public higher education was among the highest in the country.

• During that same period, UH tuition increases were among the largest in the country.

• Since 2016, tuition rates have remained relatively flat.
In recent years, UH resident tuition rates have remained relatively flat.
UH Mānoa non-resident tuition have also remained flat, except for the decrease in graduate tuition.
Summary of current tuition levels as compared to peers

• Resident undergraduate rates are close to peers

• Non-resident undergraduate rates are generally higher than peers

• Graduate resident and non-resident rates are higher than peers

• Although not what we would like, enrollment performance has been close to or better than national averages since COVID
UH Mānoa undergraduate tuition and fees are generally comparable to peers, and are lower than benchmark institutions.

Data source: IPEDS.
UH Mānoa graduate tuition and fees remain higher than at comparison institutions despite the decreases in 2019-20,
William S. Richardson School of Law (WSRSL) tuition rate is significantly lower than that of other public west coast institutions.
UH Hilo undergraduate rates are in the middle of comparison groups of institutions for residents and higher for non-residents.

Data source: IPEDS.
UH Hilo graduate tuition and fees remain higher than at comparison institutions.
UH West O‘ahu resident rates are comparable to comparison institutions; Non-Resident rates are higher

Data source: IPEDS.
UHCC Resident Tuition and fees are lower than comparison institutions; Non-Resident rate is comparable to comparisons

Data source: IPEDS. UHCC based on 12 credits per semester.
Other financial and budget considerations

• Elasticity: Will raising rates negatively affect tuition? Previous national studies have shown an approximately 3% change in enrollment relative to a $1,000 change in tuition, but the current environment is very uncertain. On balance, we expect that small changes in tuition rates will not significantly impact enrollment numbers either way.

• Energy costs are expected to increase by more than $13m this year and about $2 million per year thereafter.

• Inflation of about 8% this year will impact Other expenses and will hopefully moderate in future years.

• Legislative actions such as eliminating state support for the payment of fringe benefits for permanent positions when salaries are paid with tuition will increase costs and challenge budgets at universities.

• The current levels of TFSF reserves are strong and will be challenged by the impacts of inflation. In addition, many requirements (e.g., mental health) have been suppressed or funded externally during the pandemic and the new strategic plan will require investment.
Recurring expenses are currently projected to exceed revenues beginning in 2024-25

Revenues and expenditures UH System (in millions)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Revenues</td>
<td>$1,841.5</td>
<td>$1,536.4</td>
<td>$1,516.2</td>
<td>$1,530.9</td>
<td>$1,534.8</td>
<td>$1,533.8</td>
</tr>
<tr>
<td>Total Expenditures</td>
<td>$1,687.2</td>
<td>$1,551.2</td>
<td>$1,509.4</td>
<td>$1,545.4</td>
<td>$1,549.2</td>
<td>$1,550.9</td>
</tr>
<tr>
<td>Net (rev. less exp.)</td>
<td>$154.3</td>
<td>$(14.8)</td>
<td>6.8</td>
<td>$(14.5)</td>
<td>$(14.4)</td>
<td>$(17.1)</td>
</tr>
<tr>
<td>Non-Recur. Costs</td>
<td>$0.2</td>
<td>$71.2</td>
<td>$4.3</td>
<td>$4.2</td>
<td>$2.7</td>
<td>$0.7</td>
</tr>
<tr>
<td>Recurring Net</td>
<td>$154.4</td>
<td>$56.4</td>
<td>$11.1</td>
<td>$(10.2)</td>
<td>$(11.6)</td>
<td>$(16.4)</td>
</tr>
</tbody>
</table>

Estimate from UH Budget Office. Figures are for all methods of funding, and assume no tuition rate increase. Net figures may not sum due to rounding. See details in Appendix.
### Summary of Recommendations

Based on the financial and competitive reasons discussed, our recommendations are:

<table>
<thead>
<tr>
<th></th>
<th>AY2023-24</th>
<th>AY2024-25</th>
<th>AY2025-26</th>
<th>AY2026-27</th>
</tr>
</thead>
<tbody>
<tr>
<td>Undergraduate rate at 4 years*</td>
<td>0.0%</td>
<td>0.0%</td>
<td>2.0%</td>
<td>2.0%</td>
</tr>
<tr>
<td>Community colleges**</td>
<td>0.0%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>0.0%</td>
</tr>
<tr>
<td>Graduate school and professional schools except for WSRSL</td>
<td>0.0%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>0.0%</td>
</tr>
<tr>
<td>WSRSL*</td>
<td>0.0%</td>
<td>2.0%</td>
<td>2.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

*Non-resident rates are set at the equivalent dollar amount as the resident rate.

**Upper division rate at community colleges would be at the same rate as UHH and UHWO.
## Overall Projected UH recurring Net Revenue and Impact of Recommended Change in Tuition Revenue

(For millions)

<table>
<thead>
<tr>
<th></th>
<th>Projected 2022-2023</th>
<th>Projected 2023-2024</th>
<th>Projected 2024-2025</th>
<th>Projected 2025-2026</th>
<th>Projected 2026-2027</th>
</tr>
</thead>
<tbody>
<tr>
<td>Projected Net Revenue (recurring expenses only)</td>
<td>$56.4</td>
<td>$11.1</td>
<td>($10.2)</td>
<td>($11.6)</td>
<td>($16.4)</td>
</tr>
<tr>
<td>Projected change in Tuition Revenue due to recommended rate increase</td>
<td>($7.75)</td>
<td>$0.00</td>
<td>$0.11</td>
<td>$3.46</td>
<td>$3.76</td>
</tr>
</tbody>
</table>

Increase in tuition revenue will partially address increased expenses; Strong management controls will still be required to contain total expenses.

---

1/ Projections are based on recommended tuition rate increases and assume constant fall 2022 enrollments. Projections include certain fees and waivers, but are before scholarships. Fees include application fees, course and lab fees, and professional fees, but do not include regular student fees. Tuition includes spring and fall main terms only.
Explanation of Recommendations (1/3)

Recommendation 1. No change to undergraduate tuition for AY2023-24 and 2024-25 at the 4-year campuses. Increase resident tuition rates for AY2025-26 and AY2026-27 by 2% each year and increase non-resident tuition rates by the equivalent dollar amount.

Rationale: Hawai‘i’s economy is still in recovery mode and increasing rates at this time would create hardship for our students and their families. Further, our comparative situation is generally favorable. Additionally, using reserves to cover one-time costs for the next few years and giving campuses time to align expenditures to revenues is a reasonable approach.
Explanation of Recommendations (2/3)

Recommendation 2. Keep tuition flat at the UHCC’s from AY 2023-24 to AY 2026-27.

Rationale: Any increase at all will impact those who need us most. Utility costs will remain relatively level due to fixed price contracts and reserve levels are very healthy.

Recommendation 3. No change to any graduate or professional school tuition, except for the WSRSL for AY 2024-25 through AY 2026-27.

Rationale: Our comparative institutions have generally maintained level rates for graduate tuition, and UH tuition remains relatively higher that its peers.
Recommendation 4. Keep WSRSL tuition flat in 2023-24, and increase resident tuition rates by 2% per year in 2024-25 through 2026-27, and increase non-resident rates by the equivalent dollar amount.

Rationale for Increase:

• WSRSL has compelling needs to support students, faculty, and staff with the additional tuition revenue

• WSRSL current tuition is modest in comparison to many accredited law schools. Their Strategic Plan conducted in 2021 recommended that WSRSL:

  *Increase tuition by modest percentages for both in-state and out-of-state students. Tuition currently charged by the law school is approximately 20% lower on average than other state institutions in the country...*
# Proposed Use of Additional Tuition Revenue at WSRSL

<table>
<thead>
<tr>
<th></th>
<th>Year 2 Total</th>
<th>Year 3 Total</th>
<th>Year 4 Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$112,000</td>
<td>$232,000</td>
<td>$353,000</td>
</tr>
<tr>
<td><strong>Library</strong></td>
<td>$60,000</td>
<td>$55,000</td>
<td>$72,000</td>
</tr>
<tr>
<td><strong>Moot Court and Client Counseling Teams</strong></td>
<td>$10,000</td>
<td>$11,000</td>
<td>$15,000</td>
</tr>
<tr>
<td><strong>Student Work Assistants, Student Research and Teaching Assistants</strong></td>
<td>$18,000</td>
<td>$20,000</td>
<td>$32,000</td>
</tr>
<tr>
<td><strong>Career Services Resources</strong></td>
<td>$9,000</td>
<td>$12,000</td>
<td>$16,000</td>
</tr>
<tr>
<td><strong>Bar Examination support</strong></td>
<td>$15,000</td>
<td>$17,000</td>
<td>$21,000</td>
</tr>
<tr>
<td><strong>Faculty Research, Conference and Presentation Support</strong></td>
<td></td>
<td>$34,000</td>
<td>$36,000</td>
</tr>
<tr>
<td><strong>Staff Training and Professional Development Opportunities</strong></td>
<td></td>
<td>$18,000</td>
<td>$22,000</td>
</tr>
<tr>
<td><strong>Technology Upgrades (particularly in older buildings, case management systems, recommended library improvements and tech subscriptions/licenses)</strong></td>
<td></td>
<td>$52,000</td>
<td>$60,000</td>
</tr>
<tr>
<td><strong>Other</strong> (deferred maintenance &amp; ADA compliance and necessary upgrades)</td>
<td></td>
<td>$13,000</td>
<td>$79,000</td>
</tr>
</tbody>
</table>
Proposed updates to Executive Policy
EP 6.201 (Tuition and Fees) and EP 6.202 (Tuition-Setting Procedures)

Current exceptions to the policy are now listed on the tuition tables only and will be moved into EP 6.201

• Explicitly state that full-time tuition applies to students enrolling for 12 or more credits at Mānoa, Hilo, West O‘ahu, and Maui College’s four-year degree programs. At UHCC (except for 300-level and above classes at Maui College), tuition is charged on a per-credit basis for all enrolled credits.

• Explicitly state that higher tuition rate (UHWO/UHH) applies to upper division courses at Maui College’s four-year degree programs and select Advanced Professional Certificate courses at the UHCC’s as approved by the Board.

• At the UHCC’s, credit by institutional exam is 50% of course tuition.

Change to EP 6.202

• Modify current face-to-face requirement to permit virtual public meetings.
Appendices
### TFSF tuition revenue – actual and projected

Resident Undergraduate tuition rate is flat in 2023-24 and 2024-25 and increases 2% in 2025-26 and 2026-27. Non-resident tuition rate flat in 2023-24 and 2024-25 and increases by equivalent dollar amount as resident tuition in 2025-26 and 2026-27. Graduate tuition rate is flat over the four-year period; Law (JD) resident tuition rate increases 2% in 2024-25 through 2026-27 with non-resident rate increasing at the same dollar amount.

#### UH System Resident
Projections based on enrollment held constant at Fall 2022 level

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>$172,116,270</td>
<td>$174,717,805</td>
<td>$165,392,032</td>
<td>$160,022,622</td>
<td>$160,022,622</td>
<td>$160,022,622</td>
<td>$160,022,622</td>
<td>$160,022,622</td>
<td>$160,022,622</td>
</tr>
</tbody>
</table>

#### UH System Non-Resident
Projections based on enrollment held constant at Fall 2022 level

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>$117,630,069</td>
<td>$118,615,831</td>
<td>$128,175,982</td>
<td>$128,175,982</td>
<td>$128,175,982</td>
<td>$128,175,982</td>
<td>$128,175,982</td>
<td>$128,175,982</td>
<td>$128,175,982</td>
</tr>
</tbody>
</table>

Note: Projections based on enrollment held constant at Fall 2022 level.
### Projected Revenues and Expenditures UH System

*(in $ millions)  Estimates from UH Budget Office. Figures assume no tuition rate increase.*

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Beginning Balance</strong></td>
<td>395.6</td>
<td>549.8</td>
<td>535.0</td>
<td>541.8</td>
<td>527.3</td>
<td>512.9</td>
<td>495.8</td>
</tr>
<tr>
<td><strong>REVENUES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>General Fund Appropriation</td>
<td>498.2</td>
<td>586.7</td>
<td>590.5</td>
<td>605.3</td>
<td>605.3</td>
<td>605.3</td>
<td>605.3</td>
</tr>
<tr>
<td>Tuition and Fees</td>
<td>342.3</td>
<td>324.7</td>
<td>327.3</td>
<td>327.6</td>
<td>327.6</td>
<td>326.4</td>
<td>327.6</td>
</tr>
<tr>
<td>Research &amp; Training RF</td>
<td>62.9</td>
<td>51.0</td>
<td>51.0</td>
<td>51.0</td>
<td>51.0</td>
<td>51.0</td>
<td>51.0</td>
</tr>
<tr>
<td>Other Special Funds</td>
<td>88.6</td>
<td>98.2</td>
<td>104.3</td>
<td>105.6</td>
<td>108.0</td>
<td>109.8</td>
<td>111.5</td>
</tr>
<tr>
<td>Other Revolving Funds</td>
<td>35.6</td>
<td>39.5</td>
<td>42.8</td>
<td>41.4</td>
<td>41.5</td>
<td>41.6</td>
<td>41.6</td>
</tr>
<tr>
<td>Appropriated Federal</td>
<td>10.4</td>
<td>12.2</td>
<td>13.1</td>
<td>13.2</td>
<td>13.2</td>
<td>13.2</td>
<td>13.3</td>
</tr>
<tr>
<td>Transfers-In</td>
<td>803.5</td>
<td>424.2</td>
<td>387.2</td>
<td>386.9</td>
<td>388.2</td>
<td>386.6</td>
<td>387.7</td>
</tr>
<tr>
<td><strong>Total Revenues</strong></td>
<td><strong>1,841.5</strong></td>
<td><strong>1,536.4</strong></td>
<td><strong>1,516.2</strong></td>
<td><strong>1,530.9</strong></td>
<td><strong>1,534.8</strong></td>
<td><strong>1,533.8</strong></td>
<td><strong>1,538.0</strong></td>
</tr>
<tr>
<td><strong>EXPENDITURES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regular Employee</td>
<td>591.7</td>
<td>641.4</td>
<td>671.1</td>
<td>702.8</td>
<td>703.3</td>
<td>703.8</td>
<td>704.3</td>
</tr>
<tr>
<td>Lecturer Payroll</td>
<td>36.7</td>
<td>39.6</td>
<td>43.6</td>
<td>45.6</td>
<td>45.6</td>
<td>45.7</td>
<td>45.7</td>
</tr>
<tr>
<td>Student Help Payroll</td>
<td>11.9</td>
<td>17.7</td>
<td>18.1</td>
<td>18.5</td>
<td>18.9</td>
<td>19.0</td>
<td>19.3</td>
</tr>
<tr>
<td>Other Personnel</td>
<td>7.1</td>
<td>8.2</td>
<td>8.2</td>
<td>8.3</td>
<td>8.3</td>
<td>8.3</td>
<td>8.3</td>
</tr>
<tr>
<td>Subtotal Personnel</td>
<td>647.4</td>
<td>706.8</td>
<td>741.0</td>
<td>775.3</td>
<td>776.2</td>
<td>776.8</td>
<td>777.7</td>
</tr>
<tr>
<td>Utilities</td>
<td>67.8</td>
<td>81.2</td>
<td>83.1</td>
<td>85.0</td>
<td>87.0</td>
<td>89.0</td>
<td>91.1</td>
</tr>
<tr>
<td>Scholarships, Stipends</td>
<td>63.4</td>
<td>63.8</td>
<td>62.9</td>
<td>63.0</td>
<td>63.1</td>
<td>63.3</td>
<td>63.4</td>
</tr>
<tr>
<td>Operating Maintenance</td>
<td>17.7</td>
<td>32.1</td>
<td>28.7</td>
<td>24.0</td>
<td>27.9</td>
<td>28.3</td>
<td>28.8</td>
</tr>
<tr>
<td>Other Non-Personnel</td>
<td>142.6</td>
<td>238.2</td>
<td>174.2</td>
<td>179.3</td>
<td>179.7</td>
<td>180.0</td>
<td>182.9</td>
</tr>
<tr>
<td>Debt Service</td>
<td>12.1</td>
<td>38.8</td>
<td>38.8</td>
<td>38.8</td>
<td>38.8</td>
<td>37.8</td>
<td>38.1</td>
</tr>
<tr>
<td>Transfers-out</td>
<td>736.2</td>
<td>390.2</td>
<td>380.7</td>
<td>380.1</td>
<td>376.5</td>
<td>375.8</td>
<td>375.1</td>
</tr>
<tr>
<td><strong>Total Expenditures</strong></td>
<td><strong>1,687.2</strong></td>
<td><strong>1,551.2</strong></td>
<td><strong>1,509.4</strong></td>
<td><strong>1,545.4</strong></td>
<td><strong>1,549.2</strong></td>
<td><strong>1,550.9</strong></td>
<td><strong>1,557.1</strong></td>
</tr>
<tr>
<td>Res Use for Planned Non-Recurring Exp</td>
<td>0.2</td>
<td>71.2</td>
<td>4.3</td>
<td>4.2</td>
<td>2.7</td>
<td>0.7</td>
<td>0.6</td>
</tr>
<tr>
<td><strong>REVENUES LESS EXPENDITURES</strong></td>
<td>154.4</td>
<td>56.4</td>
<td>11.1</td>
<td>(10.2)</td>
<td>(11.6)</td>
<td>(16.4)</td>
<td>(18.5)</td>
</tr>
<tr>
<td><strong>Ending Balance</strong></td>
<td>549.8</td>
<td>535.0</td>
<td>541.8</td>
<td>527.3</td>
<td>512.9</td>
<td>495.8</td>
<td>476.8</td>
</tr>
</tbody>
</table>
Item VII.
Executive Session

ITEM TO BE DISCUSSED IN EXECUTIVE SESSION
MEMORANDUM

TO: Randolph G. Moore  
Chair, Board of Regents

VIA: David Lassner  
President

FROM: Jan Gouveia  
Vice President for Administration

SUBJECT: APPOINTMENT OF MS. JENNIFER ROSE, DIRECTOR, OFFICE OF INSTITUTIONAL EQUITY, AS EXECUTIVE DIRECTOR OF EQUITY ASSURANCE, POSITION NO. 89262, UNIVERSITY OF HAWAI'I SYSTEM

SPECIFIC ACTION REQUESTED:

It is requested that the Board approve the appointment of Ms. Jennifer Rose as Executive Director of Equity Assurance, University of Hawai'i System, effective October 21, 2022, to continue in accordance with Board of Regent (BOR) policies and subject to satisfactory annual evaluations. The requested annual salary is $190,008 ($15,834 monthly), subject to Executive/Managerial adjustments as appropriate.

RECOMMENDED EFFECTIVE DATE:

October 21, 2022

ADDITIONAL COST:

This is a new position which replaces the vacant Director of EEO/AA. Additional costs will be absorbed within the System budget.

PURPOSE:

The appointment of Ms. Jennifer Rose as Executive Director of Equity Assurance is necessary to provide leadership for all aspects of civil rights compliance and advancing
equity and inclusion, including recommending, developing, and implementing policies and procedures, and programmatic initiatives addressing Title IX, equal opportunity, and affirmative action, as consistent with relevant state and federal regulations/laws and the institutional values and community standards of the University.

BACKGROUND INFORMATION:

Pursuant to Board of Regents Policy, RP 9.212, Executive and Managerial Personnel Policies, the President shall be the Appointing Authority for all other EM positions at the University, however, positions reporting directly to the President shall be subject to Board approval.

The Executive Director of Equity Assurance position was first advertised in August 2021 in the University of Hawaii's Job Opportunities website, as well as on-line in The Chronicle of Higher Education, Inside Higher Ed, The National Association of Colleges and University Attorneys, The Association of Public Land-Grant Universities, Women in Higher Education, DiverseJobs.Net, and the National Association of Diversity Officers in Higher Education. A total of 32 applications were received.

In March 2022, the recruitment for the position was postponed to further evaluate the duties and responsibilities of this position; concurrently, President Lassner administratively assigned the Office of Equity Assurance under the Office of the Vice President for Administration. Previous applicants were notified that the search was ceased and later that the position description was revised and that they could reapply when the position was readvertised in May 2022. A total of 19 applications were received with five candidates being invited for an interview, one of whom withdrew from consideration. Ms. Rose was identified by the search committee as the most qualified and the sole finalist for this position.

Ms. Rose obtained a Bachelor of Arts degree in Communications Studies, and a Juris Doctor degree, both from the University of California at Los Angeles. She has over 25 years of relevant professional work experience as a Director of Legal Services/Community Building at the Domestic Violence Action Center in Hawaii, an Adjunct Clinician/Instructor at the UH William S. Richardson School of Law, a Gender Equity Specialist at UH Mānoa, and from August 2015 to present, Director of the System Office of Institutional Equity. Her resume is attached.

The requested salary is slightly above the UH EM Band Mean of $186,375 annual for the SM-3 classification and under the UH EM Band Maximum of $236,250. Given Ms. Rose's educational background and professional work experience, she is well qualified to manage and lead the Office of Equity Assurance. As such, the requested annual salary of $190,008 is justified.
SPECIFIC ACTION RECOMMENDED:

It is recommended that the Board approve the appointment of Ms. Jennifer Rose as Executive Director of Equity Assurance, University of Hawaii System effective October 21, 2022, to continue in accordance with BOR policies and subject to satisfactory annual evaluations. The requested annual salary is $190,008 ($15,834 monthly), subject to Executive/Managerial adjustments as appropriate.

Attachments

Salary Placement Worksheet, Jennifer Rose
Resume, Jennifer Rose

c: Kendra Oishi, Executive Administrator and Secretary to the Board
AUGUST 2015 TO PRESENT
DIRECTOR
UNIVERSITY OF HAWAI’I SYSTEM - OFFICE OF INSTITUTIONAL EQUITY

• Establish inaugural systemwide, centralized compliance organizational and infrastructure to serve and assist ten campuses, towards creating consistency of institutional responses to sex discrimination, gender violence and civil rights matters
• Lead and coordinate compliance audits and implement best practices related to findings and recommendations
• Develop core competencies for Title IX and compliance staff to ensure quality control and consistency across ten-campus system of higher education, draft position description and assist in recruitment and onboarding of Coordinators, investigators, and compliance officers.
• Advise executive leadership and campuses and devise strategic initiatives to prevent and minimize discrimination and harassment and foster respectful and safe work and learning environments
• Develop, implement update system-wide policies and procedures related to sex/gender discrimination are adequate and up-to-date, and ensure that all campuses are consistently implementing these practices and standards
• Serve as a system-wide liaison for, advisor to, facilitate technical support for campus Title IX Coordinators and administrators involved in implementing policies and procedures, and investigating and resolving sex discrimination and retaliation complaints
• Develop and implement performance measures, establish metrics and benchmarks to assess and evaluate effectiveness of gender equity and Title IX compliance programs
• Lead, coordinate and implement periodic needs assessment and climate surveys to establish baseline and comparative data on prevalence of sex discrimination and gender violence; review available data and national best practices to develop systemwide programmatic response and prevention initiatives to increase safety and civility
• Develop curricula and implement systemwide training programs for employees and students to prevent and minimize discrimination, bias, workplace violence, harassment, and gender violence; conduct systemwide
• Work collaboratively and consult with internal and community partners to assess the effectiveness of system and campus efforts to prevent sex discrimination, sexual harassment, and gender violence in UH programs; recommend strategies and solutions, as appropriate, to campuses, Chancellors, senior administrators, and executives
• Establish and maintain systemwide website, intranet, and case management tracking system to improve efficiency of case management, operating procedures, and information sharing
• Track state and federal legislation related to Title IV, VAWA, sex discrimination and gender equity; as appropriate, act as liaison to state legislature
MARCH 2007 TO AUGUST 2015
GENDER EQUITY SPECIALIST/FACULTY
UNIVERSITY OF HAWAI’I AT MĀNOA

- Design and deliver training and educational programs, provide consultation and advocacy to students, staff and faculty regarding sex discrimination, civil rights, and gender-based violence prevention and institutional reporting
- Advise Chancellor and senior administrators regarding best practices to ensure gender equity and non-discrimination in academic and work environments
- Liaise and coordinate Title IX institutional compliance audit by the U.S. Department of Education, Office for Civil Rights
- Design and implement direct services programs to prevent and minimize risk of sex discrimination, sexual assault, stalking and domestic violence
- Conduct policy development and implementation in gender equity compliance areas: Title IX, Violence Against Women Act, Title VII, university policies, state, and federal law
- Build capacity of leadership and staff to respond appropriately to sex discrimination
- Advise, negotiate, and provide training on formal and informal grievance processes

APRIL 2004 TO JANUARY 2011
Adjunct Faculty, UH William S. Richardson School of Law
Develop curricula with learner outcomes blending theory and practice. Teach principles of domestic violence, trauma-informed and victim-centered interview techniques, safety planning, risk assessment, and advocacy strategies. Provide family law framework, teach trial advocacy skills

MARCH 2005 TO MARCH 2007
Director of Community Building, Domestic Violence Action Center
Develop culturally appropriate and inclusive models of service delivery for underserved populations. Conduct training on family and immigration law, inclusiveness, and cultural humility

MAY 1997 TO MARCH 2007
Director of Legal Services, Domestic Violence Action Center
Manage statewide legal services program for victims of domestic violence. Establish quality staff training program. Create legal service delivery objectives and litigation priorities. Conduct institutional advocacy to improve the civil legal system. Supervise legal team staff regarding divorce, paternity, restraining orders and other civil legal matters. Provide training regarding domestic violence, family law. Supervise immigrant outreach and community engagement

EDUCATION

SEPTEMBER 1991 TO JUNE 1994
JURIS DOCTOR
UNIVERSITY OF CALIFORNIA AT LOS ANGELES SCHOOL OF LAW
AWARDS: Nancie J. Mintie Public Interest Award for Outstanding Pro Bono Service, Japanese American Bar Association Fellowship, Pilipino American Bar Association Award
SEPTEMBER 1986 TO JUNE 1991
BACHELOR OF ARTS, COMMUNICATIONS STUDIES
UNIVERSITY OF CALIFORNIA AT LOS ANGELES
HONORS:  Cum Laude, Deans Honor Roll, College Honors

SKILLS

- Excellent oral presentation and writing skills
- Bias identification, confrontation, and training
- Policy development and analysis
- Civil rights compliance plans and audits
- Cultural humility and diversity training
- Climate survey studies
- Inclusive management
- Risk assessment
- Informal resolution negotiation
- Civil rights investigations certification
- Title IX Coordinator certification
- Legislative drafting and analysis
- Legal research and writing
- Curricular planning and development
- Grant writing and management
- Talent management recruitment
- Qualitative metrics and benchmarks
- Facilitation and mediation

AWARDS AND BAR AFFILIATIONS

- 2018 Outstanding Female Attorney of the Year -- Hawaii Women Lawyers Association
- 2012 Patsy T. Mink Foundation Award for championing Title IX and Gender Equity
- 2012 Hawaii House of Representatives and Hawaii Senate Recognition for Outstanding Contributions to Advance Gender Equity
- 2011 Hawaii State Bar Association Champion for Social Justice for advocacy on inclusion, language access, gender equity and immigrant rights
- 2011 Honolulu County Commission on the Status of Women “Most Inspiring Women Award”
- 2011 Advocates for Public Interest Law Faculty Award – William S. Richardson School of Law
- 2006 Rhoda Lewis Award for Outstanding Public Interest Attorney – HWL Foundation
- 2005 and 2006 Law Adjunct Faculty of the Year Award(s) -- William S. Richardson School of Law
- 1995 - Admitted to the California Bar
- 1996 – Admitted to the Hawaii Bar

SELECTED PUBLICATIONS

MEMORANDUM

TO: Randolph G. Moore  
   Chair, Board of Regents

VIA: David Lassner  
     President

FROM: Michael Bruno  
      Provost

SUBJECT: APPOINTMENT OF DR. NAOTO UENO, AS DIRECTOR OF THE UNIVERSITY OF HAWAI‘I CANCER CENTER, UNIVERSITY OF HAWAI‘I AT MĀNOA

SPECIFIC ACTION REQUESTED:

It is requested that you approve the appointment of Dr. Naoto Ueno as Director of the University of Hawai‘i Cancer Center (UHCC), University of Hawai‘i at Mānoa (UH Manoa), at an annual salary of $425,004 ($35,417/monthly), effective December 12, 2022, subject to any E/M salary adjustments as appropriate.

In accordance with Executive Policy 9.215, Tenure Upon Initial Appointment, a separate request for tenure upon appointment for Dr. Ueno will be submitted.

RECOMMENDED EFFECTIVE DATE:

December 12, 2022.

ADDITIONAL COST:

There is no additional cost given the requested salary is lower than the previous permanent/regular director.

PURPOSE:

The purpose of the appointment of a regular Director is to provide stability and continuity of leadership for UHCC. The former Director, Dr. Randall Holcombe, resigned effective July 31, 2021, and Dr. Joe Ramos was appointed Interim Director effective August 1, 2021. However, Dr. Ramos resigned from UHCC effective July 31, 2022, and Dr. Loic Le Marchand has been
appointed as interim director until Dr. Ueno starts on December 12, 2022. The need for a regular executive leader is crucial in providing leadership and guidance in all aspects of UHCC locally, nationally, and internationally, maximizing the benefit of its multicultural and Asia/Pacific region, intellectual development, fundraising, and management of all aspects of UHCC operations.

BACKGROUND:

In consideration of Executive Policy, EP 9.212, Executive/Managerial Classification and Compensation, the Board of Regents is authorized to appoint, reappoint, and make compensation decisions for salaries that are above the maximum of the pay range in the salary schedule.

In August 2021, the Office of the Provost organized a Search Advisory Committee (SAC) comprised of two executives (co-chairs), faculty members (internal and external to UHCC), support staff, a graduate student, an undergraduate student, Kuailii Council representatives, and community members from the local health systems. An executive level search was formally announced in September 2021 to identify an individual for the position of Director, UHCC. After an extensive review by the SAC, six (6) candidates were deemed to be the best qualified and interviewed. The interviews were conducted via Zoom videoconference. The SAC forwarded four (4) names to me who they recommended as finalists. All four (4) candidates were invited for the campus visit phase of the search process.

The four (4) finalists’ campus visits were held during the period February 14-March 16, 2022. After each of the candidates’ sessions, which included meetings with all UHCC faculty, staff, and students, John A. Burns School of Medicine faculty, campus deans/directors, administrators, a public presentation, and community sessions, online evaluations were made available to all attendees and collected by the Office of the Provost.

After careful consideration and review of all evaluations and references, Dr. Naoto Ueno was deemed the best candidate. After negotiations, an offer was made and accepted contingent upon Board posting and Board of Regents’ approval. Dr. Ueno is the best qualified at this time to lead UHCC in its goals and mission and will be a valuable leadership team member in fulfilling our vision at UH Mānoa.

Dr. Ueno is a tenured Professor of Medicine at The University of Texas MD Anderson Cancer Center; his research is in the area of aggressive breast cancer, especially inflammatory breast cancer (IBC) and triple negative breast cancer (TNBC). He is best known for his preclinical development and biomarker research efforts that have been translated into novel investigator-initiated clinical trials.

Dr. Ueno is the executive director of the MD Anderson IBC Research Program and Clinic and chief of the Section of Translational Breast Cancer Research in the Department of Breast Medical Oncology. Working with his team members, he has created a comprehensive research program and clinic devoted to IBC, which under his leadership has become the world's largest and most renowned for rare breast cancer. His visionary perspective has earned him opportunities to collaborate on the local and global levels and create a novel, robust strategy that has inspired his team members to thrive and achieve high productivity in the clinical,
research, education, and patient communities. His passion is developing and serving a team that creates and provides research-driven compassionate patient care.

Dr. Ueno has a wide range of leadership skills that have helped him to build a team culture reflecting diversity and psychological safety. His research includes the roles and underlying mechanisms of several signaling pathways, including epidermal growth factor receptor, c-Jun N-terminal kinase (JNK), and Axl receptor tyrosine kinase, in promoting the progression of TNBC and IBC.

Dr. Ueno has sustained significant extramural funding and currently has grants from National Institutes of Health (NIH) (two R01s and one R21), Cancer Prevention and Research Institute of Texas (CPRIT), Department of Defense (DOD), and Breast Cancer Research Foundation (BCRF) (two awards). In addition, he conducts numerous investigator-initiated clinical trials (Phase I/III) for patients with advanced breast cancer as a principal investigator, based on his laboratory discoveries. He has also assisted and guided numerous colleagues in obtaining grants and research contracts.

Outside of MD Anderson, Dr. Ueno has had extensive experience in teaching leadership/communication skills and clinical research skills for drug development. He is a DDI-certified leadership facilitator and TEDx speaker. Further, he has published two books related to patient empowerment in cancer care (10,000 copies each). He is deeply committed to sharing his knowledge and experience and has mentored numerous medical students, graduate students, and clinical residents and fellows at MD Anderson and The University of Texas Graduate School of Biomedical Sciences.

Dr. Ueno received the Nylene Eckles Distinguished Professorship of Breast Cancer Research in 2012. In addition, he received The University of Texas System Regents' Outstanding Teaching Award for his mentoring contributions in 2014 and the MD Anderson Distinguished Clinical Faculty Mentor Award in 2019. He serves as a standing member of the NIH's Drug Discovery and Molecular Pharmacology Study Section. In addition, he is the editor-in-chief of the Journal of Cancer and serves as an editorial board member of the Journal of the National Cancer Institute.

Dr. Ueno obtained his M.D. from Wakayama Medical College in Japan, and his Ph.D. in Cancer Biology from The University of Texas Graduate School of Biomedical Sciences. He is board certified by the American Board of Internal Medicine in internal medicine and medical oncology.

The Director position is currently assigned to band SM-5 of the University's Executive/Managerial Salary Schedule proposed rates effective October 1, 2022 with a minimum of $283,500, midpoint of $338,625 and maximum of $393,750. Given Dr. Ueno's accomplishments and his administrative experience, he is well qualified to manage and lead the operations and staff at UHCC. Thus, the proposed annual salary of $425,004 is justified.

Critical to the selection of Dr. Ueno is his commitment to and knowledge regarding maintenance of the Cancer Center's National Cancer Institute (NCI) designation. In addition to Dr. Ueno's UH responsibilities and related UH salary, he has been offered the opportunity to maintain his clinical administrative skills for up to 8 hours each week as an employee of the University Health
Partners of Hawaiʻi (UHP), a 501(c)3 organization which serves as the UH affiliated practice plan. We understand that his compensation from UHP will be in the range of $100,000 per year and will be conditioned upon retention of the Director position. The University is not responsible for this compensation, and UHP will determine whether or not to continue or terminate his UHP employment. As a UHP employee, Dr. Ueno will build translational research opportunities and bring federal funds to that task; provide a venue and support for cancer investigators to bring cutting edge research to Hawai’i; assist the health systems with their clinical research offerings; and assist with the recruitment and development of clinical cancer investigators. These activities will assist in strengthening the clinical collaboration between major cancer care hospitals affiliated with UH and the UH Cancer Center, an expectation of the NCI. Attention will be paid to maintaining a clear separation of these duties and his UH responsibilities. This arrangement will extend that which is afforded faculty and will not interfere with Dr. Ueno’s ability to perform the duties and meet the responsibilities of his job as Cancer Center Director. In fact, this additional outside employment is viewed as an enhancement to his ability to perform his duties as Cancer Center Director. Details of this (non-UH funds) arrangement will be finalized with Dr. Ueno in compliance with applicable laws and UH policy.

**ACTION RECOMMENDED:**

It is recommended that you approve the appointment of Dr. Naoto Ueno as Director of the University of Hawaiʻi Cancer Center (UHCC), University of Hawaiʻi at Mānoa (UH Manoa), at an annual salary of $425,004 ($35,417/monthly), effective December 12, 2022, subject to any E/M salary adjustments as appropriate.

**Attachments:**

1. Executive/Managerial (E/M) – Salary Placement Analysis
2. Curriculum Vitae of Dr. Naoto Ueno

cc: Kenda Oishi, Executive Administrator and Secretary of the Board
MEMORANDUM

TO: David Lassner
President

FROM: Michael Bruno
Provost

SUBJECT: TENURE UPON INITIAL APPOINTMENT AND FACULTY Fallback SALARY FOR DR. NAOTO UENO, DIRECTOR, JOHN A. BURNS SCHOOL OF MEDICINE, UNIVERSITY OF HAWAI‘I AT MĀNOA

SPECIFIC ACTION REQUESTED:

It is requested that you approve the tenure upon initial appointment and faculty fallback salary of Dr. Naoto Ueno at the rank of Professor (M-5) in a fallback tenured faculty position (11-month) in the Department of Medicine, John A. Burns School of Medicine (JABSOM), University of Hawaii‘i at Mānoa (UHM).

RECOMMENDED EFFECTIVE DATE:

The recommended effective date is December 12, 2022 concurrent with his EM appointment.

ADDITIONAL COST:

There will be no additional cost.

PURPOSE:

The purpose of this request is to provide tenure upon initial appointment for a fallback faculty position and salary to Dr. Naoto Ueno, Director-Designate, University of Hawai‘i Cancer Center (UHCC), which is essential for the recruitment of Dr. Ueno to UHM. Dr. Ueno comes to UHM with an extensive and broad range of academic and medical experiences in higher education, which includes an accomplished academic leadership.

BACKGROUND:

Pursuant to Board of Regents Executive Policy EP 9.215 approved by the Board on January 10, 2008, the President is authorized to approve tenure upon initial appointments and faculty fallback salary for all faculty positions and classified executives who have previously held tenure at a comparable institution.
Dr. Ueno is a tenured Professor of Medicine at The University of Texas MD Anderson Cancer Center; his research is in the area of aggressive breast cancer, especially inflammatory breast cancer (IBC) and triple negative breast cancer (TNBC). He is best known for his preclinical development and biomarker research efforts that have been translated into novel investigator-initiated clinical trials.

Dr. Ueno is the executive director of the MD Anderson IBC Research Program and Clinic and chief of the Section of Translational Breast Cancer Research in the Department of Breast Medical Oncology. Working with his team members, he has created a comprehensive research program and clinic devoted to IBC, which under his leadership has become the world's largest and most renowned for rare breast cancer. His visionary perspective has earned him opportunities to collaborate on the local and global levels and create a novel, robust strategy that has inspired his team members to thrive and achieve high productivity in the clinical, research, education, and patient communities. His passion is developing and serving a team that creates and provides research-driven compassionate patient care.

Dr. Ueno has a wide range of leadership skills that have helped him to build a team culture reflecting diversity and psychological safety. His research includes the roles and underlying mechanisms of several signaling pathways, including epidermal growth factor receptor, c-Jun N-terminal kinase (JNK), and Axl receptor tyrosine kinase, in promoting the progression of TNBC and IBC.

Dr. Ueno has sustained significant extramural funding and currently has grants from NIH (two R01s and one R21), CPRIT, DOD, and BCRF (two awards). In addition, he conducts numerous investigator-initiated clinical trials (Phase I/II) for patients with advanced breast cancer as a principal investigator, based on his laboratory discoveries. He has also assisted and guided numerous colleagues in obtaining grants and research contracts.

Outside of MD Anderson, Dr. Ueno has had extensive experience in teaching leadership/communication skills and clinical research skills for drug development. He is a DDI-certified leadership facilitator and TEDx speaker. Further, he has published two books related to patient empowerment in cancer care (10,000 copies each). He is deeply committed to sharing his knowledge and experience and has mentored numerous medical students, graduate students, and clinical residents and fellows at MD Anderson and The University of Texas Graduate School of Biomedical Sciences.

Dr. Ueno received the Nylene Eckles Distinguished Professorship of Breast Cancer Research in 2012. In addition, he received The University of Texas System Regents' Outstanding Teaching Award for his mentoring contributions in 2014 and the MD Anderson Distinguished Clinical Faculty Mentor Award in 2019. He serves as a standing member of the NIH's Drug Discovery and Molecular Pharmacology Study Section. In addition, he is the editor-in-chief of the Journal of Cancer and serves as an editorial board member of the Journal of the National Cancer Institute.

Dr. Ueno obtained his M.D. from Wakayama Medical College in Japan, and his Ph.D. in Cancer Biology from The University of Texas Graduate School of Biomedical Sciences. He is board certified by the American Board of Internal Medicine in internal medicine and medical oncology.
He currently holds tenure in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center (see attached confirmation letter).

In compliance with Executive Policy EP 9.215, Dr. Scott Kuwada, Chair of JABSOM, Department of Medicine’s Department Personnel Committee, in concurrence with other committee members, supports Dr. Ueno’s tenure upon appointment at the rank of Professor (M-5, 11-month).

The recommended fallback salary for Dr. Ueno is $204,000 ($17,000/month) which is comparable with (current) faculty salaries (M-5, 11-month) at JABSOM. If tenured as a Professor (M-5), the recommended fallback salary of $204,000 will be reconstructed upon Dr. Ueno’s return to faculty status in JABSOM to include all negotiated faculty adjustments, as well as depending on whether Dr. Ueno’s faculty duties include clinical care or clinical research.

Attached for your review are Dr. Ueno’s curriculum vitae, recommendations for granting of tenure from the Co-chair of the Search Advisory Committee, Dr. Lee Buenconsejo-Lum, and JABSOM, Department of Medicine’s Personnel Committee Chair, Dr. Scott Kuwada, and documentation of tenure status at The University of Texas MD Anderson Cancer Center.

**ACTION RECOMMENDED:**

It is requested that you approve the tenure upon initial appointment and faculty fallback salary of Dr. Naoto Ueno at the rank of Professor (I-5M) in a fallback tenured faculty position (9-month) in the Department of Medicine, John A. Burns School of Medicine (JABSOM), University of Hawai‘i at Mānoa (UHM).

**Attachments:**  Curriculum vitae of Dr. Naoto Ueno  Recommendation from Dr. Buenconsejo-Lum  Recommendation from Dr. Scott Kuwada and Dean Jerris Hedges  Documentation of tenure status for Dr. Ueno

**APPROVED/DISAPPROVED:**

____________________________________       Date  
David Lassner       President

**c:**  Interim Director Jeff Long, OHR
CURRICULUM VITAE

Naoto Tada Ueno, M.D., Ph.D., F.A.C.P.

PRESENT TITLE AND AFFILIATION

Primary Appointment

Section Chief, Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Nylene Eckles Distinguished Professorship in Breast Cancer Research, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Executive Director, The University of Texas MD Anderson Cancer Center Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX

Professor, with Tenure, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

N/A

OFFICE ADDRESS

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd
Unit Number: Unit 1354
Houston, TX 77030
Room Number: CPB5.3552
Phone: 713-792-8754
Fax: 713-794-4385
Email: nueno@mdanderson.org

EDUCATION

Degree-Granting Education

Wakayama Medical College, Wakayama, Japan, MD, PhD, Doctor of Medicine

The University of Texas Graduate School of Biomedical Sciences, Houston, TX, PHD, Cancer Biology

Postgraduate Training

Clinical Internship, Rotating Internship, United States Naval Hospital, Yokosuka, Kanagawa, Japan, 4/1989–3/1990
Clinical Internship, Internal Medicine, Montefiore University Hospital - University of Pittsburgh, Pittsburgh, PA, 7/1990−4/1991

Clinical Residency, Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, 7/1991−6/1993

Clinical Fellowship, Medical Oncology and Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/1993−6/1996

CREDENTIALS

Board Certification
American Board of Internal Medicine - Internal Medicine, 147710, 1993−2024, Recertification Date: 2014
American Board of Internal Medicine - Medical Oncology, 147710, 1995−2025, Recertification Date: 2015

Licensures
Active
Japan, 328034, 4/1989
TX, J4676, 11/1993
Florida Telehealth, FL, TPME1758, 6/2021

Inactive
N/A

EXPERIENCE/SERVICE

Academic Appointments
Instructor, Department of Hematology, Division of Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1996−1998
Assistant Professor, Stem Cell Transplantation & Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1998−2004
Associate Professor, Department of Molecular and Cellular Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/1999−5/2006
Associate Professor, Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2004−2009
Associate Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007−2009
Professor, Stem Cell Transplantation & Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009−2011
Professor, with Tenure, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009−present

Administrative Appointments/Responsibilities
Director, The University of Texas M. D. Anderson Cancer Center Breast Cancer Translational Research Laboratory, Houston, TX, 2002−2004
Executive Director, The University of Texas MD Anderson Cancer Center Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX, 6/2011−present
Section Chief, Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 6/2011−present

Other Appointments/Responsibilities
Member, Graduate School of Biomedical Sciences, Houston, TX, 12/1999−present
Leader, The University of Texas MD Anderson Cancer Center, SCT Solid Tumor Program, Houston, TX, 2006–2010

Member, The University of Texas Health Science Center at Houston, Center for Clinical and Translational Research, Houston, TX, 2007–2009

Visiting Professorship, Keio University School of Medicine Center for Clinical Cancer Research, Shinjuku, Japan, 5/2009–present

Board Member of Program Advisory Committee, Cancer Net Japan, Tokyo, Tokyo, Japan, 7/2009–present

Breast Cancer Committee Member, Southwest Oncology Group, San Antonio, TX, 2010–present

Visiting Professorship, Wakayama Medical College, Wakayama, Japan, 4/2010–present

Medical Advisor, Inflammatory Breast Cancer Foundation, Milford, MI, 6/2011–present

Guest Professor, Keio University School of Medicine, Tokyo, Tokyo, Jordan, 4/2012–present

Founder, Japan Team Oncology Leadership Academy, Tokyo, Japan, 8/2013–present

Committee Member, Tokyo Oncology Consortium Gap Committee, Tokyo, Japan, 10/2013–present

Nomination Advisory Committee, The University of Texas System, Office of Health Affairs Regents’ Outstanding Teaching Awards 2014, Houston, TX, 11/2013–10/2014

Committee Member, Breast Cancer Research Foundation - AACR Grants Scientific Review Committee, Houston, TX, 11/2013–present

Member, Department of Health and Human Services Food and Drug Administration, Silver Spring, MD, 2/2015–2/2021

Committee Member, National Consortium of Breast Center International Committee, Las Vegas, NV, 3/2018–present

TNBC Immunomedics plans for Sacituzumab Govitecan, Immunomedics Advisory Board, Dallas, TX, 4/2018

Visiting Director, Showa University, Advanced Cancer Translational Research Institute, Tokyo, Jordan, 8/2018–present

President, U.S. Naval Hospital Yokosuka, Intern Alumni Club, Yokosuka, Japan, 3/2019–present

Advisor, Japan Foundation for Cancer Research, Tokyo, Japan, 11/2019–present

Mentor, American Society of Clinical Oncology (IDEA Program), Houston, TX, 2/2020–present

Endowed Positions

Nylene Eckles Distinguished Professorship in Breast Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 6/2012–present

Consultantships

Junai of the Tokyo Hospital Pharmacists Association, Tokyo Japan, Consultant, 2003–present

Japan Comprehensive Cancer Network, Breast, Tokyo, Japan, Board of Directors, 2005–present

Military or Other Governmental Service

U.S. Naval Hospital, Department of Medicine, Civilian, 1989–1990

Institutional Committee Activities

Fellows Education Committee, Member, 1994–1995

M. D. Anderson Associates, Member, 1995–2000

M. D. Anderson Associates, Vice Chair, 2000–2001
Asia Task Force, Member, 2000–2003

BMT in Breast and Kidney Cancer, Dept of Blood and Marrow Transplantation Division of Cancer Medicine, Program Leader, 2000–2006

M. D. Anderson Alumni and Faculty Associates, Chairman, 2001–2009

MD Anderson & St. Luke International Hospital & Keio University Sister Institution Committee, Extramural activity (GAP), Chairman, 2003–present

Japanese International Advisory Committee, Member, 2007–2009

Breast Cancer Bone Metastasis Working Group, Chair, 2007–2014

Breast Medical Oncology Department Concepts & Protocols Review Committee, Committee Chairman, 12/2010–12/2011

Educational Role Recognition Committee, Member, 2011–2012

Global Academic Programs Oversight Steering Committee, Member, 8/2012–2/2014

MD Anderson Cancer Center Breast Cancer Research Program (BCRP) Steering Committee, Member, 1/2013–present

MD Anderson Moonshot Program, Committee Member, 8/2013–2017

Synthetic Lethal Screen Oversight Committee, Member, 10/2013–6/2017

Scientific Publication Advisory Board, Member, 10/2013–present

International Advisory Board, Board Member, 3/2014–present

Research Charges for Innovative New Trials Committee (ReCINT), Member, 12/2014–present

Translational Research Strategic Planning Committee, Member, 5/2015–present

Oversight Committee of the Biostatistics Resource Group, Member, 5/2016–present

Multidisciplinary Research Advisory Committee, Member, 6/2016–present

Multidisciplinary Research Advisory Committee (MRAC), Committee member, 6/2016–present

PEAC of Breast Center, Committee Member, 12/2017–present

Patient Experience Operational Task Force, Task Force Member, 8/2018–present

Academy of Health Education, Committee Member, 4/2019–present

MD Anderson Cancer Center’s 2019 Alfred G. Knudson, Jr., Award, Committee Member, 2/2020–4/2020

HONORS AND AWARDS

Clinical Fellow Research Award, M. D. Anderson Cancer Center, 1995–1996

Cancer Research Achievement Award, M. D. Anderson Cancer Center, 1996

Houston Endowment, Jesse H. Jones Fellowship in Cancer Education, 1996

Outstanding Achievement in Cancer Research Award, Pharmacia and Upjohn, 1996

American Association Cancer Research-Glaxo Wellcome Oncology Clinical Research Scholar Award for Promising Translation or Clinical Research, Glaxo Wellcome, 1998


6th Robert M. Chamberlain Distinguished Mentor Award Nomination (Finalist top 3), MD Anderson Cancer Center, 2008–2009
6th Annual Robert M. Chamberlain Distinguished Mentor Award, M. D. Anderson Postdoctoral Association, 2009

MD Anderson's Distinguished Faculty Mentor Award Nomination, The University of Texas MD Anderson Cancer Center, 2010

Amgen Basic Research Award, 2nd Prize for Mentoring, MD Anderson Cancer Center, 2011

Waun Ki Hong Award for Excellence in Team Science, Division of Cancer Medicine Faculty Recognition and Awards Program, 2012–present

Regents Outstanding Teaching Award, The University of Texas System, 2013–2014

Emil Frei, III Award for Excellence in Translational Research (nominated), DOCM, MDA, 2015

Unknown Hero Award, Run for the Cure Foundation, 2018

MD Anderson Distinguished Clinical Faculty Mentoring Award, MD Anderson Cancer Center, 2019

MD Anderson Distinguished Educator, MD Anderson Cancer Center, 2019–present

RESEARCH
Grants and Contracts
Funded


Principal Investigator, 1%, A phase II study of anti-PD-1 (MK-3475) therapy in patients with metastatic inflammatory breast cancer who have received prior chemotherapy with clinical response, 13576 (2014-0533), MERCK, 2/18/2015–2/28/2022, $592,961 ($81,668/year)

Principal Investigator, 1%, A phase II study using talimogene laherparepvec (T-VEC) as a single agent for IBC or non-IBC patients with inoperable local recurrence, 16026 (2014-0034), AMGEN, 7/21/2015–7/31/2021, $694,736 ($93,899/year)

Principal Investigator, 5%, Morgan Welch Inflammatory Breast Cancer Research Program, and State of Texas Rare and Aggressive Breast Cancer Research Program Grant, State of Texas, 9/1/2015–present ($1,600,000/year)

Principal Investigator, Cathy Rain SMith Inflammatory Breast Fund, 600143-80-115583-19, Cathy Rain Smith IBC Fund, 9/25/2015–present, $75,000

Principal Investigator, 1%, Tissue biomarker study of T-DM1 and/or pertuzumab resistant or refractory breast cancer N10000-A-U002, 51248 (PA15-0499), Daiichi Sankyo, 1/6/2016–1/31/2022, $264,265 ($40,509/year)

Principal Investigator, 1%, Determine in vitro and in vivo anti-tumor activity of Naclynamide in inflammatory breast cancer, 52092, Therimunex, 4/28/2016–4/30/2022, $545,458 ($68,182/year)

Co-Principal Investigator, 1%, A phase IIIB study of neoadjuvant ZT regimen (enzalutamide therapy in combination with weekly paclitaxel) for androgen receptor (AR)-positive triple-negative breast cancer, 52135 (2015-0488), Astellas Pharma Global Development, 6/13/2016–9/30/2022, $442,047 ($73,933/year)

Principal Investigator, 1%, Determining the anti-tumor efficacy of DS-8201a or patritumab based on novel HER2 targeted drug resistant HER2 positive breast cancer cell lines, 52951 (LS2016-00052951-RM), Daiichi Sankyo, 8/12/2016–3/31/2025, $260,143 ($44,930/year)
Principal Investigator, 1%, Comparison of the predictability of recurrence of mult-gene classifier CurebestTM 95GC and Oncotype DX in ER positive and node negative breast cancer patients who have undergone surgery, 51882 (PA15-0905), Sysmex, 10/1/2016−3/31/2021, $180,249 ($114,530/year)


Co-Investigator, 1%, A phase 1b study of neratinib, pertuzumab and trastuzumab with taxol (3HT) in primary metastatic and locally advanced breast cancer, and phase II study of 3HT followed by AC in HER2+ primary IBC, and neratinib with taxol (NT) followed by AC in HR+, 52913 (2016-0537), Puma Biotechnology, Inc., PI - Lim, 1/30/2017−1/28/2022, $486,336 ($4,826/year)

Co-Investigator, 1.5 months, Phase 1, Two-Part, Multi-Center, Non-Randomized, Open-Label, Multiple Dose First-In-Human Study of DS-8201A, In Subjects with Advanced Solid Malignant Tumors, 53157 (2016-0583), Daiichi Sankyo, PI - Krishnamurthy, 2/8/2017−7/27/2024, $598,386 ($60,325/year)

Principal Investigator, 8%, Enhancing anti-EGFR therapeutic efficacy in inflammatory breast cancer, 5R01CA205043-5477, NIH/NCI, 3/15/2017−2/28/2022, $1,453,019 ($230,000/year)

Principal Investigator, 1%, Identification of Therapeutic Molecular Targets that Enhance Anti-Tumor Activity of Neratinib in Breast Cancer, 54145, Puma Biotechnology, Inc., 4/20/2017−4/19/2022, $295,779 ($48,490/year)

Principal Investigator, 4%, A Phase I Study of OTS167PO, a MELK inhibitor, to Evaluate Safety, Tolerability and Pharmacokinetics in Patients with Advanced Breast Cancer and Dose-Expansion Study in Patients with Triple Negative, 53715 (2016-1096), OncoTherapy, 4/26/2017−4/30/2022, $192,772 ($33,210/year)

Co-Investigator, 0.12 months, SIV Division of Cancer Medicine Genentech SIV Alliance, 53251 (2016-0916), Genentech Inc, PI - Flowers, 7/11/2017−8/11/2023, $6,555,000

Co-Investigator, 5%, Combinatorial Treatment Strategies to Counteract EGFR Resistance, R01 CA218036, NIH/NCI, PI - Yang, Liqiang, 9/18/2017−8/31/2022, $943,617 ($22,630/year)

Principal Investigator, 1%, Phase II study of combination ruxolitinib (INCB018424) with preoperative chemotherapy for triple negative inflammatory breast cancer TBCRC039, 55364 (2018-0002), Johns Hopkins University, 5/1/2018−4/30/2023, $13,500 ($12,873/year)

Principal Investigator, 1%, Determine in vitro anti-proliferation effect of PMD-026 in triple-negative breast cancer, 13034242, Phoenix Molecular Designs, LTD, 12/1/2018−11/30/2026, $58,578 ($16,010/year)

Principal Investigator, 7%, Development of Novel Combinational Therapy with Enzalutamide in AR+ TNBC, 57051, BCRF, 2/1/2019−8/30/2022, NCE, $170,000 ($141,000/year)

Principal Investigator, 0.12 months, A Phase 3, multicenter, randomized, open-label, active-controlled trial of DS-8201a, an anti-HER2-antibody drug conjugate (ADC), versus treatment of physician’s choice for HER2-low, unresectable and/or metastatic breast cancer subjects, 2018-0828, Daiichi Sankyo Co., Ltd, 2/22/2019−2/21/2026, $808,536 ($316,355/year)

Principal Investigator, 3%, Phase 1/2, Multicentr, nonrandomized, open-label, multiple dose firs-inhuman study of U3-1402, in subjects with HER3 positive metastatic breast cancer, 56378 (2018-1014), Daiichi Sankyo Co., Ltd., 2/27/2019−2/26/2026, $770,449 ($296,342/year)

Principal Investigator, 1%, Determining the anti-tumor effect of U3-1402 and the best synergistic partner in targeting hormone receptor positive breast cancer, 56841, Daiichi Sankyo Co., LTD, 3/27/2019–3/26/2022, $553,945 ($173,108/year)

Co-Investigator, 1%, Enhancing the efficacy of Axl inhibitor TP-0903 in inflammatory breast cancer and triple-negative breast cancer, 56911, Tolero, 4/11/2019–4/30/2022, $240,551 ($87,672/year)

Principal Investigator, 1%, Determining the anti-tumor effect of U3-1402 and the best synergistic partner in targeting hormone receptor positive breast cancer, 56841, Daiichi Sankyo Co., LTD, 3/27/2019–3/26/2022, $553,945 ($173,108/year)

Co-Investigator, 1%, Enhancing the efficacy of Axl inhibitor TP-0903 in inflammatory breast cancer and triple-negative breast cancer, 56911, Tolero, 4/11/2019–4/30/2022, $240,551 ($87,672/year)


Co-Investigator, 1%, Targeting GD3 synthesis (ST8SIA1) in GD2+breast cancer stem-like cells to prevent tumor growth and metastases in triple negative breast cancer, BC181493, Department of Defense (DOD), PI - Venkata Lokesh Battula, 8/1/2019–7/31/2022, $399,999 ($4,826/year)

Principal Investigator, 0.12 months, Biomarker Discovery Study of DS-8201a, an Anti-HER2-antibody Rug Conjugate, in Randomized Phase III Trials in Unresectable and/or Metastatic Breast Cancer, 56360 (PA18-1100), Daiichi Sankyo Co, Ltd, 9/4/2019–9/3/2026, $199,390 ($199,390/year)

Co-Principal Investigator, 1%, Exploring the role of estrogen receptor beta in progression and metastasis of inflammatory breast cancer, R01 CA237200, NIH/NCI, PI - Thomas/Jung, 12/1/2019–11/30/2024, $94,102 ($5,769/year)

Co-Principal Investigator, 2.5%, Development of a novel Tumor-targeting and Penetrating Nanosystem for Breast Cancer Therapy, BC190193P1, Department of Defense (DOD), 1/1/2020–3/31/2022, $334,559 ($158,136/year)

Principal Investigator, 0.18 months, BC190193P1: Development of a Novel Tumor-targeting and Penetrating Nanosystem for Breast Cancer Therapy, W81XWH-20-10123, EnduRx, 3/1/2020–2/28/2023, $344,559 ($107,675/year)


Principal Investigator, 1%, Development of Novel Therapy by targeting the tumor microenvironment in inflammatory breast cancer, 5130 (BCRF-20-164), Breast Cancer Research Foundation (BCRF), 10/1/2020–9/30/2022, $174,788 ($174,788/year)

Principal Investigator, 0.12 months, DROPLET-BRC study, 5211 (2020-0724), Preferred Medicine, Inc., 10/23/2020–10/22/2027, $375,190 ($375,190/year)

Principal Investigator, 0.12 months, Study on the predictability of hormone and chemo resistance in luminal BC patients who have received CDK4/6 inhibitor by Gene Expression Analysis (and analyze TNBC Patients who have FGFR mutations.), 58502, Showa University, 10/30/2020–10/29/2027, $19,800 ($19,800/year)
Principal Investigator, 0.12 months, Preclinical study of OBI-999 targeting Globo-H in metastatic breast cancer, 5478, OBI Pharma, 12/14/2020−12/13/2022, $149,215 ($149,215/year)

Principal Investigator, 0.12 months, Multi, Open-Label Ph 1/2 Trial, Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRA)-Targeting Antibody-Drug Conjugate (ADC) in Subjects with Selected Tumor Types, 5388 (2020-0017), Eisai, Inc., 12/14/2020−12/13/2027, $36,700 ($36,700/year)

Principal Investigator, Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancer, NIH/NCI, 3/1/2022−2/28/2027

Pending

Principal Investigator, 0.48 months, IBC ExPaND: An Open-Access Resource and Community Platform to Advance Research in Inflammatory Breast Cancer, RA200075, Department of Defense (DOD), 3/1/2022−2/28/2025, $835,090 ($20,000/year)

Principal Investigator, Biomarker Development for Immunotherapy/EGFR-Targeted Therapy in Inflammatory Breast Cancer, NIH/NCI

Co-Principal Investigator, Validation of a novel 3D culture platform for TNBC treatment selection, NIH/NCI

Other

Principal Investigator, 1%, Role of Downstream EGFR Signaling in Erlotinib Sensitivity, Undergoing Renewal Process, R01CA123318-01, NIH/NCI, 6/1/2007−12/31/2014, $950,000

Principal Investigator, 1%, Role of mitotic checkpoint in breast cancer by KPS inhibitor (AR520), Funded Contract but cancelled due to Economy Crisis of 2009, Array BioPharma, Array BioPharma, Inc., 1/1/2009, $43,500 ($43,500/year)

Completed


Principal Investigator, Adenovirus E1A gene as a chemosensitizer in breast cancer, M. D. Anderson Cancer Center, 3/1/1998−present, $10,010

Principal Investigator, 1%, Adenovirus E1A gene as a Therapeutic Agent in Breast Cancer, 1 KO-8 CA76450-1, NIH/NCI, 9/1/1998−8/31/2003 ($90,480/year)

Principal Investigator, 1%, Adenovirus E1A gene therapy combined with chemotherapy or the p53 gene therapy in human breast cancer, IRG, M. D. Anderson Cancer Center, 4/1/1999, $50,000

Principal Investigator, 1%, Systemic (intravenous) Gene Therapy in Breast Cancer, M.D. Anderson Cancer Center, 5/1/1999−4/30/2001, $41,060

Principal Investigator, 1%, Multi-Institutional Phase II Study of Combined Herceptin, CS99-150 1, Genentech Inc., 7/5/1999−12/31/2007, $398,599

Principal Investigator, 1%, Intravenous administration of E1A complexed with cationic liposome, M. D. Anderson Cancer Center, 8/22/2000−present, $74,000

Principal Investigator, 1%, Reduction of radiation- or chemotherapy-induced toxicity by specific expression of anti-apoptotic molecules in normal cells, DOD, Idea Award, U.S. Army, DOD, 6/1/2001−5/31/2004, $382,065

Collaborator, Development of a patient - health care provider information sharing, multidisciplinary approach to cancer care in Japan., Grants-in-Aid for Scientific Research, 4/1/2003−present, $96,662

Principal Investigator, 1%, Cell-cycle profiling of cancer cells to predict chemotherapy response, Sysmex, Research Development Award, Sysmex, 5/12/2003−6/30/2009, $400,000
Principal Investigator, 1%, Bone Metastasis: role of imaging modalities, M.D. Anderson Cancer Center, 4/1/2005–3/31/2007, $42,010

Principal Investigator, 1%, PEA-15 as at therapeutic target for enhanced sensitization to paclitaxel in metastatic breast cancer, Postdoctoral Award, Susan G. Komen Breast Cancer Foundation, 6/1/2006–5/30/2009, $135,000

Principal Investigator, 1%, Role of Mitotic Checkpoint in the sensitivity in breast cancer in paclitaxel, Susan G. Komen Breast Cancer Foundation, 6/1/2006–5/30/2010, $190,000

Principal Investigator, 1%, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation with Bevacizumab for Advanced Solid Tumor, UL1RR024148 02, CCTS Pilot Project Award, 9/1/2007–8/31/2010, $50,000 ($25,000/year)

Principal Investigator, 10%, Development of PEA15 as a therapeutic gene for ovarian cancer, R01CA127562-01, NIH/NCI, 10/1/2007–8/31/2013, $950,000

Principal Investigator, 1%, Academy of Cancer Expert (ACE), AZ46032, AstraZeneca Medical Education Grants Office, 7/1/2008–6/30/2009, $300,000 ($100,000/year)

Co-Investigator, 1%, Profiling ER, PR, EGFR and HER2 in Breast Cancer Using Multiplex Tissue Immunostaining, NIH/NCI, 7/1/2008–6/30/2010, $226,800

Principal Investigator, 1%, Japan TeamOncology Program, St. Luke Life Science Foundation, 7/1/2008, $3,000,000

Project Member, 1%, Education and Research Center for Stem Cell Medicine, GCOE, GCOE Award, 9/1/2008–8/31/2013, $1,108,051


Mentor, 1%, Development of EGFR Tyrosine Kinase Inhibitor as a Targeted Therapy in Inflammatory Breast Cancer, KG09119201, Susan G. Komen Breast Cancer Foundation, 6/3/2009–6/30/2012, $220,000 ($60,000/year)

Mentor, Development of Targeted Therapy for ERK Pathway in Breast Cancer, 1K99CA139006-01A1, NIH/NCI, PI - Chandra Bartholomeusz, 9/30/2009–8/31/2014, $927,000

Principal Investigator, 1%, Phase II CT Study of Panitumumab, Nb-Paclitaxel, and Car, CS2010-00030471RG, Abraxis Bioscience LLC, 10/29/2009–10/31/2016 ($165,094/year)


Principal Investigator, 1%, Phase II Study of Panitumumab, Nab-paclitaxel, and Carboplatin for Patients with Primary Inflammatory Breast Cancer (IBC) without HER2 Overexpression, 2008-0372, AMGEN & Celgene, 5/19/2010–12/31/2015 ($406,814/year)

Principal Investigator, 0.12 months, Phase I Trastuzumab Cohort Study of Entinostat, Lapatinib and Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer in Whom Trastuzumab has Failed, 2010-0842, GlaxoSmithKline, 7/17/2010–12/31/2017, $160,875 ($160,875/year)

Co-Investigator, 2%, A New Radiopharmaceutical for the Treatment of Metastatic Breast Cancer, RSG-11-187-01-TBG, American Cancer Society (ACS), 7/1/2011–6/30/2015, $720,000 ($150,000/year)

Principal Investigator, 1%, Phase I/II study of entinostat and lapatinib in patients with HER2-Positive Metastatic Breast Cancer in whom Trastuzumab has failed, CS2011-00035423LG 01, GlaxoSmithKline, 9/30/2011–12/31/2019, $365,740 ($365,740/year)

Principal Investigator, 1%, A phase I/II to study to evaluate the safety, tolerability and preliminary efficacy of KW-2450 in combination with lapatinib and letrozole in subjects with advanced or metastatic breast cancer whose tumor overexpress HER2., LS2011-00034728JW 01, Kyowa Hakko Kirin Co., Ltd., 11/15/2011–3/30/2014, $175,938

Principal Investigator, 1%, IGFR Kinase Inhibitor and HER2 targeting therapy - a preclinical study, LS2010-00031741JW 01, Kyowa Hakko Kirin Co., Ltd., 11/15/2011–10/30/2016 ($117,542/year)

Co-Investigator, 1%, Phase I studies or targeted anti-cancer therapies, 5U01CA062461-19, NIHN/NCI, PI - Razelle Kurzrok, MD, 3/2012–3/2013 ($436,197/year)

Principal Investigator, 5%, EMD preclinical (SAR245409 / MSC1936369), 04-12-04431, EMD Serono, 5/7/2012–8/6/2014, $232,081

Principal Investigator, 5%, Role of combinatory therapy of MEK inhibitor (MSC1936369)/PI3K inhibitor (SAR245409) in breast cancer with basal-like phenotype and inflammatory breast cancer, MSC1936369, EMD Serono Research Institute, Inc., 5/7/2012–8/6/2014, $232,081

Principal Investigator, My Oncology Dream Award, Lance Armstrong Foundation Award, Lance Armstrong Foundation, 8/1/2012–7/30/2013, $40,000 ($20,000/year)

Principal Investigator, 1%, Phase II Study of Lapatinib and Trastuzumab followed by Concurrent Lapatinib, trastuzumab, and Paclitaxel followed by Surgery for Primary HER2-positive Breast Cancer, 13096642, Non-Profit Org Adv Clin Res Org NPO-ACRO, 9/1/2012–12/31/2015 ($21,260/year)

Principal Investigator, 1%, A Phase 1, Multicenter, Open Label Dose Escalation Study of ASP3026 in Subjects with Advanced Malignancies, 2012-0142, Astellas Scientific and Medical Affairs, Inc., 11/21/2012–11/20/2015 ($207,504/year)

Principal Investigator, Understanding EGFR's Role in TNBC by an animal model, Fred ID 37057, Sister Institute Network Fund, 1/1/2013–12/31/2014, $100,000 ($50,000/year)

Principal Investigator, 1%, A Phase 1A/1B, mult-center, open-label, dose finding study to assess the safety, tolerability, pharmacokinetics and prelim. efficacy of the pleiothropic pathway mod. CC-122admin. orally to subjects with advanced solid tumors, non-Hodgkin's I, CC-122-ST-001, Celgene, 4/1/2013–3/31/2014 ($20,000/year)

Principal Investigator, 5%, In Vitro Pre-clinical Testing of Bio-Path's Drug Candidate BP-100-1.01 in Human Inflammatory Breast Cancer ("IBC") and Triple Negative Breast Cancer ("TNBC") Cell Lines, BP-100-1-01, BioPath Holdings, 5/28/2013–5/31/2015 ($87,669/year)

Principal Investigator, 5%, Anti-tumor Activity of p70S6K/AKT dual inhibitor in triple-negative breast cancer, 11-11-12631, EMD Serono Research Institute, Inc., 8/6/2013–8/6/2019 ($237,000/year)

Principal Investigator, 5%, Targeting CMET on Triple Negative Breast Cancer, WCMS2014Targeting CMETTNBC (710499-80-116858-21), Women's Cancer Moon Shot, 3/1/2014–3/31/2015, $100,000 ($100,000/year)

Consultant, 1%, Southwest Early Clinical Trials Consortium, UM1CA186688 (Multi-PI: Merick-Bernstam, Eckhardt, Yao), NIHN/NCI, PI - Meric-Bernstam, Eckhardt, Yao, 3/14/2014–2/28/2020, $85,344 ($85,344/year)
Principal Investigator, 1%, Prediction of mTOR inhibitor everolimus treatment efficacy by gene signature, PA14-0091, Sysmex, 4/1/2014–6/30/2018 ($22,030/year)

Principal Investigator, 1%, Anti-tumor effect of LDK378 in triple-negative breast cancer, CLDK378AUS26T, Novartis Pharmaceuticals Corporation, 4/29/2014–8/20/2016 ($30,000/year)

Principal Investigator, 5%, Identification of molecules that enhance anti-metastasis and anti-proliferative activity in breast cancer with high androgen receptor expression using a high-throughput siRNA-library screening, 600143-0002094, Astellas Scientific and Medical Affairs, Inc., 6/3/2014–9/30/2016, $161,984 ($161,984/year)


Collaborator, 1%, Challenging the stem cell paradigm: reprogramming differentiated cells with valproic acid to reproduce tumor burden in metastatic breast cancer, Institutional Research Grant, The University of Texas MD Anderson Cancer Center, PI - Wendy Woodward, MD, PhD, 7/1/2014–6/30/2016, $49,590 ($49,590/year)

Principal Investigator, 1%, Phase II study of denosumab to define the role of bone related biomarkers in breast cancer bone metastasis, 2013-0007, AMGEN, 11/10/2014–12/31/2019, $630,811 ($129,650/year)

Principal Investigator, 2%, Determine the in vivo anti-tumor effect of BP-100-1.01 in triple negative breast cancer using a mammary fat pad xenograft model (single treatment), 15060968, Bio-Path Holdings, Inc., 11/12/2014–11/30/2018, $56,287 ($35,180/year)


Principal Investigator, 1%, A Phase II Study of BIBF 1120 (Nintedanib) for Patients with HER2 Normal Metastatic Inflammatory Breast Cancer (IBC), 2014-0464, Boehringer Ingelheim, 3/1/2015–12/31/2019, $984,220 ($984,220/year)

Principal Investigator, 1%, Targeting the variant form of CD44 in triple-negative and inflammatory breast cancer, FRED ID 40129, SINF, 4/1/2015–2/28/2019, $100,000 ($50,000/year)

Co-Investigator, 1%, Expansion and characterization of tumor-infiltrating and tumor-associated T cells from primary and metastatic TNBC & IBC patients, PA12-0728, Lion Biotechnologies Inc., PI - Reuben, 8/6/2015–10/4/2017, $401,080 ($401,080/year)

Principal Investigator, 1%, Study2: Identify Molecules that Enhance Anti-Tumor Activity of EP-100 in ER-Positive, Triple-Negative and Inflammatory Breast Cancer Cells, 51350, Esperance (Strategic Alliance), 8/6/2015–8/29/2020, $313,048 ($313,048/year)

Principal Investigator, 1%, A Preclinical and Clinical research Protocol of KAPt Project, 13015462, Nittobo, 8/27/2015–7/30/2019, $60,000 ($12,500/year)

Principal Investigator, Project #3 Establishment of patient derived xenografts (PDX) model using circulating tumor cells (CTSs) from apheresis samples., CS2015-13015504-RM, ANGLE North America, Inc., 10/15/2015–1/14/2018 ($65,651/year)


Principal Investigator, 3%, Monitoring of CTCs in newly diagnosed metastatic breast cancer, 52717, Hitachi Chemical Co., Ltd., 4/19/2016–4/30/2021, $705,705 ($176,426/year)

Principal Investigator, 1%, In vitro anti-tumor and in vivo anti-metastasis effect of E6201 in triple-negative breast cancer, 00052534, Strategia Therapeutics, 4/21/2016–3/31/2019, $64,686 ($80,858/year)

Co-Investigator, 5%, Comparative Effectiveness of Cancer Research: Use Data from Multiple Sources, 15071198 (R01CA193878), NIH/NCI, PI - Ning, 5/1/2016–4/30/2021 ($200,000/year)

Mentor, Immune and molecular determinants of response to neoadjuvant chemotherapy in inflammatory breast cancer, FF2016-0052516-HM, American Society of Clinical Oncology (ASCO), PI - Sangeetha Meda Reddy, 7/1/2016–6/30/2017, $50,000 ($50,000/year)


Principal Investigator, 1%, A Randomized Phase II Study of Neoadjuvant Carboplatin/Paclitaxel (CT) versus Panitumumab/Carboplatin/Paclitaxel (PaCT) followed by Anthracycline-Containing Regimen for Newly Diagnosed Triple Negative Inflammatory Breast Cancer (TN-IBC), 2016-0177, UT MD Anderson Cancer Center, 9/21/2016–2/10/2019, $100,000 ($100,000/year)

Principal Investigator, 1%, Identification of molecules that enhance anti-tumor activity of eribulin in metastatic breast cancer cell lines, 53448 (LAB07-0950), EISAI, Inc., 8/14/2017–8/13/2021, $56,835 ($11,840/year)

Principal Investigator, 1%, Determination of the anti-tumor and anti-metastatic effect of OR-S2, a EXH1/2 dual inhibitor, in metastatic breast cancer, LAB07-0950, Daiichi Sankyo, 8/15/2017–8/14/2020, $67,341 ($14,029/year)

Co-Principal Investigator, 5%, Targeting ubiquitination for cancer therapy, 52784 (RP170333), Cancer Prevention & Research Institute of Texas (CPRIT), PI - Shuxing Zhang, 8/31/2017–8/31/2021, $869,251 ($289,750/year)

Co-Investigator, 1%, T-Regulatory Cells TREGs derived from umbilical cord blood, 54964, Cellenkos, 9/7/2017–7/31/2020, $4,826 ($769,231/year)

Principal Investigator, 3%, Development of novel therapy by targeting the tumor microenvironment in inflammatory breast cancer, BCRF-17-161 (BCRF-18-164), BCRF, 10/1/2017–9/30/2019, $499,819 ($348,037/year)

Principal Investigator, 1%, Harvest of Circulating Tumor Cells (CTCs) from Patients with Metastatic Breast Cancer (MBC) using the Parsortix TM PC1 System, 55359 (PA17-1047), ANGLE North America, Inc., 3/13/2018–3/12/2021, $168,932 ($53,012/year)

Principal Investigator, 5%, Adipose Stromal Cell Targeting: A New Approach to Breast Cancer Treatment, R21 CA16745, NIH/NCI, 4/1/2018–3/31/2021, $168,080 ($65,000/year)

Principal Investigator, Prognostic and predictive role of the Oncotype DX Breast Recurrence Score test in treatment selection for patients presenting with stage IV breast Cancer, PA18-0184, Genomic Health Inc., 7/18/2018–10/25/2019, $10,000 ($8,920/year)
Principal Investigator, 1%, Modulation of cancer microenvironment by combination therapy with Axl inhibitor, DS-1205, in triple-negative breast cancer, 56824, Daiichi Sankyo Co., Ltd, 3/28/2019–9/30/2021, $235,293 ($73,529/year)


Principal Investigator-MDACC, 1%, CPRIT Single Cell Core, A-Single Cell User Allotment-2906465, MD Anderson Cancer Center, 1/1/2020–8/31/2020, $10,000 ($10,000/year)

Not Funded

Co-Investigator, 1%, A Novel Dose Calculation Method for Targeted Radionuclide Therapy, R01CA138986-01, NIH/NCI, 4/1/2009–3/31/2012, $750,000

Principal Investigator, Development of anti-metastasis therapy for inflammatory breast cancer, Susan G. Komen Breast Cancer Foundation, 4/1/2009–3/31/2012, $600,000 ($200,000/year)


Principal Investigator, 0.5%, Identification of EMT-related molecules involved in basal-like breast cancer metastasis, DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP), 9/30/2010–9/29/2012, $577,500 ($288,750/year)

Principal Investigator, Preventing Triple Negative Breast Cancer Metastasis, Cancer Prevention & Research Institute of Texas (CPRIT), 5/1/2012–4/30/2017, $5,851,515 ($5,558,952/year)

Principal Investigator, Preventing Triple Negative Breast Cancer Metastasis (P01), NIH/NCI, 12/1/2012–11/30/2017, $8,860,780 ($5,879,814/year)

Co-Investigator, 4%, Optimized Radiation Therapy of Inflammatory Breast Cancer with Theranostic Gold Nanoparticles, Individual Investigator Research Award, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Sunil Krishnan, 8/1/2014–7/31/2017, $850,496 ($283,378/year)

Co-Investigator, 4%, Theranostic nanoparticle enhanced radiation therapy of inflammatory breast cancer, Research Program Grant (Parent R01), NIH/NCI, PI - Sunil Krishnan, 9/1/2014–8/31/2019, $1,715,629 ($341,926/year)


Protocols Funded

Principal Investigator, Phase II study of combined Herceptin and GM-CSF for Herceptin-Resistant Her-2/neu-overexpressing metastatic breast cancer, DM01-0100, 2002–2012, $150,000, Berlex

Principal Investigator, Phase II Study of GnRH Analogue For Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients, ID01-710, 2002, $150,000, TAP Pharmaceutical

Principal Investigator, Phase III randomized study of a goserelin acetate for preservation of ovarian function in patients with primary breast cancer, 2005-0464, 2006, $150,000, St. Luke Life Science Institute

Principal Investigator, Phase II study of purging of CTCs from Metastatic Breast Cancer, 2006-0280, 2007–present, $375,000, Cellerant Therapeutics

Principal Investigator, Phase 2 Study of 153 Sm-EDTMP Followed by Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients with Bone Only Metastases, 2006-0349, 2007, $290,368, Cytogen


Principal Investigator, Phase II Study of Panitumumab, Nab-paclitaxel, and carboplatin for Patients with Primary Inflammatory Breast Cancer (IBC) without HER2 Overexpression, 2008-0372, 2010–2013, $406,814, Amgen & Celgene


Principal Investigator, IGFR preclinical (KW-2450), N/A, 2011–present, $121,542, Kyowa Hakko Kirin

Principal Investigator, CTEP lapatinib (Lapatinib, Trastuzumab, Paclitaxel), N/A, 2012–2016, $21,260, Advanced Clinical Research Organization (ARCO)

Principal Investigator, ALK Astellas (ASP3026), 2012-0142, 2012, $493,550, Astellas


Unfunded

Unfunded
Principal Investigator, Inflammatory Breast Cancer (IBC), 2006-1072, 2007–present

**Patents and Technology Licenses**

**Patents**

University of Texas System, Board of Regents, Naoto T. Ueno, Mien-Chie Hung. Sensitization of HER-2/NEU Overexpressing Cancer Cells to Chemotherapy, United States, Australia 733737, 9/6/2001, Issued

Sensitization of HER-2/NEU Overexpressing Cancer Cells to Chemotherapy, United States, USA 6395712, 5/28/2002, Issued

The University of Texas MD Anderson Cancer Center, Michael Mego, Sendurai Mani, Massimo Cristofanilli, Naoto T. Ueno, James M. Reuben. Quantitative RT-PCR Detection for Genes Involved in Epithelial Mesenchymal Transition in Peripheral Blood of Breast Cancer Patient, United States, MDA09-075, Serial # 61/312,971, 3/11/2010, Filed
University of Texas System, Naoto T. Ueno, Hideki Ishihara, Tamotsu Sudo, Tomoko Matsushima. Taxane Chemosensitivity Prediction Test. Filed on 8/25/03, United States, 10/926,409, 8/25/2004, Pending

**Technology Licenses**
Sysmex Corporation, Taxane Chemosensitivity Prediction Test, 10/926, 409, 4/27/2007

**Grant Reviewer/Service on Study Sections**

Reviewer, Associazione Italiana per la Ricerca sul Cancro, Grant Review Committee, Member, 2003–2004


Reviewer, CancerCare Manitoba Foundation, Reviewer, A molecular mechanism of androgen independent prostrate cancer through interaction between androgen receptor and HER2/neu., 2008

BMCT, NIH, Ad Hoc Member, 2008–2017

AACR Clinical and Translational Cancer Research Fellowships Scientific Review Committee, AACR, Member, 2009–2014

Health Sciences Centre Foundation, Canadian Grant Agency, Reviewer, 2010

NCI Omnibus – Cancer Therapy Special Emphasis Panel, NIH, Ad Hoc Member, 2012–2013

NIH Bioengineering Sciences and Technologies (BST), NIH, Ad Hoc Member, 2014–present

Drug Discovery and Molecular Pharmacology (DMP) Study Section, NIH, Ad Hoc Member, 2015–2018

Division of Research & Graduate Studies, United Arab Emirates University, Ad Hoc Member, 2017–present

Drug Discovery and Molecular Pharmacology (DMP) Study Section of NCI/NIH, NIH, Member, 2018–present

AACR Distinguished Lectureship in Breast Cancer Research, AACR, Member, 2019–present

**PUBLICATIONS**
**Peer-Reviewed Original Research Articles**


390. Invited Articles


**Editorials**


**Other Articles**


Abstracts


Book Chapters


Books (edited and written)


Letters to the Editor

Manuals, Teaching Aids, Other Teaching Publications

Other Publications
N/A

EDITORIAL AND REVIEW ACTIVITIES
Editor/Service on Editorial Board(s)
Editor-in-chief, Breast Cancer, M.D. Anderson Monograph, 1999–present
Editor, Oncology Magazine, M. D. Anderson Cancer Center Medical Exchange Program, 2005–2006
Editor in Chief, Journal of Cancer, Ivyspring International Publisher Pty Ltd, 2010–2019
Editor, Journal of Carcinogenesis, 2013–present
Guest Editor, Breast Disease: A Year Book Quarterly, Elsevier, 2015–present
Editor-in-chief, Oncomedicine, Ivyspring International Publisher, 2016–2018
Editor, JNCI Cancer Spectrum, 2019–2021
Editor, Hormones and Cancer, Springer, 2019–present
Editor, Journal of the National Cancer Institute, 2019–present
Editor, Journal of the National Cancer Institute Cancer Spectrum, 2019–present
Editor, Cancer Letters, Elsevier, 2020–present
Editor, Cancers, 2020–present

Member of Editorial Review Board
Editor Board Member, Journal of Clinical Oncology, American Society of Clinical Oncology, 2011–2017

Journal Reviewer
Reviewer, Blood, 1996–present
Reviewer, Cancer Research, 1996–present
Reviewer, Bone Marrow Transplantation, 1997–present
Reviewer, Cancer Letter, 1997–present
Reviewer, Clinical Cancer Research, 1997–present
Reviewer, Journal of Clinical Oncology, 1997–present
Reviewer, Journal of Immunological Methods, 1997–present
Reviewer, Journal of National Cancer Institute, 1997–present
Reviewer, Annals of Oncology, 1999–present
Reviewer, Biology of Blood and Marrow Transplantation, 1999–present
Reviewer, Journal of Biological Chemistry, 1999–present
Reviewer, Oncogene, 1999–present
Reviewer, Breast Cancer Research, 2000–present
Reviewer, International Journal of Hematostudy, 2000–present
Reviewer, Lancet, 2000–present
Reviewer, Cancer Control: Journal of Moffitt Cancer Center, 2002–present
Reviewer, Molecular Cancer Therapeutics, 2005–present
Reviewer, Gynecologic Oncology, 2008–present
Reviewer, Lancet Oncology, 2009–present
Reviewer, Breast Cancer Research and Treatment, 2010–present
Reviewer, Nature Reviews Endocrinology, 2010–present
Reviewer, Oncotarget, 2013–present
Reviewer, Nature Cell Biology, 2015–present
Reviewer, Nature Communications, 2015–present
Reviewer, Cancer Discovery, 2016–present
Reviewer, JAMA Oncology, 2016–present
Reviewer, Cells, 2019–present

**Other Editorial and Review Activities**
Reviewer, San Antonio Breast Cancer Symposium, 2009–present

**TEACHING**

**Teaching Within Current Institution - The University of Texas MD Anderson Cancer Center**

**Formal Teaching**

**Courses Taught**
- Instructor, Molecular Principles of Virology, GSBS, Course Number: GS04 1043, Course Hours: 6
- Instructor, GSBS Cancer Biology Program, GSBS, Course Number: GS04 1063, Course Hours: 1
- Instructor, Human Gene Therapy: Basic Science/Clinical Trial, GSBS, Course Number: GS04 1153, Course Hours: 2
  Spring, 1/2008–8/2010
- Instructor, GSBS Cancer Biology, GSBS, Course Number: GS04 1063, Course Hours: 1
  Fall, 8/2011–2016
Lecturer, Translational Sciences: From Bench to Bedside and Back, GSBS, Course Number: GS21 0232, Course Hours: 2
Fall, 9/2018−12/2018

Lecturer, Translational Sciences: From Bench to Bedside and Back, GSBS, Course Hours: 1
9/2019−12/2019

Training Programs
N/A

Other Formal Teaching
N/A

Supervisory Teaching
Committees

Advisory Committees
Member, Marcela Bolontrade, PhD, 2001–2003
Research Mentor, Graduate School of Biomedical Sciences, Marcela Bolontrade, PhD, 5/2001–8/2002
Committee Chair, Graduate School of Biomedical Sciences, Chandra Bartholomeusz, PhD, 9/2001–5/2004
Member, J. Kyle Wathen, PhD, 2002–2005
Research Mentor, Examining Committee, Graduate School of Biomedical Sciences, J. Kyle Wathen, Ph.D, MS, 9/2002–5/2005
Member, Graduate School of Biomedial Sciences, David Crotzer, MS, 11/2003–8/2004
Chair, GSBS, Jason Aguilar, PhD, 9/2005–7/2006
Research Mentor, GSBS, Evan Cohen, PhD, 10/2007–5/2013
Member, Simone Anfossi, Graduate School of Biomedical Sciences, Simone Anfossi, Ph.D., 12/2009–4/2013
Committee Member, Simone Anfossi, PhD, 12/2009–5/2013
Member, MS Advisory Committee, The University of Texas Graduate School of Biomedical Sciences (GSBS) at Houston, Graduate School of Biomedical Sciences, Maryam Shariati, MS, 3/2011–8/2012
Secondary Mentor, Angela Alexander, DOD TRIUMPH, Angela Alexander, 7/2011–present
Seema Mukherjee, PhD, 12/2011–4/2016
Research Mentor, Advisory Committee, Kin Man Suen, The University of Texas Graduate School of Biomedical Sciences Houston, 4/2012–5/2015
Research Mentor, Examining/Advisory Committee, Biomedical Sciences, University of Texas Graduate School of Biomedical Sciences, Arvind Bambhroliya, MS, 11/2013–5/2015
Research Mentor, Carlos Hernando Barcenas, MD, K grant, 3/2015–present
Hsiang-Hsi Ling, Ph.D., 2/2021–present
Commitee Member, GSBS, Shu-Hsien Cho, 7/2021–present

**Supervisory Committees**
Committee member, Shraddha Subramanian, MS, 3/2018–present

**Examining Committees**
N/A

**Direct Supervision**

**Undergraduate and Allied Health Students**
N/A

**Medical Students**
Eun Lee, 1999
Mentor, Tulane University School of Medicine, Fahad Faruqi, MD/MPH Candidate, 5/2014–7/2014

**Graduate Students**
Research Mentor, Travel Award for travel to the American Associated for Cancer Research, The University of Texas Graduate School of Biomedical Sciences, Chandra Bartholomeusz, 6/2002–6/2008
Research Mentor, The University of Texas Graduate School of Biomedical Sciences, Alison Schwein, 1/2008–6/2008
Faculty, The University of Texas Graduate School of Biomedical Sciences, Tiffany LaFortune, 1/2009–4/2011
Faculty, The University of Texas Graduate School of Biomedical Sciences, Radhika Thokala, 9/2009–12/2009
Faculty, The University of Texas Graduate School of Biomedical Sciences, Chia Ching Chang, 12/2009–2/2010
Faculty, Tutorial Student, The University of Texas Graduate School of Biomedical Sciences, Tsai-Yu Chen, Ph.D., 1/2011–3/2011
Faculty, The University of Texas Graduate School of Biomedical Sciences, Monica Reyes, Ph.D., 1/2011–5/2015
Faculty, Tutorial Student, Angie Torres-Adorno, Ph.D., 9/2011–6/2017
Research Mentor, Bharat K Chaganty, PhD, 1/2012–3/2012
Research Mentor, GSBS, Lan Phi, MS, 9/2019–12/2019
Research Mentor, GSBS, Thi-Thu-Trang Luu, MS, 9/2020–2/2021

**Postdoctoral Research Fellows**
Research Mentor, Rita Nahta, PhD, 2000–2003
Faculty, Tamotsu Sudo, MD, PhD, 2001–2004
Faculty, Hiroaki Itamochi, MD, PhD, 4/2002–3/2004
Faculty, Tsuyoshi Hamaoka, MD, PhD, 7/2002–12/2004
Faculty, Takeshi Takahashi, PhD, 12/2002–12/2003
Faculty, Chandra Bartholomeusz, MD, PhD, 5/2004–2009
Faculty, Takeshi Sugimoto, MD, PhD, 8/2004–4/2006
Faculty, Kazutaka Nakayama, MD, 8/2004–1/2007
Faculty, Dongwei Zhang, MD, PhD, 7/2006–6/2012
Faculty, Tetsuro Oishi, MD, PhD, 6/2007–12/2009
Faculty, Xiaoping (Maggie) Wang, PhD, 7/2008–6/2013
Faculty, Naoki Hayashi, MD, 2/2009–12/2010
Faculty, Naoki Niikura, MD, PhD, 12/2009–12/2010
Faculty, Jangsoo Lee, PhD, 1/2010–12/2012
Faculty, Xuemei Xie, 1/2010–11/2015
Faculty, Oula Mansour, 2/2010–12/2010
Faculty, My Oncology Dream Award by JCS, Hiroko Masuda, MD, PhD, 2011–2013
Research Mentor, One of eight posters chosen for the MD Anderson Trainee & Alumni Poster Competition of Trainee Research Day 2011, MD Anderson Alumni and Faculty Association, Xue Mei Xie, 4/2011–5/2011
Takahiro Kogawa, 9/2012–9/2014
Adriana Priscilla Trape, 5/2014–11/2015
Research Mentor, My Oncology Dream Award by JCS, Kenichi Harano, MD, 7/2014–3/2016
Research Mentor, Naoko Matsuda, MD, 8/2014–10/2016
My Oncology Dream Award by JCS, Miho Kono, MD, 10/2014–10/2016
Research Mentor, MD Anderson Cancer Center, Yohei Funakoshi, MD, PhD, 4/2015–3/2017
Rodrigo Espinosa, MD, 7/2016–present
UTMDACC, Toshiaki Iwase, MD, PhD, 11/2016–present
Research Mentor, UTMDACC, Huihui Li, MD, PhD, 3/2017–11/2017
Research and Career Mentor, MD Anderson Cancer Center, Kida Kumiko, MD, 10/2017–present

Clinical Residents and Fellows
Faculty, Ralph Zinner, Medical Oncology, 7/1998–6/1999
Faculty, Alvaro Aguayo-Gonzalez, Stem Cell Transplantation, 1/2001–9/2001
Faculty, Raymond Wong, Stem Cell Transplantation, 8/2001–6/2002
Faculty, Yee Chung Cheng, Medical Oncology, 8/2001–1/2004
Faculty, Yasuhiro Oki, Medical Oncology, 7/2003–6/2006
Research Mentor, Sangeetha Meda Reddy, 3/2014–present
Research Mentor, Nour Abuhadra, MD, 3/2019–present
Other Supervisory Teaching


Mentor, Japanese Team Oncology Program (JTOP), Hiromi Okuyama, Direct Supervision - Japanese Team Oncology Program Participant, 4/2003–present

Mentor, Japanese Team Oncology Program (JTOP), Kenjiro Aogi, Direct Supervision - Japanese Team Oncology Program Participant, 4/2003–present

Career Mentor, Japanese Team Oncology Program (JTOP), Masumi Yamazaki, Direct Supervision - Japanese Team Oncology Program Participant, 4/2003–present

Mentor, Japanese Team Oncology Program (JTOP), Ryunsa Kim, Direct Supervision - Japanese Team Oncology Program Participant, 4/2003–present

Mentor, Japanese Team Oncology Program (JTOP), Shigehira Saji, Direct Supervision - Japanese Team Oncology Program Participant, 4/2003–present

Mentor, Japanese Team Oncology Program (JTOP), Bibari Nakamura, Direct Supervision - Japanese Team Oncology Program Participant, 4/2004–present

Mentor, Japanese Team Oncology Program (JTOP), Hiromi Shinano, Direct Supervision - Japanese Team Oncology Program Participant, 4/2004–present

Mentor, Japanese Team Oncology Program (JTOP), Jungi Matsuoka, Direct Supervision - Japanese Team Oncology Program Participant, 4/2004–present

Mentor, Japanese Team Oncology Program (JTOP), Keiko Hosokawa, Direct Supervision - Japanese Team Oncology Program Participant, 4/2004–present

Mentor, Japanese Team Oncology Program (JTOP), Keiko Mori, Direct Supervision - Japanese Team Oncology Program Participant, 4/2004–present

Mentor, Japanese Team Oncology Program (JTOP), Koichiro Tsugawa, Direct Supervision - Japanese Team Oncology Program Participant, 4/2004–present

Mentor, Japanese Team Oncology Program (JTOP), Aiko Okano, Direct Supervision - Japanese Team Oncology Program Participant, 4/2005–present

Mentor, Japanese Team Oncology Program (JTOP), Hiroshi Ueda, Direct Supervision - Japanese Team Oncology Program Participant, 4/2005–present

Mentor, Japanese Team Oncology Program (JTOP), Kunie Maeda, Direct Supervision - Japanese Team Oncology Program Participant, 4/2005–present

Mentor, Japanese Team Oncology Program (JTOP), Masahiro Kashiwaba, Direct Supervision - Japanese Team Oncology Program Participant, 4/2005–present

Mentor, Japanese Team Oncology Program (JTOP), Takahiro Nakayama, Direct Supervision - Japanese Team Oncology Program Participant, 4/2005–present

Mentor, Japanese Team Oncology Program (JTOP), Tomoko Izawa, Direct Supervision - Japanese Team Oncology Program Participant, 4/2005–present

Career Mentor, Japanese Team Oncology Program (JTOP), Shigeru Murakami, Direct Supervision - Japanese Team Oncology Program Participant, 4/2006–2/2014

Mentor, Japanese Team Oncology Program (JTOP), Mariko Takagi, Direct Supervision - Japanese Team Oncology Program Participant, 4/2006–present

Mentor, Japanese Team Oncology Program (JTOP), Sanae Nakajima, Direct Supervision - Japanese Team Oncology Program Participant, 4/2006–present
Mentor, Japanese TeamOncology Program (JTOP), Tomoe Yoshizawa, Direct Supervision - Japanese TeamOncology Program Participant, 4/2006–present
Mentor, Japanese TeamOncology Program (JTOP), Yuka Furuya, Direct Supervision - Japanese TeamOncology Program Participant, 4/2006–present
Japanese TeamOncology Program Participant, Yumiko Sato, Direct Supervision - Japanese TeamOncology Program Participant, 4/2006–present
Mentor, Japanese TeamOncology Program (JTOP), Eiji Sasaki, Direct Supervision - Japanese TeamOncology Program Participant, 4/2007–present
Mentor, Japanese TeamOncology Program (JTOP), Mitsue Saito, Direct Supervision - Japanese TeamOncology Program Participant, 4/2007–present
Mentor, Japanese TeamOncology Program (JTOP), Miyuki Tajima, Direct Supervision - Japanese TeamOncology Program Participant, 4/2007–present
Mentor, Japanese TeamOncology Program (JTOP), Ryuta Urakawa, Direct Supervision - Japanese TeamOncology Program Participant, 4/2007–present
Mentor, Japanese TeamOncology Program (JTOP), Yoshiko Taguchi, Direct Supervision - Japanese TeamOncology Program Participant, 4/2007–present
Mentor, Japanese TeamOncology Program (JTOP), Yukako Okude, Direct Supervision - Japanese TeamOncology Program Participant, 4/2007–present
Career Mentor, Joe Ishizawa, 12/2007–present
Mentor, Japanese TeamOncology Program (JTOP), Atsuo Takashima, Direct Supervision - Japanese TeamOncology Program Participant, 4/2008–present
Mentor, Japanese TeamOncology Program (JTOP), Hironobu Hashimoto, Direct Supervision - Japanese TeamOncology Program Participant, 4/2008–present
Mentor, Japanese TeamOncology Program, Hitomi Sato, Direct Supervision - Japanese TeamOncology Program Participant, 4/2008–present
Mentor, Japanese TeamOncology Participant (JTOP), Naoko Sugiyama, Direct Supervision - Japanese TeamOncology Program Participant, 4/2008–present
Mentor, Japanese TeamOncology Program (JTOP), Sayuri Kitayama, Direct Supervision - Japanese TeamOncology Program Participant, 4/2008–present
Mentor, Japanese TeamOncology Program (JTOP), Youichi Osato, Direct Supervision - Japanese TeamOncology Program Participant, 4/2008–present
Mentor, Japanese TeamOncology Program (JTOP), Hirotoshi Iihara, Direct Supervision - Japanese TeamOncology Program Participant, 4/2009–present
Mentor, Japanese TeamOncology Program (JTOP), Masako Ishizuka, Direct Supervision - Japanese TeamOncology Program Participant, 4/2009–present
Mentor, Japanese TeamOncology Program (JTOP), Masayo Nogi, Direct Supervision - Japanese TeamOncology Program Participant, 4/2009–present
Mentor, Japanese TeamOncology Program (JTOP), Mayumi Yamaguchi, Direct Supervision - Japanese TeamOncology Program Participant, 4/2009–present
Mentor, Japanese TeamOncology Program (JTOP), Noriko Miwa, Direct Supervision - Japanese TeamOncology Program Participant, 4/2009–present
Mentor, Japanese TeamOncology Participant, Toru Mukohara, Direct Supervision - Japanese TeamOncology Program Participant, 4/2009–present
Mentor, Japanese TeamOncology Program (JTOP), Aiko Hashimoto, Direct Supervision - Japanese TeamOncology Program Participant, 4/2010–present
Mentor, Japanese TeamOncology Program Participant, Kuiseon Min, Direct Supervision - Japanese TeamOncology Program Participant, 4/2010–present
Mentor, Japanese TeamOncology Program (JTOP), Noriko Koga, Direct Supervision - Japanese TeamOncology Program Participant, 4/2010–present
Mentor, Japanese TeamOncology Program (JTOP), Satoko Takahashi, Direct Supervision - Japanese TeamOncology Program Participant, 4/2010–present
Mentor, Japanese TeamOncology Program (JTOP), Yoshitaka Asakura, Direct Supervision - Japanese TeamOncology Program Participant, 4/2010–present
Mentor, Anil Sood (Chair), Menesha Bar-Eli, Division of Surgery Faculty Mentor Committee, Yunfei Wen, Instructor, Contact Hours: Annual, 10/2010–present
Faculty, Applicant Interviews, Karen Rossi, GSBS Applicant Interviews, 2/2011
Faculty, Applicant Interviews, Justine Ngo, Applicant Interviews, 3/2011–present
Mentor, Japanese TeamOncology Program (JTOP), Hitoshi Kawazoe, Direct Supervision - Japanese TeamOncology Program Participant, 4/2011–present
Mentor, Japanese TeamOncology Program (JTOP), Koji Hashiguchi, Direct Supervision - Japanese TeamOncology Program Participant, 4/2011–present
Mentor, Japanese TeamOncology Program (JTOP), Masanori Toyoda, Direct Supervision - Japanese TeamOncology Program Participant, 4/2011–present
Mentor, Japanese TeamOncology Program (JTOP), Tokie Nakata, Direct Supervision - Japanese TeamOncology Program Participant, 4/2011–present
Mentor, Japanese TeamOncology Program (JTOP), Tomoyo Taito, Direct Supervision - Japanese TeamOncology Program Participant, 4/2011–present
Mentor, Japanese TeamOncology Program (JTOP), Yuji Miura, Direct Supervision - Japanese TeamOncology Program Participant, 4/2011–present
Career Development Mentor, Medical Oncology Fellowship, Kouichi Takahashi, MD, Mentor, 7/2011–present
Mentor, Japanese TeamOncology Program (JTOP), Bando Hiroko, Direct Supervision - Japanese TeamOncology Program Participant, 4/2012–present
Mentor, Japanese TeamOncology Program (JTOP), Chiba Ikuko, Direct Supervision - Japanese TeamOncology Program Participant, 4/2012–present
Mentor, Japanese TeamOncology Program (JTOP), Hamajima Yuko, Direct Supervision - Japanese TeamOncology Program Participant, 4/2012–present
Mentor, Japanese TeamOncology Program, Miyamoto Keisuke, Direct Supervision - Japanese TeamOncology Program Participant, 4/2012–present
Preceptor, Essential Services of Public Health, Morgan Welch Inflammatory Breast Cancer, Summer Jackson, Masters Public Health, MPH, Preceptor, Contact Hours: 180, 4/2012–present
Mentor, Japanese TeamOncology Program (JTOP), Yamaguchi Tetsuro, Direct Supervision - Japanese TeamOncology Program Participant, 4/2012–present
Mentor, Japanese TeamOncology Program (JTOP), Yokota Mari, Direct Supervision - Japanese TeamOncology Program Participant, 4/2012–present
Research Mentor, MD Anderson Training & Alumni Affairs, Tamer Fouad, 9/2012–present


Mentor, Japanese Team Oncology Program (J-TOP), Aya Shimogai, Direct Supervision - Japanese Team Oncology Program (J-TOP), 4/2013–present

Mentor, Japanese Team Oncology Program (J-TOP), Futaba Miyaji, Direct Supervision - Japanese Team Oncology Program (J-TOP), 4/2013–present

Mentor, Japanese Team Oncology Program (J-TOP), Mitsuki Kariya, Direct Supervision - Japanese Team Oncology Program (J-TOP), 4/2013–present

Mentor, Japanese Team Oncology Program (J-TOP), Nor Shazrina Binti Sulaiman, Direct Supervision - Japanese Team Oncology Program (J-TOP), 4/2013–present

Mentor, Japanese Team Oncology Program (J-TOP), Sayako Ouchi, Direct Supervision - Japanese Team Oncology Program (J-TOP), 4/2013–present

Mentor, Japanese Team Oncology Program (J-TOP), Yasuyuki Kojima, Direct Supervision - Japanese Team Oncology Program (J-TOP), 4/2013–present

Mentor, MD Anderson Training & Alumni Affairs, Jon A. Fuson, 6/2013–9/2013

Mentor, Kazuharu Kai, Instructor, Instructor, 5/2014–10/2015

Research and Career Mentor, Faculty Mentoring Team, Bisrat Godefay Debeb, PhD, Junior Faculty, 1/2016–present

Research Mentor, Anjali James, 9/2016–5/2017

Research Mentor, Clinton Yam, MD, MS, 8/2020

Teaching Outside of Current Institution

Formal Teaching

Courses Taught

Lecturer, Career Development in Oncology, Kansai Medical Student Association
7/2008

Lecturer, Case Presentation, Multiple Myeloma, Colon Cancer, Gastric Cancer, Wakayama Medical College
7/2008

Training Programs

N/A

Other Formal Teaching

N/A

Supervisory Teaching

Committees

Advisory Committees
N/A

Supervisory Committees
N/A

Examining Committees
N/A

Direct Supervision

Undergraduate and Allied Health Students

### Medical Students
- Mentor, Okayama University, Yuko Takahashi, MD, 11/2008–3/2010

### Graduate Students
- Research Mentor, Keio University, Kazuhara Kai, 10/2008–4/2011
- Mentor, Kurume University, Yuya Sasaki, 1/2013
- Research Mentor, Doctorate in Biomedical Sciences from the National Autonomous University of Mexico, Ruben Rodriguez Bautista, PhD, 9/2019–11/2019

### Graduate Students
- Research Mentor, Keio University, Kazuhara Kai, 10/2008–4/2011
- Mentor, Kurume University, Yuya Sasaki, 1/2013
- Research Mentor, Doctorate in Biomedical Sciences from the National Autonomous University of Mexico, Ruben Rodriguez Bautista, PhD, 9/2019–11/2019

### Postdoctoral Research Fellows
- N/A

### Clinical Residents and Fellows
- Career Mentor, Pennsylvania Hospital of the University of Pennsylvania, Hitomi Hosoya, MD, PhD, 12/2017–6/2019

### Other Supervisory Teaching
- Career Mentor, Japanese TeamOncology Program (JTOP), National International Medical Center, Chikako Shimizu, Direct Supervision - Japanese TeamOncology Program Participant, 4/2003–present
- Career Mentor, The Rockefeller University, Norihiro Yamaguchi, 1/2009–present
- Research and Career Mentor, Princess Margaret Cancer Centre, Akina Natori (Ogino), 2/2009–present
- Career Mentor, Yokohama City University, Koichi Murakami, 4/2010–present
- Career Mentor, Keio University School of Medicine, Aiko Nagayama, 9/2012–present
- Career Mentor, Massachusetts General Hospital, Satoru Matsuda, MD, PhD, 10/2012–present
- Asahikawa Medical University Hospital, Yukiko Hibino, MD, 11/2013–present
- Research and Career Mentor, University of Hawaii Cancer Center, Takeo Fujii, MD, MPH, 6/2015–present
- Career Mentor, Toranomon Hospital, Chihiro Kondoh, MD, 9/2015–present
- Career Mentor, Tokyo Rosai Hospital, Akiko Urabe, 2/2017–present
- Mentor, ASCO IDEA, National institute of cancer research & hospital(NICRH), Bangladesh, Muhammad Rafiquil islam, 9/2020–present

### Conferences and Symposia
#### Organization of Conferences/Symposia (Include chairing session)
- The University of Texas MD Anderson Cancer Center and St. Luke International Hospital Joint Open Forum, M. D. Anderson Cancer Center and St. Luke International Hospital Joint Open Forum, Yokohama, Japan, Chair, 11/2001
- The University of Texas MD Anderson Cancer Center and St. Luke International Hospital Joint Sponsored Symposium, 39th Japan Society of Clinical Oncology, Hiroshima, Japan, Chair, 11/2001
The University of Texas MD Anderson Cancer Medical Exchange Program, 2nd M. D. Anderson Cancer Medical Exchange Program, Kyoto, Japan, Chair, 9/2002

iwNST, 4th International Workshop on Non-myeloablative Stem Cell Transplantation, Bermuda, Chair, 2/2003

The University of Texas MD Anderson Cancer Medical Exchange Program, M. D. Anderson Cancer Medical Exchange Program, Kazusa, Japan, Chair, 9/2003

The University of Texas MD Anderson Cancer Medical Exchange Program, 3rd M. D. Anderson Cancer Medical Exchange Program, Tokyo, Japan, Chair, 9/2004

Japanese Breast Cancer Society, NCCN guideline in Breast Cancer, Okayama, Japan, Chair, 6/2005

The University of Texas MD Anderson Cancer Medical Exchange Program, 4th M. D. Anderson Cancer Medical Exchange Program, Osaka, Japan, Chair, 9/2005

The European Group for Blood & Marrow Transplantation, 2nd International Meeting of Allogeneic Transplantation for Solid Tumor, Milan, Italy, Chair, 10/2005

The University of Texas MD Anderson Cancer Medical Exchange Program, 5th M. D. Anderson Cancer Medical Exchange Program, Kyoto, Japan, Chair, 10/2006

St. Luke Life Science Foundation, 1st Japan TeamOncology Workshop, Makuhari, Japan, Chair, 11/2007

The European Group for Blood & Marrow Transplantation, 3rd International Meeting of Allogeneic Transplantation for Solid Tumor, Siena, Italy, Chair, 3/2008

Academy of Cancer Experts (ACE) Program, 1st Multidisciplinary Clinical and Translational Research Workshop, Tokyo, Japan, Chair, 8/2008

2nd Japan TeamOncology Workshop, St. Luke Life Science Foundation, Sapporo, Japan, Chair, 11/2008

Japan Patient Advocacy Liaison, Japan Patient Advocacy Liaison Workshop "Patient Empowerment," Tokyo, Japan, Moderator, 12/2008

Academy of Cancer Experts (ACE) Program, 2nd Multidisciplinary Clinical and Translational Research Workshop, Tokyo, Japan, Chair, 2/2009

Academy of Cancer Experts (ACE) Program, 3rd Multidisciplinary Clinical and Translational Research Workshop, Academy of Cancer Experts (ACE) Program @ Keio University, Tokyo, Japan, Chair, 7/2009


Career Development in Oncology, Pfizer, St. Luke Life Science Foundation, Tokyo, Japan, Chair, 10/2009

3rd Japan TeamOncology Workshop, St. Luke Life Science Foundation, Tokyo, Japan, Chair, 11/2009

32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, CTRC-AACR, San Antonio, TX, Abstract Reviewer Committee, 12/2009

4th Japan TeamOncology Workshop, Oncology Education Project, Fukuoka, Japan, Chair, 11/2010

Autologous and Allogeneic Cellular Therapy in Solid Tumors, Venice, Italy, Chair, 3/2011

5th Japan TeamOncology Workshop, Oncology Education Project, Tokyo, Japan, Founder, 11/2011
J-HOPE, Oncology Education Project, Obihiro, Japan, Chair, 11/2011

1st TeamOncology Leadership Academy, Oncology Education Project Association, Tokyo, Japan, Mentor, 10/2012

Third International Inflammatory Breast Cancer Conference, Fox Chase Cancer Center, Philadelphia, PA, Planning Committee, 12/2012

The University of Texas MD Anderson Cancer Center, Breast Cancer Research Program (BCRP), Houston, TX, Committee Member, 1/2013

2nd TeamOncology Leadership Academy, Oncology Education Project Association, Tokyo, Japan, Mentor, 11/2013

29th Nagoya International Cancer Treatment Symposium, Bristol-Myers Squibb, Japan, Chair, 2/2014

5th ACE Workshop, Academy of Cancer Experts (ACE), Tokyo, Japan, Chair, 3/2014

Radium Ra 223 Dichloride Bone Metastasis, Bayer HealthCare Pharmaceuticals, San Diego, CA, Advisory Board, 4/2014

4th Int'l IBC Conference, IBC Consortium, Antwerp, Belgium, Chair - NeoAdjuvant - Adjuvant Therapy, 5/2014

4th International IBC Conference, IBC Consortium, Antwerp, Belgium, Chair - Translational Science in Inflammatory Breast Cancer II, 5/2014

3rd JHOPE Workshop, Management of Adverse Effects by Cancer Treatment, Wakayama, Japan, Chair, 7/2014

3rd TeamOncology Leadership Academy, Oncology Education Project Association, Tokyo, Japan, Mentor, 11/2014

4th JTOP Academy Workshop, Oncology Education Project Association, Tokyo, Japan, Mentor, 12/2015

4th Clinical Skill Advancement Workshop, JHOPE - Oncology Education Project Association, Tokyo, Japan, Mentor, 3/2016

The University of Texas MD Anderson Cancer Center, Multidisciplinary Research Advisory Committee (MRAC), Houston, TX, Member, 6/2016

JSMO, Presidential Symposium / Memorial Program for Ten Thousand JSMO-Certified Medical Oncologists “Career Formation of the JSMO-Certified Medical Oncologists –Learning from the USA–”, Sapporo, Japan, Chair, 2017

MD Anderson Cancer Center, Morgan Welch Inflammatory Breast Cancer Research Program and Clinic International Conference, TX, Chair, 2/2017

6th International Inflammatory Breast Cancer Symposium, Madrid, Spain, Moderator, 9/2018

CancerX 2019 Summit, Tokyo, Japan, Cofounder, 1/2019

CancerX Summit 2019, CancerX, Tokyo, Japan, Keynote Speaker, 2/2019

CancerX Summit 2019, CancerX, Tokyo, Japan, Chair, 2/2019

7th Management of Adverse Effects by Cancer Treatment: Beyond the Evidence, Mishima, Japan, Founder, 9/2019

CancerX Summit 2020, CancerX, Tokyo, Japan, Chair, 2/2020

CancerX Summit 2020, CancerX, Tokyo, Japan, Keynote Speaker, 2/2020

CancerX, Tokyo, Japan, Chair, 4/2020
Japan TeamOncology Program: New Online workshop to build multidisciplinary care, overcoming the distance, Tokyo, Japan, Chair, 10/2020

4th Team Science Workshop, Japan TeamOncology Workshop, Founder, 11/2020

7th International Inflammatory Breast Cancer and Metastatic Breast Cancer Conference, Houston, TX, Chair, 12/2020

International Inflammatory Breast Cancer: Virtual Education Day - A Live Internet Event, Houston, Chair, 12/2020

World Cancer Week, CancerX, Tokyo, Japan, Chair, 1/2021

CancerX x JCA Special Session, Japan Cancer Association, Yokohama, Japan, Chair, 10/2021

Presentations at National or International Conferences

Invited


Chemosensitization of HER-2/neu-overexpressed breast cancer cells to paclitaxel (Taxol) by adenovirus 5 E1A, Cold Spring Harbor Laboratory, Gene Therapy meeting, Poster presentation, Cold Spring Harbor, NY, 9/1996


E1A-mediated paclitaxel (Taxol) sensitization in HER-2/neu-overexpressing ovarian cancer through apoptosis involving caspase-3 pathway, Annual meeting of American Association for Cancer Research, Mini-symposium, Philadelphia, PA, 4/1999


Allogeneic transplantation in breast cancer, Strategie Innovativve Nel Trattamento Del Carcinoma Mammario, Oral Presentation, Castellanza, Italy, 1/2000

Experience of allogeneic transplantation in metastatic breast cancer, 26th Annual European Group for Blood and Marrow Transplantation and 16th Annual Nurses Group Meeting, Oral Presentation, Innsbruck, Austria, 3/2000

Transplantation in Hematology and Oncology II, Satellite symposium II: autologous vs. allogeneic transplantation: Current concepts and future trends, Oral Presentation, Münster, Germany, 4/2000

High-dose chemotherapy (HDCT) for primary breast cancer refractory to neoadjuvant chemotherapy (NAC), International Conference on High-dose Chemotherapy in breast and ovarian cancer, Oral Presentation, Florence, Italy, 9/2000


Non-myeloablative transplantation, NST forum, Oral Presentation, Kurashiki, Japan, 11/2000

High-dose chemotherapy (HDCT) for primary breast cancer refractory to neoadjuvant chemotherapy (NAC), Annual meeting of the American Society of Clinical Oncology, Poster presentation, San Francisco, CA, 5/2001


Hiroshima Consensus Meeting for Breast Cancer, 39th Japan Society of Clinical Oncology, Hiroshima, Japan, 11/2001


Allogeneic Transplantation with Reduced Intensity Conditioning Regimes., Kozukata Hematology Symposium, Oral Presentation, Morioka, Japan, 3/2002

Complete donor chimerism by fludarabine/melphalan in mini-allogeneic Peripheral Blood Progenitor Cell (PBPC) Transplantation for Metastatic Renal Cell Carcinoma (RCC) and Metastatic Breast Cancer (BC), Annual meeting of American Society of Clinical Oncology, Oral presentation, Orlando, FL, 5/2002

Complete donor chimerism by fludarabine/melphalan in mini-allogeneic transplantation for metastatic breast carcinoma, Milan, Italy, 6/2002

Role of Bone Marrow Transplantation in RCC, New Direction in Renal Cell Carcinoma, Kidney Cancer Society, Oral Presentation, Houston, TX, 8/2002

E1A gene therapy in Solid Tumor, Osaka, Japan, 2/2003

Preparation of preprinted order at M. D. Anderson Cancer Center, Tokyo, Japan, 2/2003

The latest update for Allogeneic Transplantation in Solid Tumor, 8th Tokai Hematopoietic Stem Cell Transplantation Symposium, Oral Presentation, Nagoya, Japan, 2/2003

International bone marrow transplant registry/The European Group for Blood and Marrow Transplantation review of allogeneic hematopoietic stem-cell transplantation in metastatic breast cancer, Annual meeting of American Society of Clinical Oncolog, Oral presentation, Chicago, IL, 6/2003
Low prevalence of premature ovarian failure (POF) in women who received reduced-intensity conditioning (RIC) regimens for hematopoietic stem-cell transplantation (HST), Annual meeting of American Society of Clinical Oncology, Poster Discussion, Chicago, IL, 6/2003

Multidisciplinary approach in breast cancer management: role of pharmacist, Oncology PharmD Tokyo Forum, Tokyo, Japan, 8/2003

Recent update of Cancer Medicine in USA, Kobe, Japan, 8/2003

The latest update for Allogeneic Transplantation in Solid Tumor, 41st Annual Meeting of Japanese Society of Clinical Oncology, Oral Presentation, Sapporo, Japan, 10/2003

Update of Cancer Gene Therapy, 41st Annual Meeting of Japanese Society of Clinical Oncology, Oral Presentation, Sapporo, Japan, 10/2003

Ethical Issues in Transplantation: Panel Discussion, American Society for Blood and Marrow Transplantation, Orlando, FL, 2/2004

Hematopoietic stem cell transplantation for breast cancer: Resolved Issue, American Society for Blood and Marrow Transplantation, Oral Presentation, Orlando, FL, 2/2004


Outpatient chemotherapy-Multidisciplinary Approach, 7th Breast Cancer up-to-date meeting, Yokohama, Japan, 3/2004

US Medical Oncology Fellowship, 2nd Annual Meeting of Japanese Society of Medical Oncology, Tokyo, Japan, 3/2004

Novel prognostic profiling in breast cancer, 1st Tokyo Metropolitan PharmD mtg, Tokyo, Japan, 7/2004


Depends on Cyclin-Dependent Kinase 2 Activity, Annual meeting of the American Association for Cancer Research. Mini-symposia, Anaheim, CA, 4/2005

Role of Hematopoietic Stem Cell Transplantation in Non-myeloablative allogeneic transplantation, Oral Presentation, Bern, Switzerland, 5/2005

Outpatient chemotherapy for breast cancer, 6th Breast Cancer Conference Up to date, Oral Presentation, Karuizawa, Japan, 7/22/2005

Bone Metastasis: Strategy and Tactics, Japanese Society of Clinical Oncology, Oral Presentation, Nagoya, Japan, 10/2005

Exploring the future of Oncology Specialists, Japanese Society of Clinical Oncology, Oral Presentation, Nagoya, Japan, 10/2005

Recent advances in allogeneic transplantataion for breast cancer, 2nd International Meeting of Allogeneic Transplantation for Solid Tumor, Oral Presentation, Stretsa, Italy, 10/2005

Development of Clinical Pathway, Japanese Society of Clinical Pathway, Oral Presentation, Niigata, Japan, 12/2005

Role of Allogeneic Transplantation in Solid Tumor, 28th Annual meeting of Japanese Society of Hematopoietic Cell Transplantation, Oral Presentation, Tokyo, Japan, 2/2006

Multidisciplinary Cancer Care, Japanese Society of Clinical Oncology, Oral Presentation, Tokyo, Japan, 10/2006

Role of Circulating Tumor Cells in Breast Cancer, Japanese Society of Clinical Oncology, Oral Presentation, Tokyo, Japan, 10/2006

Role of Family in Cancer Care, 3rd Wellness Community, Oral Presentation, Tokyo, Japan, 10/2006

Role of pharmacist in multidisciplinary cancer treatment, 16th Annual Meeting of the Society of Pharmaceutical Careas and Science, Oral Presentation, Kanazawa, Japan, 10/2006

Use of Breast Cancer Treatment Guideline, 14th Annual Meeting of the Japanese Breast Cancer Society, Oral Presentation, Kanazawa, Japan, 10/2006


Phase III randomized study of Adjuvant High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation vs Adjuvant Dose-Dense Chemotherapy for Patients with High-Risk Primary Breast Cancer, JSCT, Yokohama, Japan, 6/2007


Prospective study of spindle assembly checkpoint a (SAC) to predict breast tumor response to taxanes, Annual meeting of American Society of Clinical Oncology. Poster Presentation, Chicago, IL, 6/2007


Creation of TeamOncology ABC: Current Status and Future View of Multidisciplinary Care, 45th Annual Meeting of the Japanese Society of Clinical Oncology, Kyoto, Japan, 10/2007

Systemic Treatment Options for Bone Metastasis, 8th Annual Oncology Update Advance and Controversies, Park City, UT, 1/2008

Can allogeneic transplantation cure metastatic breast cancer, 3rd International Meeting of Allogeneic Transplantation for Solid Tumor, Italy, 3/2008

Development of Biomarker for Non-novel Drug, Kobe University & 6th Hyogo Cancer Society, Kobe, Japan, 7/2008

Development of Biomarkers and Clinical Trials Based on Laboratory Findings, Japan Society of Clinical Oncology, Nagoya, Japan, 10/31/2008

EBM: Examiner, Creator, and Follower, Japan Society of Clinical Oncology, Nagoya, 11/1/2008
Zhang D, LaFortune TA, Hortobagyi GN, Cristofanilli M, Lucci A, Singh B, Hung, MC, Ueno NT. Reversal of mesenchymal to epithelial phenotype by EGFR tyrosine kinase inhibitor in inflammatory breast cancer, First International Inflammatory Breast Cancer Conference, Houston, TX, 12/5/2008

Transmembrane growth factor receptor pathways in IBC, First International Inflammatory Breast Cancer Conference, Houston, TX, 12/5/2008

Paradigm Shift in Oncologic Drug/Biomarker Development, Japanese Association for Molecular Target Therapy of Cancer, Tokushima, Japan, 6/25/2009


Ueno NT. Practical use of guidelines for management of breast cancer, ASCO/JSMO, The 8th Annual Meeting of Japanese Society of Medical Oncology, Tokyo, Japan, 3/18/2010

Ueno NT. Multi-disciplinary Care with Targeted Therapies, The 8th Asia Pacific Oncology Summit, Tokyo, Japan, 3/21/2010

Multidisciplinary Cancer Care at MD Anderson Cancer Center, 9th International Conference of Asian Clinical Oncology Society, Gifu, Japan, 8/26/2010

Multidisciplinary Care at MD Anderson Cancer Center: Past, Present, and Future and the Role of Pharmacist, The Japanese Society of Hospital Pharmacists, Tokyo, Japan, 8/28/2010

Molecular Changes and Targeted Therapy in Inflammatory Breast cancer, 4th Seoul Breast Cancer Symposium, Seoul, Korea, Republic of, 8/29/2010

Successful team building in multidisciplinary cancer care, Ryukyu University, Naha, Japan, 9/2/2010

Synergestic Effect of Conventional Therapy with Targeted Therapy, 2010 Taipei International Breast Cancer Symposium, Taipei, Taiwan, 9/5/2010

Ueno NT. Targeting the Epithelial-mesenchymal Transition to Reduce Metastasis of Inflammatory Breast Cancer, Breast Cancer Symposium, ASCO, Washington DC, 10/1/2010

Ueno NT. Role of Cancer Stem Cells in Breast Cancer. Is this a real target?, 1st Regional Conference on Cancer MOlecular Targeted Therapy, Minister of Health, Kuwait, Kuwait City, Kuwait, 2/19/2011

Regulation of Metastasis by EGFR targeted therapy, 4th Autologous and Allogeneic Cellular Therapy in Solid Tumors meeting, 4th Autologous and Allogeneic Cellular Therapy in Solid Tumors meeting, Venice, Italy, 3/21/2011

Breast Cancer Meta-analysis of High Dose Chemotherapy, 4th Autologous and Allogeneic Cellular Therapy in Solid Tumors meeting, 4th Autologous and Allogeneic Cellular Therapy in Solid Tumors meeting, Venice, Italy, 4/1/2011

Ueno NT. ABC of Multidisciplinary Approach in Cancer, Hokkaido Hospital Congress, Hokkaido Hospital Congress, Sapporo, Japan, 7/9/2011


Clinical Trials in USA, JSCO, Nagoya, Japan, 10/30/2011

Inflammatory Breast Cancer: An update and progress, Bristol-Myers, Japanese Breast Cancer Society, Kumamoto, Japan, 6/29/2012

Inflammatory Breast Cancer, Japanese Society of Medical Oncology, Japanese Society of Medical Oncology, Osaka, Japan, 7/26/2012
Bone Management of Cancer Patients, Novartis, Japanese Society of Medical Oncology, Osaka, Japan, 7/27/2012

Medical Oncology Training Programs, Japanese Society of Medical Oncology, Japanese Society of Medical Oncology, Osaka, Japan, 7/28/2012

2013 ACE Seminar and Workshop, Keio University Hospital, Academy of Cancer Experts (ACE), Tokyo, Japan, 2/1/2013

Ueno NT. Training Programs at the UT MD Anderson Cancer Center Need for Clinical Cancer Biologist, JSMO, Sendai, Japan, 8/31/2013

Ueno NT. Medical innovation from Patients’ Perspective, Rice University, MEST Conference, Houston, TX, 9/18/2013

Ueno NT. Molecular Characterization of Chemoresistance in Breast Cancer, 13th International Cancer Induced Bone Disease, Miami, FL, 11/9/2013


Ueno NT. Need for leadership in career development. Interactive Discussion, Keio University, Academy of Cancer Experts, Tokyo, Japan, 3/22/2014


Ueno NT. Translatinal Cancer Resesarch, J-HOPE, Tokyo, Japan, 1/15/2015

Kogawa T, Fujii T, Liu DD, Wei C, Harano K, Park YS, Lim B, Tripathy D, Ueno NT, Litton JK. Association of baseline body mass index and change in body mass index with overall survival in different breast cancer subtypes, JSMO - Japanese Society of Medical Oncology, Japan, 7/16/2015


Need for Clinical Cancer Biologists

Medical Oncology Training Programs, US Embassy, Japan Cancer Society, Toyo, Jordan, 4/26/2016


Treatment strategy of luminal type early breast cancer patients using multi-gene classifier
—Perspectives based on the experience at MD Anderson Cancer Center, Sysmex, JBCS, Tokyo, Japan, 6/15/2016

New Challenges in
Triple-Negative Breast Cancer, JBCS, Tokyo, Japan, 6/17/2016

Development of Novel Targeted Therapeutic Strategies for Inflammatory Breast Cancer (IBC), The 5th International Inflammatory Breast Cancer Conference, Harvard Medical School, Houston, TX, 7/9/2016

Therapeutic Strategies for Inflammatory Breast Cancer (IBC) and Triple Negative Breast Cancer (TNBC): Plenary Talk, XXI Congreso Chileno de Cancerología, Santiago, Chile, 10/14/2016

Update of Neoadjuvant Chemotherapy in Triple Negative Breast Cancer, XXI Congreso Chileno de Cancerología, Santiago, 10/14/2016

Ueno NT. Multidisciplinary Approach to Cancer Treatment and Supportive Care at MD Anderson Cancer Center - Using Adjuvant Chemotherapy for HER2 Negative Primary Breast Cancer, Kyowa-Kirin, JASCC, Omiya, Japan, 10/27/2017

Febrile Neutropenia, Kyowa Hakko Kirin Co., Ltd., Controversies in Breast Cancer, Tokyo, Japan, 10/28/2017

Ueno NT. Advances in Oncology; Systemic Breast Cancer Treatment in the US vs Abroad, National Consortium of Breast Centers - NCoBC, 28th Annual Interdisciplinary Breast Center Conference, Las Vegas, NV, 3/12/2018

Leadership and Shared Vision that promotes Multidisciplinary Cancer Care, Oncology Education Promotion Associates, Mingaku Gifu, Gifu, Japan, 5/13/2018

Current Status and Future Prospects of MBC treatment at MD Anderson Cancer Center, Eisai, JBCS, Kyoto, Japan, 5/16/2018

Recent Advances in Inflammatory Breast Cancer Management, JBCS, Kyoto, Japan, 5/17/2018

Treatment strategy for HER2-negative perioperative breast cancer according to the risk of recurrence, Kyowa-Kirin, JBCS, Kyoto, Japan, 5/17/2018

Ueno NT. The Advancement in the Treatment of Inflammatory Breast Cancer, Pink and Teal Conference, 2nd Pink and Teal Conference, Bermuda, 6/14/2018

Ueno NT. Inflammatory Breast Cancer Biology; the tumor microenvironment is the key, Chugai Academy for Advanced Oncology, International Academy for Advanced Oncology, Tokyo, Japan, 7/27/2018

Ueno NT. Current strategy of perioperative chemotherapy in patients with HER2-negative early stage breast cancer, Kyowa Hakko Kirin Co., Ltd, Webinar of the Early Stage Breast Cancer, Tokyo, Japan, 9/13/2018

Development of novel targeted therapy in IBC baed on cancer microenvironment preclinical data, 6th International IBC Symposium, Madrid, Spain, 9/20/2018

Future Trend and Development of Immunotherapy in Breast Cancer, Roche, Taiwan International Breast Cancer Symposium, Taipei, Taiwan, 9/29/2018

State of the Art of Neoadjuvant/Adjuvant treatment for HER2+ EBC/ABC: goal, target population, and post-treatment decision, Taiwan International Breast Cancer Symposium, Taiwan International Breast Cancer Symposium, Taipei, Taiwan, 9/30/2018

Team Science, Japan TeamOncology Program, Tokyo, Japan, 1/25/2019

Current strategies for inflammatory breast cancer, Lynn Sage Breast Cancer Symposium, Northwestern University, Chicago, IN, 10/4/2019

The Best Practice in Inflammatory Breast Cancer, Georgia Cancer Center, Georgia Cancer Center 1st Annual Symposium, Savannah, GA, 10/5/2019

Patient Empowerment Through Multidisciplinary Care, Japanese Society of Cancer Nursing, Tokyo, Japan, 2/23/2020
Introduction of Inflammatory Breast Cancer Program and Medical Management, Advanced Breast Cancer Conference, Houston, TX, 2/28/2020

Tumor Microenvironment (TME)
Modulation in Inflammatory Breast Cancer, Breast Cancer Research Foundation, New York, NY, 10/15/2020

CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor-Positive Advanced Breast Cancer, Pfizer, Taipei International Breast Cancer Symposium, Taipei (Virtual), Taiwan, 10/23/2020

Patient Empowerment Process, Global Health Management, Tokyo, Japan, 11/3/2020

Recent Advancement of POST CDK 4/6 inhibitor Treatment Strategy in HR+ HER2-Metastatic Breast Cancer, Taipei International Breast Cancer Symposium, Taipei (Virtual), Taiwan, 11/8/2020

Summary of Inflammatory Breast Cancer Basic and Translational Research Progress, IBC-IC & MD Anderson Cancer Center, 12/5/2020

Patient Empowerment, PEP JHOPE, Tokyo, Japan, 12/6/2020

Current status of the COVID-19 and Cancer Survivor, Japan Federation of Cancer Patient Groups, 12/27/2020

CancerX Society, CancerX, Tokyo, Japan, 1/31/2021

Patient Empowerment Program in World Cancer Week, CancerX, Tokyo, Japan, 2/1/2021

Novel Targeted Therapy Development in Triple-Negative Breast Cancer, Japan Society of Medical Oncology, Kyoto, Japan, 2/19/2021

Multidisciplinary care for patient empowerment, Japan Society of Medical Oncology, Kyoto, Japan, 2/20/2021

Clinical Molecular Testing for Breast Cancer Management, GBCC, Seoul, Korea, Republic of, 4/8/2021

Experience of Education Program in Asia (Japan TeamOncology Program), GBCC, Seoul, Korea, Republic of, 4/8/2021

Recent Advancement of POST CDK 4/6 inhibitor Treatment Strategy in HR+ HER2-Metastatic Breast Cancer, 5th Hangzhou Xianghu International Breast Cancer Symposium, China, 5/15/2021

Cancer Management under Disaster, Cancer Fitness Foundation, Tokyo, Japan, 5/22/2021

Targeting Inflammation-Driven Cancer Microenvironment of Aggressive Breast Cancer, Japan Cancer Association, Yokohama, Japan, 10/2/2021

Multidisciplinary care for immunotherapy side effect management, Chugai-Roche, JSCO, Yokohama, Japan, 10/23/2021

Role of 27-gene signature in solid tumors, Oncocyte, Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, Washington DC, DC, 11/12/2021


Meet the expert: Career Development, The 39th Annual Meeting of the Japan Society for Neuro-Oncology, 12/6/2021

Other, Including Scientific Exhibitions
Systemic E1A gene therapy breast and head/neck cancer, Annual meeting of the American Association for Cancer Research. Poster presentation, New Orleans, LA, 3/2001

Bench to Clinic. What are the issues that we are facing at MDA?, Japanese Cancer Association, Nagoya, Japan, 10/30/2008


Team Oncology, Japan TeamOncology Program, Osaka, Japan, 2/15/2009

Creating the best Team for Cancer Care, Kochi University, Kochi, Japan, 2/17/2009

How to receive the best medical care?, Itsuki-kai, Kochi, Japan, 2/17/2009

ACE activity in Japan, Development of CTEP investigator initiated trials, CTEP, US Embassy, Tokyo, Japan, 7/3/2009


Practical use of CTCs in Metastatic Breast Cancer, Japanese Breast Cancer Society, Tokyo, Japan, 7/4/2009


Creating Research-driven TeamOncology, The 47th Annual Meeting of Japanese Society of Clinical Oncology, Yokohama, Japan, 10/22/2009


What can we do to bring Health Care Reform in Cancer?, The 47th Annual Meeting of Japanese Society of Clinical Oncology, Yokohama, Japan, 10/23/2009

What do you need to know when you are diagnosed cancer?, The 47th Annual Meeting of Japanese Society of Clinical Oncology, Yokohama, Japan, 10/24/2009


Role of EGFR Pathway Regulation in EMT of Inflammatory Breast Cancer, AACR, Arlington, VA, 2/28/2010

Inflammatory Breast Cancer Registry Consortium, 2nd International Inflammatory Breast Cancer Conference, Marseilla, Italy, 10/7/2010

Ueno NT. Molecular Changes and Targeted Therapy in Inflammatory Breast Cancer, 1st Regional Conference on Cancer Molecular Targeted Therapy, Minister of Health, Kuwait, Kuwait City, Kuwait, 2/19/2011


Recent advances of genome researches and related clinical trials in breast cancer, International Symposium on Emerging Female Cancers in Asia, Taipei, Taiwan, 6/30/2012

1st Team Oncology Leadership Academy, Japan Team Oncology Program (JTOP), Japan Team Oncology Program (JTOP), Tokyo, Japan, 10/24/2012


Ueno NT, Iwamoto T, Pusztai J, Hortobagyi GN, Saya H, Kai K. IGFR as a candidate therapeutic target for cancer-initiating cells in triple-negative breast cancer (TNBC), AACR Advances in Breast Cancer Research, American Association for Cancer Research, Chicago, IL, 10/3/2013


Ueno NT. Social Media for Scientist: Using Twitter to Enhance and Advance Your Career, AACR Harnessing Breakthroughs Targeting Cures, American Association for Cancer Research, San Diego, CA, 4/5/2014

Ueno N. Medical Oncology Training Programs in USA - Need for Clinical Cancer Biologist, Medical Oncology Seminar for Medical Students and residents, 12th Annual Meeting of JSMO, Fukuoka, Japan, 7/19/2014


Management of Febrile Neutropenia by Pegfilgrastim in the United States, JSMO, Sapporo, 2015
Ueno NT. Development of novel treatment for triple-negative breast cancer (TNBC) and inflammatory breast cancer (IBC) through a collaboration between USA, Japan, and Egypt, GAP 2015 Conference, Houston, TX, 4/15/2015

Improving multidisciplinary treatment through high-quality supportive care: the importance of exploring other supportive care options beyond evidence - Participants will have the opportunity to discuss case studies –, JSMO, Sapporo, Japan, 7/18/2015

Management of Febrile Neutropenia by Pegfilgrastim in the United States, JSMO, Sapporo, Japan, 7/18/2015

Presidential Symposium / Memorial Program for Ten Thousand JSMO-Certified Medical Oncologists “Career Formation of the JSMO-Certified Medical Oncologists –Learning from the USA–”, JSMO, Sapporo, Japan, 7/18/2015

Team Approach for Supportive Care to Control Adverse Effects of Systemic Cancer Treatment, JSMO, Sapporo, Japan, 7/18/2015

Ueno NT. The Future of Clinically Oriented Medical Oncologists; A need for clinical cancer biologists to advance the field of medical oncology, JSMO, Sapporo, Japan, 7/18/2015

「今」と「夢」をつなぐVision, Mission, Career Planの考え方 Speacker, Asahikawa, Japan, 7/19/2015

Leading from Wherever You Are, JTOP 4th Leadership Academy, Oncology Education Promotion Foundation, Tokyo, Japan, 12/18/2015

Ueno NT. Multidisciplinary Cancer Care by Shared Vision and Leadership, Mingaku Fukushima, Japan TeamOncology Program, Fukushima, Jordan, 4/23/2016

Recent Clinical Progress in Immunotherapy for Breast Cancer, Cancer Immunology and Immunotherapy: Recent Progress and Future Perspectives, Tokyo Oncology Consortium and MD Anderson Cancer Center, Tokyo, Japan, 5/14/2016

ABC of Chemotherapy for patient with Early Stage Breast Cancer, Kyowa Hakko Kirin, JBCS, Tokyo, Japan, 6/17/2016

Patient empowerment, JSMO, JSMO, Kobe, Japan, 7/29/2016

Differences in cancer treatment between the USA and Japan, JSMO, JSMO, Kobe, Japan, 7/30/2016

Optimizing Clinical Outcomes of Breast Cancer in the Bones and beyond, Taiwan Breast Cancer Society, Taipei International Breast CANcer Symposium., Taipei, Taiwan, 11/19/2016

Updates in Inflammatory Breast Cancer (IBC), Taiwan Breast Cancer Society, Taipei International Breast Cancer Symposium, Taipei, Taiwan, 11/20/2016

The future of Personalized Therapy in TNBC, Taiwan Breast Cancer Society, Taipei International Breast Cancer Conference, Taipei, Taiwan, 11/21/2016

Ueno NT. New Issues in Cancer Research and Treatment, Global Breast Cancer Conference (GBCC), Jeju Island, Korea, Republic of, 4/20/2017

Ueno NT. Implication of NGS in breast cancer: Promises and Challenges, Global Breast Cancer Conference (GBCC), Jeju Island, Korea, Republic of, 4/21/2017

Ueno NT. Management of febrile neutropenia by pegfilgrastim in the United States: Importance of relative dose intensity and control of toxic effects of chemotherapy in early breast cancer, GBCC, Incheon, Korea, Republic of, 4/5/2018

Patient Advocates and Research Funding, JBCS, Kyoto, Japan, 5/18/2018
Ueno NT. Cancer and Employment, Japan Society of Occupational Medicine and Traumatology, 10/20/2018

Introduction to Inflammatory Breast Cancer Collaboration!, MD Anderson Cancer Center, GAP 2019 Conference, Houston, TX, 5/1/2019

Ueno NT. Recent Advancement and Challenges of Immunotherapy in Breast Cancer, Human and Animal Bridging Organization, Tokyo, Japan, 6/21/2019

Patient Empowerment Education by Healthcare Providers, Japanese Society of Cancer Nursing, Tokyo, Japan, 2/23/2020

CancerX COVID-19 Special Live Discussion, Tokyo, Japan, 4/13/2020

Leadership in TeamOncology, Japan TeamOncology Program, Japan, 5/24/2020

Patient Empowerment Education Skill for Healthcare Providers, JBCS, Nagoya, Japan, 10/11/2020

Patient Empowerment Process for Pharmacist, Japanese Society of Pharmaceutical Health Care and Science, Tokyo, Japan, 11/1/2020

MD Anderson IBC-related protocols, IBC-IC & MD Anderson Cancer Center, 12/5/2020

Japan TeamOncology Program in World Cancer Week, CancerX, Japan, 2/2/2021

CancerX Global, CancerX, Japan, 2/3/2021

Patient Empowerment Program for Cancer Patients, Japan Society of Medical Oncology, Kyoto, Japan, 2/20/2021

Impact of COVID-19 on Clinical Practice and Research in Oncology, Japan Society of Medical Oncology, Kyoto, Japan, 2/21/2021

TeamOncology and Immunotherapy, Chugai, JSMO, Kyoto, 2/21/2021

Multidisciplinary Team Management of Metastatic Breast Cancer, GBCC, Seoul, Korea, Republic of, 4/9/2021


Inflammation-Driven Tumor Microenvironment of Triple-Negative Breast Cancer, BCRF, NY, 10/13/2021

Early Drug Development Program, University of Hawaii, Honolulu, HI, 10/29/2021

Advances in Inflammatory Breast Cancer Management & Research, Hebei Medical University Hebei Provincial Cancer Hospital, 4th International Forum on the theory and practice of cancer prevention and control, Shijiazhuang, China, 10/30/2021

Advancement in Management & Research Related to Inflammatory Breast Cancer, Medical Oncology Society in Bangladesh, Dhaka, Bangladesh, 11/28/2021

History/Present/Future of Multi-Disciplinary Cancer Care at MD Anderson, The 39th Annual Meeting of the Japan Society for Neuro-Oncology, Kobe, Japan, 12/7/2021

**Seminar Invitations from Other Institutions**

Development of novel treatment for aggressive breast cancer, University of Houston College of Pharmacy, Houston, TX, 11/29/1964

E1A gene therapy against HER-2/neu-overexpressing cancer. Bench research to clinical trial, Mexico City, Mexico, 11/1/1997

Allogeneic transplantation in breast cancer. Allogeneic transplantation: What every oncologist needs to know, Ireland Cancer Center at Case Western Reserve Univ, Cleveland, OH, 6/1998

Development of gene therapy in breast and ovarian cancer, Encino Tarzana Regional Medical Center, Tarzana, CA, 11/1998

Development of E1A gene therapy in breast and ovarian cancer, Wakayama Medical College, Wakayama City, Japan, 12/1998

High-dose chemotherapy and autologous transplantation combined with Herceptin and Taxol, Herceptin investigators meeting, San Francisco, CA, 8/1999


Current update in non-myeloablative Allogeneic Transplantation, Center for Adult Disease, Osaka, Japan, 7/2000

Development of E1A gene therapy in breast and ovarian cancer, Wakayama Medical College, Wakayama City, Japan, 7/2000

How to Become a Medical Oncologist, St. Luke International Hospital, Tokyo, Japan, 7/2000


Current update in Allogeneic Transplantation in solid tumor, Tokyo, Japan, 7/14/2000

Development of E1A gene therapy in breast and ovarian cancer, Karmonas Cancer Institute, Detroit, MI, 10/2000

Non-myeloablative transplantation, Japan Medical College, Tokyo, Japan, 11/2000

Future Direction of Non-myeloablative Allogeneic Transplantation, GRAN Scientific Symposia, Yokohama, Japan, 7/2001

Future Direction of Non-myeloablative Allogeneic Transplantation, GRAN Scientific Symposia, Nagoya, Japan, 7/2001

Future Direction of Non-myeloablative Allogeneic Transplantation, GRAN Scientific Symposia, Wakayama, Japan, 7/2001

Future Direction of Non-myeloablative Allogeneic Transplantation, GRAN Scientific Symposia, Morioka, Japan, 7/2001

Role of Multidisciplinary Care in success of Non-myeloablative Allogeneic Transplantation, GRAN Scientific Symposia, Chiba, Japan, 7/2001

Role of Multidisciplinary Care in success of Non-myeloablative Allogeneic Transplantation, GRAN Scientific Symposia, Sakai, Japan, 7/2001
Non-myeloablative Stem Cell Transplantation (NST) in Metastatic Solid tumor (MDACC/EBMT Breast Cancer Experience, Breast Cancer Experience, Breast Cancer Experience, Captiva Island, FL, 1/2002
Transplantation in Breast Cancer, Breast Cancer Experience, Captiva Island, FL, 1/2002
Gene Therapy for Gynecologic Cancers, Bristol-Myers Squibb International Oncology Visiti, Houston, TX, 3/2002
Future Direction and Issues-related to targeted therapy: E1A gene therapy in solid tumor, Kumamoto University, Kumamoto, Japan, 7/2002
Latest update of allogeneic transplantation in solid tumor, National Defense Medical College, Ommaya, Japan, 7/2002
The latest update in NST: hematological malignancy and solid tumor, Okayama University, Okayama, Japan, 7/2002
The latest update in NST: hematological malignancy and solid tumor, Nagasaki University, Nagasaki, Japan, 7/2002
The latest update of allogeneic transplantation in solid tumor, Hiroshima University, Hiroshima, Japan, 7/2002
The latest update of allogeneic transplantation in solid tumor, Kyushu University, Fukuoka, Japan, 7/2002
The latest update of allogeneic transplantation in solid tumor, Imamura Hospital, Kagoshima, Japan, 7/2002
What is a standard therapy in breast cancer? Experience of clinical trial development at M. D. Anderson Cancer Center, Tokyo, Japan, 7/26/2002
High Risk Breast Cancer Patients for Recurrence and their prevention, Tokyo, Japan, 7/27/2002
Future direction of non-myeloablative allogeneic transplantation in solid tumor, Kanazawa University, Kanazawa, Japan, 7/2003
Role of pharmacist in multidisciplinary care, Kobe Pharmacy Association, Kobe, Japan, 7/2003
Role of G-CSF in breast cancer management, Kirin Corp, Tokyo, Japan, 8/2003
Role of pharmacist in multidisciplinary care, Tokyo Metropolitan Pharmacy Association, Kobe, Japan, 8/2003
Mindset, Multidisciplinary Care, Tokyo Cancer Research Hospital, Tokyo, Japan, 6/2004
Advancement in NST, Tokyo, Japan, 6/26/2004
Advancement in NST, Kyoto Prefectural Medical College, Kyoto, Japan, 7/2004
Mindset, Multidisciplinary Care, Shizoka Cancer Center, Mishima, Japan, 7/2004
Development of E1A gene therapy, Osaka Adult Disease Center, Osaka, Japan, 11/2004
Development of E1A gene therapy, Tottori University, Yonago, Japan, 11/2004
Role of Hematopoietic Stem Cell Transplantation in Breast Cancer, Mofitt Cancer Center, Tampa, FL, 11/2004
Development of novel biomarker in breast cancer, Kumamoto University, Kumamoto, Japan, 7/2005
Multidisciplinary Care in Cancer, Juntendo University, 7/2005
Multidisciplinary Care in Cancer, Wakayama Oncology Symposium, Wakayama Medical College, Wakayama, Japan, 12/2005
Hig-Dose Chemotherapy in Breast Cancer, Is it Obsolete?, West German Study Group, Oral Presentation, West German Study Group, Duserdorff, Germany, 5/2006
Multidisciplinary Care in Cancer, Hyogo Medical Center for Adults, Hyogo, Japan, 6/2006
Development of Novel Prognostic Markers in Breast Cancer, Iwate Medical College, Iwate Medical College, Morioka, Japan, 7/2006
Multidisciplinary Cancer Treatment, Kanazawa Medical College, Kanazawa Medical College, Kanazawa, Japan, 9/2006
Is There Really a Role of Taxene?, 7th Annual Oncology Update: Advances and Controversies. M. D. Anderson Cancer Center, Oral Presentation, 7th Annual Oncology, Steamboat, CO, 1/2007
Role of Biomarker in Breast Cancer, International Conference of Medical Education in Oncology, Medical Education in Oncology, Izumo, Shimane, Japan, 1/2007
Translational Research in Breast Cancer, Keio University, Tokyo, Japan, 4/2007
Opportunities and Challenges in Advancing Breast Cancer Treatment, Bristol Myers 10th Anniversary of Paclitaxel, Bristol Myers, Tokyo, Japan, 9/2007
Role of minimal residual disease in breast cancer, Kirin Pharmaceutical Research Group for Discovery, Takasaki, Japan, 9/2007
Role of Medical Oncologist in US, International Conference of Medical Education in Oncology, International Conference of Medical Education in Oncology, Tohoku, Sendai, Miyagi, Japan, 2/2008
Development of Biomarker Based on Non-Novel Drugs, Tokai University, Tokai University, Yokohama, Japan, 7/2008
Multidisciplinary Care at M. D. Anderson Cancer Center, Mission and Vision, St. Luke Life Science Foundation, Japan, 7/2008
Patient Advocacy, Japan Pharmaceutical Manufacturers Association, JPMA, Tokyo, Japan, 7/2008
What is Multidisciplinary Cancer Care?, Tokyo University Hospital, Tokyo University Hospital, Tokyo, Japan, 7/2008
What is Multidisciplinary Cancer Care?, Hokuto Hospital, Hokuto Hospital, Obihiro, Japan, 7/2008
What is Multidisciplinary Cancer Care?, Kanagawa Cancer Center, Kanagawa Cancer Center, Yokohama, Japan, 7/2008
Present Status of Medical School in US, Tokyo Metropolitan Government, Tokyo, Japan, 10/30/2008
The issues in cancer care in Japan, Media Forum (Chugai-Roche), Tokyo, Japan, 10/31/2008
Success of Multidisciplinary Care in Oncology, Shikoku Cancer Center, Matsuyama, Japan, 11/18/2008
Career Development in Nursing, Kochi Univerisity, Kochi, Japan, 2/17/2009
Creating the best Team for Cancer Care, National Cancer Center Hospital (NCI Japan), Tokyo, Japan, 2/18/2009
How to receive the best medical care?, JPMA, Tokyo, Japan, 2/18/2009
Development of Biomarkers in Breast Cancer, Kyoto University, Kyoto, Japan, 3/21/2009
Development of Biomarkers in Breast Cancer. Difficulties and Excitement, University of Calgary, Graduate School of Biomedical Science, Calgary, Canada, 5/7/2009
Role of Allogeneic Transplantation in Solid Tumor, University of Texas, Houston, Houston, TX, 5/28/2009
Creating an Effective Oncology Team, Hokuto Hospital, Obihiro, Japan, 7/14/2009
Multidisciplinary Care in Oncology, Tokyo Medical University, Tokyo, Japan, 7/15/2009
Multidisciplinary Care in Oncology, Aomori Health University, Aomori, Japan, 7/17/2009
What do you do when you are diagnosed cancer?, Astrazeneca and Evidence, Inc., Astrazeneca and Evidence, Inc., Tokyo, Japan, 10/17/2009
Special Remark for Creating the Sarcoma Center at NCI Japan, National Cancer Center Hospital, Tokyo, Japan, 10/19/2009
The Importance of Government Support for an Academic/Public Clinical Trial Network to Complement Industry-Supported Trials, US Government, State Department, US Embassy, Tokyo, Tokyo, Japan, 10/20/2009
The Importance of Patient Advocacy Movement, US Government, State Department, US Embassy, Tokyo, Tokyo, Japan, 10/20/2009
Successful team building in multidisciplinary care, Okayama University, Surgery, Okayama, Japan, 11/9/2009
Successful team building in multidisciplinary care, Himeji Red Cross Hospital, Humeji, Japan, 11/10/2009
Multi-disciplinary Cancer Care, Democratic Party, Japan, Tokyo, Japan, 3/18/2010
Patient Empowerment Process: How to receive the best medical care !, Life Time Empowerment Program, Tokyo, Japan, 3/20/2010
Triple Negative Breast Cancer = TNBC, Hokuto Hospital, Obihiro, Japan, 6/12/2010
Successful team building for cancer care by mid-level practitioner!,Tokia University, Japan, 6/17/2010
Cancer Survivor Ship Talk, Cancer Net Japan, Tokyo, Japan, 6/26/2010
Role of Alternative Medicine, Cancer Net Japan, Tokyo, Japan, 6/27/2010
Success of Multidisciplinary Care in Oncology, Aomori University of Health and Welfare, Aomori, Japan, 6/30/2010
Molecular Changes and Targeted Therapy in Inflammatory Breast cancer, Case Western Comprehensive Cancer Center, Cleveland, OH, 7/30/2010
Successful team building for multi-disciplinary cancer care (TeamOncology), Saitama Medical College, Medical Oncology, Oomiya, Japan, 8/31/2010
Targeted Therapy in Breast Cancer, Kumamoto University, Kumamoto, Japan, 10/31/2011
Team Medicine: Shared Vision and Mentorship, University of Nagoya, Nagoya, Japan, 11/1/2011
Advances in inflammatory breast cancer: Why is IBC clinical, translational, and basic research important for breast cancer research?, University of Montreal, Montreal, Canada, 1/11/2012
Development of the Inflammatory Breast Cancer Program at MD Anderson Cancer Center: What have we learned, and where are we headed?, University of Utah, Huntsman Cancer Center, Salt Lake City, UT, 1/4/2013

Development of the Inflammatory Breast Cancer (IBC) Program at MD Anderson Cancer Center:, Celgene, Summit, NJ, 5/13/2013

11th Annual Meeting of the Japanese Society of Medical Oncology, Japanese Society of Medical Oncology, Tohoku University, Department of Clinical Oncology, Institute of Development Aging and Cancer, Tokyo, Japan, 8/1/2013

ABC of TeamOncology, Hyogo Cancer Center, Akashi, Japan, 10/28/2013

Development of the Inflammatory Breast Cancer (IBC) Program at MD Anderson, Hyogo Cancer Center, Akashi, Japan, 10/28/2013

Patient Support Care System at MD Anderson Cancer Center, National Cancer Center Hospital, Tokyo, Japan, 10/30/2013

Management of neutropenia induced by cancer treatment, 3rd JHOPE Workshop, Wakayama, Japan, 7/12/2014

My Oncology Dream Workshop, 12th Annual Meeting of JSMO, Patient Advocacy Activity, Fukuoka, Japan, 7/17/2014

Coordination between patients advocates and healthcare providers, 12th Annual Meeting of JSMO, Fukuoka, Japan, 7/19/2014

Development of the Inflammatory Breast Cancer (IBC) Program at MD Anderson Cancer Center: What have we learned? And Where are we headed?, UT Southwestern Cancer Center, Medicine, Dallas, TX, 8/4/2014

Targeted Therapy for Triple-Negative and Inflammatory Breast Cancer, Kansas University Cancer Center, Medicine, Kansas City, KS, 8/15/2014

Therapeutic Strategies Directed at Prevention and Management of Bone Metastasis in Women With Breast Cancer, CancerNet, LLC, Houston, TX, 4/4/2015

The Oncotype DX® Assay in the Contemporary Management of Invasive Early-stage Breast Cancer, Genomic Health, Inc., Japan, 7/21/2015


Actual Management of Febrile Neutropenia by Pegfilgrastim in the United States”, Tokyo Breast Cancer Conference, Tokyo, Japan, 7/31/2015

Metastatic Breast Cancer Patients: Long Term Support Continuum, University of South California Dornsife, Biological Sciences, Vermont, CA, 10/7/2015

Cutting Edge trial for TNBC at MD Anderson, Kyowa Hakko Kirin, San Antonio Breast Cancer Symposium Satellite Symposium, San Antonio, TX, 12/9/2015

Tissue Banking and Clinical/Translational Research, Eli Lilly, MBC Alliance Research Task Force, Irving, TX, 2/1/2016

Past, Present and Future of Breast Cancer Treatment, Wayne State University, Karmanos Cancer Institute, Hematology Oncology, Troy, MI, 3/19/2016

Needed leadership and share vision to promote multidisciplinary care, Fukushima Mingaku, JTOP, Fukushima, Japan, 4/16/2016

Immunotherapy Update: Interactive Session for Young Investigators, Keio University, Tokyo, Japan, 5/13/2016

ABC of Chemotherapy for patient with Early Stage Breast Cancer, Kyowa Hakko Kirin, Utsunomiya, Japan, 6/20/2016

Development of Novel Therapeutic Strategies for Inflammatory Breast Cancer, Houston Methodist Research Institute, Cell and Developmental Biology, Houston, TX, 6/27/2016

Development of Novel Therapeutic Strategies for Inflammatory Breast Cancer (IBC), Methodist Research Institution, Nanomedicine, Houston, TX, 6/27/2016

Therapeutic Strategies for Inflammatory Breast Cancer (IBC) and Triple Negative Breast Cancer (TNBC), Fox Chase Cancer Center, Philadelphia, PA, 8/18/2016

Issues Related to a Clinical Trial Development, Bayer, Tokyo, Japan, 1/11/2017

Rare Diseases and Rare Disease Fractions, J-HOPE, 5th Clinical Research Skill Advancement Workshop, Tokyo, 1/13/2017

Targeting EGFR in Inflammatory Breast Cancer, Duke University, Duke Consortium for Inflammatory Breast Cancer, Durham, NC, 2/28/2017

Patient Empowerment, Yokohama City University/City of Yokohama, Yokohama, Jordan, 1/22/2018

Patient Empowerment: how to receive the best cancer care, San Diego Nikkei Network, San Diego, CA, 2/4/2018

Global Partnership in Clinical Management of IBC, Duke University, Duke Consortium for Inflammatory Breast Cancer, Durham, NC, 2/28/2018

Pragmatic Approach for Conducting Translational Research in Oncology, The 6th Clinical Research Skill Advancement Workshop, Makuhari, Japan, 3/17/2018

Strategic Development of Targeted Therapy for Triple Negative and Inflammatory Breast Cancer: New Challenges for Neoadjuvant Chemotherapy, Kyowa Hakko Kirin Pharma Inc., Tokyo, Japan, 3/22/2018

Why should you study abroad?, Japan Cancer Society, Tokyo, Japan, 5/11/2018

How to receive the best cancer care and treatment, Eiraku Club, Tokyo, Japan, 5/14/2018

How to develop a successful medical career, US Naval Hospital, Yokosuka, Japan, 7/26/2018

Recent Advances in Inflammatory Breast Cancer Management, International Academy for Advanced Oncology, Tokyo, Japan, 7/27/2018

Career Development in Cancer Research, Chang Gung Memorial Hospital, Taipei, Taiwan, 9/28/2018

Recent Advances in Inflammatory Breast Cancer, Emory University, Atalanta, GA, 10/15/2018

Catalytic Leader, Nova Southeastern University, Phi Delta Chi Professional Pharmaceutical Fraternity Nova Southeastern University, Fort Lauderdale, FL, 10/16/2018

Oncology Genome Conference in Chicago, Chugai Roche, Chicago, IL, 6/1/2019

My Oncology Dream (MOD)

Dream Catcher (DC)を目指して, Japan Cancer Society, Tokyo, Japan, 7/7/2019

Leading from Wherever You Are, US Naval Hospital Yokosuka, Yokosuk, Japan, 7/8/2019

Role of nurses and pharmacist in the ambulatory treatment center, Japan Breast Cancer Society, Tokyo, Japan, 7/11/2019
State of the Art of Neoadjuvant/Adjuvant treatment for HER2+ EBC/ABC: goal, target population, and post-treatment decision, Japan Breast Cancer Society, Tokyo, Japan, 7/12/2019

Breast Cancer Researcher
What Works and Does Not Work?
Rule of 10, Japan Breast Cancer Society, Tokyo, Japan, 7/13/2019

Triple Negative Breast Cancer and Genomic Medicine, Japan Breast Cancer Society, Tokyo, 7/13/2019

Recent Advances in Inflammatory Breast Cancer Management, JFCR, Tokyo, Japan, 9/17/2019
Chemotherapy for Primary Breast Cancer and Management of Related Side Effects, Kyowa Kirin, Xiamen, China, 9/19/2019

Recent Advances in Inflammatory Breast Cancer Management, US-China Center of Medical Exchange Chinese Oncologist Conference, Houston, TX, 9/25/2019
Recent Advances in Inflammatory Breast Cancer Research & Management: Impact the World from Texas, The University of Texas System, Austin, TX, 10/2/2019
Leading from Wherever You Are, Kameda Medical Center, Kamogawa, Japan, 1/9/2020
Patient Empowerment, Pink Ring, Tokyo, Japan, 2/2/2020
Essential Skills Needed for Multidisciplinary Cancer Treatment, Tottori University, Yonago, Japan, 2/25/2020
Advances in Inflammatory Breast Cancer Management & Research, The University of Texas Houston Medical School, Houston, TX, 9/21/2020

Advances in Inflammatory Breast Cancer Management & Research, Susan E. Donelan Lecture, Dana Farber Cancer Institute, Susan F. Smith Center for Women’s Cancers at Dana-Farber, Boston, 9/30/2020
Future of the Novel Education Platform, Japan TeamOncology Program, Tokyo, Japan, 10/11/2020
IBC Treatment – the standard of care, IBC Learning Academy, Houston, TX, 10/23/2020
Fund Raising – Where does the majority of research funds come from?, IBC Learning Academy, Houston, TX, 10/24/2020
IBC Specialty Care – Who, What, When, How and Why? What makes a specialist clinic, IBC Learning Academy, Houston, TX, 10/24/2020
Pragmatic Approach for Conducting Translational Research in Oncology, J-HOPE, he 8th Clinical Research Skill Advancement Workshop, Tokyo, Japan, 10/30/2020
Advances in Inflammatory Breast Cancer Management & Research, Brenham Clinic, Brenham, TX, 11/4/2020
Delivering Your Presentation, COMPASS, Tokyo, Japan, 6/19/2021
Successful Scientists: Stories behind the CV: Unexpected Challenges, The University of Texas MD Anderson Cancer Center, Houston, TX, 6/28/2021
Leading and team science, 1st Taiwan TeamOncology Workshop, Taipei, Taiwan, 8/28/2021

Controversies in Genomic Testing in Early Breast Cancer, Kyowa Kirin Pharma, Inc, Tokyo, Japan, 9/30/2021

Disparities in Cancer Care and the Asian American Population, SWOG Group Meeting, SWOG, Chicago, 10/13/2021


Career Development, Oncologist, JFCR, Tokyo, Japan, 12/10/2021

Lectureships and Visiting Professorships

Promotion of Multidisciplinary Care, Wakayama Oncology Symposium, Wakayama Oncology Symposium, Wakayama, Japan, 7/2006

Multidisciplinary Translational Research, Wakayama Oncology Symposium, Wakayama Oncology Symposium, Wakayama, Japan, 7/2007

Progress of Oncologic Multidisciplinary Care, Kobe University Graduate School, Kobe, Japan, 8/2008

Role of Allogeneic Transplantation in Solid Tumors, CCTS, University of Texas Medical School, Center for Clinical & Translation Sciences, Houston, TX, 5/28/2009

Preclinical development in Refractory Breast Cancer, Keio University, Tokyo, Japan, 10/19/2009

Visiting Professor, Wakaya Medical College, Oncology, Wakayama, Japan, 4/1/2010

Cancer Medicine and its future, Medical Topics, Waseda University, Tokyo, Japan, 10/27/2011

Advances in inflammatory breast cancer: Why is research on IBC important to research on all breast cancer?, Division of Cancer Medicine Grand Round, MD Anderson Cancer Center, Division of Cancer Medicine, Houston, TX, 6/19/2012

The power of one =Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, MD Anderson Cancer Center Grand Round, MD Anderson Cancer Center, Houston, TX, 6/22/2012

Development of the Inflammatory Breast Cancer (IBC) Program at MD Anderson Cancer Center:, Indiana University, School of Medicine, Indianapolis, IN, 2/7/2013

State of Huntsman Cancer Institute, Seminar, Huntsman Cancer Institute, Division of Oncology, Salt Lake City, UT, 5/8/2013

Development of the Inflammatory Breast Cancer (IBC) Program: What have we learned? And Where are we headed?, University of Hawaii Cancer Center, Honolulu, HI, 7/13/2013

Writing and Publishing Scientific Articles (WAPSA) Workshop, The University of Texas MD Anderson Cancer Center, Department of Scientific Publications, Houston, TX, 4/23/2014

Writing and Publishing Scientific Articles (WAPSA) Workshop, The University of Texas MD Anderson Cancer Center, Department of Scientific Publications, Houston, TX, 9/9/2015

リーダーシップと専門性チームワークとコミュニケーションを考える, Clinical Research Promotion Study Group, Keio University, Tokyo, Japan, 8/5/2016

Multidisciplinary approach to breast cancer treatment and supportive care at MD Anderson Cancer Center, 2nd Annual Meeting of the Japanese Association of Supportive Care in Cancer, Japanese Association of Supportive Care in Cancer, Omiya Sonic city, Japan, 10/27/2017

Best Practice for Inflammatory Breast Cancer, Delaware Society for Clinical Oncology 2018 Lecture Series, Medical Society of Delaware, Philadelphia, PA, 9/6/2018
Other Presentations at State and Local Conferences

E1A as a tumor suppressor, Fifth annual radiation workshop at Round Top, Round Top, TX, 5/8/1997

Is there a role for high-dose chemotherapy with bone marrow rescue, Is there a role for high-dose chemotherapy with bone marrow rescue, M. D. Anderson Cancer Center, 2/14/2001

Advances in the Management of Breast Cancer, M. D. Anderson Cancer Center, M. D. Anderson Cancer Center, 6/2001


Development of biomarkers based on non-novel drugs, Ground Round, M. D. Anderson Cancer Center, Houston, TX, 3/2008

Yamauchi H, Iwata H, Nakamura S, Ueno NT. Epidemiology, characteristics, and outcomes of inflammatory breast cancer (IBC) in Japan, First International Inflammatory Breast Cancer Conference, The University of Texas M. D. Anderson Cancer Center, The University of Texas M. D. Anderson Cancer Center, Breast Medical Oncology, Houston, TX, 12/6/2008

Zhang D, LaFortune TA, Hortobagyi GN, Cristofanilli M, Lucci A, Singh B, Hung MC, Ueno NT. Reversal of mesenchymal to epithelial phenotype by EGFR tyrosine kinase inhibitor in inflammatory breast cancer, First International Inflammatory Breast Cancer Conference, The University of Texas M. D. Anderson Cancer Center, The University of Texas M. D. Anderson Cancer Center, Breast Medical Oncology, Houston, TX, 12/6/2008

Naoto Ueno. Role of Allogeneic Transplantation in Solid Tumors, The Center for Clinical and Translational Sciences, M. D. Anderson Cancer Center, Houston, TX, 5/28/2009

Effective Manuscript Writing, MD Anderson Cancer Center, The workshop Writing and Publishing Scientific Articles, Scientific Publication, Houston, TX, 10/20/2010

Ueno NT. Development of Novel Targeted Therapy in Inflammatory Breast Cancer, The University of Texas MD Anderson Cancer Center, Breast Cancer Research Program, Houston, TX, 4/9/2011

Ueno, NT. Advances in Inflammatory Breast Cancer, Physician Relations Grand Rounds, MD Anderson Cancer Center, Physicians Relations, Houston, TX, 2/22/2012

Apted J, Ueno NT. Being A Team Leader, GME Competency Lecture, The University of Texas MD Anderson Cancer Center, Trainee & Alumni Affairs, Houston, TX, 4/5/2012

Targeting ERK as a Therapeutic Strategy for Triple-Negative Breast Cancer, The University of Texas MD Anderson Cancer Center, Virology and Gene Therapy GSBS Program, Houston, TX, 8/15/2012

Ueno, NT. Collaborating Globally to Fight Cancer, 2012 Ethics and Compliance in Oncology Research (ECOR) Conference, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/5/2012

Novel Strategies for Inflammatory Breast Cancer, Medical Oncology and Hematology 2012: Clinical and Scientific Approaches that Enhance Patient Outcomes, MD Anderson Cancer Center, Houston, TX, 10/19/2012

Ueno N. Identification of novel targets by 2 vs 3-dimentional synthetic lethal screening in TNBC, RNAi Screening Workshop, BioScience Research Collaborative, TxsACT & John Dunn Gulf Coast Consortium for Chemical Genomics, Houston, TX, 11/13/2013


Ueno N. Targeted Therapy for Triple-Negative and Inflammatory Breast Cancers, Division of Cancer Medicine Grand Rounds, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/28/2014

Career Development for Junior Faculty, 2014 Clinical Trial Methods and Design Workshop for Junior Faculty, MD Anderson Cancer Center, Houston, TX, 3/7/2014

Ueno N. Gaps in the Understanding of IBC Metastasis, Insights on Cancer Metastasis from Research on IBC, Institutional Grand Rounds "Advances in Oncology," UT MD Anderson Cancer Center, Medical Education, Houston, TX, 10/31/2014

INSIGHTS ON IBC; CANCER METASTISIS FROM RESEARCH ON Gaps in the Understanding of IBC Metastasis, MD Anderson Institutional Grand Round, MD Anderson Cancer Center, Houston, TX, 10/31/2014

Ueno N. Advancements utilizing circulating tumor cell technology to predict outcomes in patients with breast cancer, Nektar Therapeutics, Nektar Product Theater Presentation at SABCS, San Antonio, TX, 12/10/2014

Ueno N. Team Creation when the Team is dysfunctional, Faculty Leadership Academy, MD Anderson Cancer Center, Houston, TX, 12/12/2014

Ueno NT. Does Redness over the breast indicate inflammatory breast cancer (IBC)? Why it is important to know the signs of IBC, Houston Dermatological Society, Harris County Medical Society, Houston, TX, 2/2/2015


Role of EGFR in Breast Cancer, Breast Cancer Research Program, MD Anderson Cancer Center, Houston, TX, 8/7/2015

Life After: Living with Cancer, Cancer Survivorship Program, The University of Texas MD Anderson Cancer Center, Academic Affairs, Houston, TX, 6/9/2016

IBC Clinical Trial, The University of Texas MD Anderson Cancer Center, Cancer Network, Houston, TX, 2/12/2019
Management of inflammatory breast cancer, Medical Oncology and Hematology 2019, The University of Texas MD Anderson Cancer Center, Houston, TX, 2/15/2019

Ueno NT. Morgan Welch IBC Research Program and Clinic Direction, Breast Cancer Research Program, MD Anderson Cancer Center, Houston, TX, 6/17/2019

Inflammatory Breast Cancer Program, The ABCs of Healthy Living in Challenging Time, MD Anderson Cancer Center, Houston, TX, 7/24/2020


Impacting the Outcome in Rare Cancers IBC (Inflammatory Breast Cancer) Connect, MD Anderson Cancer Network, Houston, TX, 12/3/2020

ddd, Shine Academy Innovation Conference, Austin, TX, 2/26/2021

Personalized Treatment Planning for Metastatic Breast Cancer, MD Anderson Cancer Center, Division of Radiation Oncology, Houston, TX, 11/12/2021

PROFESSIONAL MEMBERSHIPS/ACTIVITIES
Professional Society Activities, with Offices Held
National and International
Japan Comprehensive Cancer Network, Breast, Tokyo, Japan
  Board of Directors, 2005–present

Center for International Blood and Marrow Transplant Research (CIBMTR), Milwaukee, WI

Keio University School of Medicine Center for Clinical Cancer Research, Shinjuku, Japan
  Visiting Professor, 5/2009–present

South West Oncology Group (SWOG), San Francscop, CA
  Breast Working Group, 5/2013–present

SWOG Recruitment and Retention Committee (RRC), Chicago, IL
  Committee Member, 6/2017–present

American Association for Cancer Research, PA
American Society of Blood and Marrow Transplantation
American Society of Clinical Oncology
American Society of Gene Therapy
American Society of Hematology
International Bone Marrow Transplant Registry

Local/State
UT Graduate School of Biomedical Sciences - Virology and Gene Therapy, Houston, TX
  Member, 8/2000–12/2012

UT Graduate School of Biomedical Sciences - Cancer Biology, Houston, TX
  Member, 9/2000–present

UT Graduate School Biomedical Sciences Advisory Committee, Houston, TX
  Member, 10/2007–present

UT Graduate School of Biomedical Sciences, Houston, TX
  Reviewer, 3/2020

Harris County Medical Society, Houston, TX
UNIQUE ACTIVITIES

5. Ueno NT, Need for patient to speak up to change the medical system. RIS FAX, Japanese Press (Pharma Economy), 7/2008.
7. Book - ”How to defend yourself from Breast cancer by diet and lifestyle.” Author, Yuriko Oyabu; Published by Parade Publishing in Japan; Acknowledgement is found throughout the book to Dr. Ueno for providing data and discussing the book content. Published 2008
8. Third Breast Cancer Seminar in NY, BC Network, Yomitime, NY, USA, 10/08
9. Ueno, N, Protein forces ovarian cancer cells to eat themselves, Cancer Research UK news article, 11/19/2008
14. Ueno NT, TV Asahi, ”Suikan no michi (Road to Survival),” 08/22/2009
15. Dream Team Oncology Program Press Conference on 03/19/10
18. Invited to be a featured speaker for "TalkAboutHealth" which is a program with the social media where patients and caregivers get personalized, helpful, and accurate health answers from leading medical professionals and trained peer survivors. Featured Speaker in November 2011 and March 2012. http://talkabouthealth.com/static/aboutus
20. DDI Education System Facilitator: Certified professional leadership educator (10/2012)
21. Created a video entitled "Fortune Cookies in Love." The most viral video of 2013 related to oncology. This is to increase awareness that it takes a team to fight cancer. http://www.youtube.com/watch?v=0XGnzYMoX3g&list=PLTnoe1_OqtAYi04bMOGC26tsa9b_P- dEw&index=12
22. Featured in USA Today: inflammatory breast cancer on 10/16/2012. Further, professional twitter chat with USA Today Scientific Editor.
24. Ueno NT, Houston Chronicle September 26, 2014 - Many women not getting correct care for breast cancer;  

25. Life After: Living with Cancer: A panel discussant as a cancer survivor. MD Anderson Cancer Center.


27. December 30, 2015. NTV Bankisha Special: Featured in Japanese TV show about how the patient empowerment process impacted the cancer care and treatment at MD Anderson Cancer Center.

28. 一流患者と三流患者 (First Class Patient and Third Class Patient), a paperback from Asahi Publication, 04/13/16. 10,000 copies have been published

29. My presentation「Symposium 7: Challenging Treatment for Triple Negative Breast Cancer」「NEW TREATMENT DIRECTIONS FOR TRIPLE-NEGATIVE BREAST CANCER」, has been chosen as one of the most meaningful sessions, and the lectures presented at this session will be summarized and re-presented at the Highlight of GBCC 2016 Shandong on Nov 19, 2106.

30. Featured in Cancer Wise. When a doctor becomes a cancer patient.  


34. Completed GSBS Mentoring Works! session on 2/8/18.


36. CancerX cofounder activities highlighted by all major media in Japan.
MEMORANDUM

August 12, 2022

TO: Michael Bruno
    Provost

FROM: Lee Buenconsejo-Lum
    Co-chair, University of Hawaii Cancer Center Search Advisory Committee
    Associate Dean for Academic Affairs, JABSOM

SUBJECT: Recommendation for Tenure Upon Initial Appointment for Dr. Naoto Ueno for Director, University of Hawai‘i Cancer Center

As co-chair of the Search Advisory Committee (SAC) for the Director of the University of Hawai‘i Cancer Center (UHCC), I am recommending that Dr. Naoto Ueno, the recommended finalist candidate for the position of Director, UHCC, be granted tenure upon initial appointment. This action is requested pursuant to University Executive Policy E9.215, relating to tenure upon initial appointment for qualified personnel.

The UHCC SAC reviewed Dr. Ueno’s application materials including his letter of interest, curriculum vitae, biographical information, the results of his interviews, and reference checks. Based on the information obtained, Dr. Ueno is highly qualified for the position as an executive as well as academic professor on the Mānoa campus. It is critical to fill this executive position at the UH Mānoa with a highly qualified individual that includes a fallback tenured position that is commensurate to the candidate’s professional attainment.

Dr. Ueno is a tenured professor of medicine at The University of Texas MD Anderson Cancer Center since 1996 and has held the rank of professor since 2009. He has an MD degree from Wakayama Medical College, Japan in 1989 and has had a career of over 27 years in research and clinical positions, accumulating an impressive record of accomplishments including gathering support for and creating the MD Anderson Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, which has grown to include a national network of centers. He has done extensive work in understanding signaling pathways that contributes to hematological cancers and solid tumor cancers. His laboratory discoveries have led to investigator-initiated trials in therapeutics, and he has sustained extramural funding from numerous sources (NIH, DOD, private foundation funding, and the legislature). He has been in progressive leadership positions since 2002 at the MD Anderson Cancer Center, received awards for outstanding teaching, clinical faculty mentoring, and breast cancer research, among others stated in his curriculum vitae.

As summarized above and documented by his attached CV, Dr. Naoto Ueno has demonstrated a record of outstanding academic scholarship, leadership and administrative experience at the academic rank of tenured Professor, which is deemed comparable to the Professor rank at the University of Hawai‘i at Mānoa. I highly recommend that Dr. Ueno be provided, upon his initial
appointment, a fallback tenured Professor position at the John A. Burns School of Medicine in the Department of Medicine, which was also approved by the department.

Attachment: Curriculum Vitae of Dr. Naoto Ueno
August 11, 2022

MEMORANDUM

To: Michael Bruno
    Provost

From: Jerris Hedges
      Dean

Re: Fallback Position for Naoto Ueno, MD

Pursuit to our prior discussions, the department of medicine’s departmental personnel committee (with the inclusion of senior, full-professor, and tenured faculty members from the departments of surgery and family medicine to create a valid faculty personnel committee) took action on the review of Dr. Naoto Ueno for the purpose of a ranked faculty appointment with fall-back tenure assignment should he wish to leave the post of cancer center director. The committee and departmental chair recommend his rank appointment as a professor in the department of medicine at the John A. Burns School of Medicine and (should he no longer serve as director of the UH cancer center after initial hire into that position) that he be assigned a compensated, tenured faculty appointment as a professor in the department of medicine at the John A. Burns School of Medicine. (See attached documents)

As you noted in the Provost memo of August 4, 2022, UH Manoa will provide the medical school with the additional permanent position count and the salary for this fallback tenure position if Dr. Ueno returns to the faculty. I am forwarding this recommendation based on the above information. I look forward to seeing the synergy Dr. Ueno should bring to the UH cancer center and the medical school. Further, as per prior discussions with UH leadership, I look forward to extending a complementary offer for Dr. Ueno to hold a non-compensated position supporting cancer research within the medical school.

Attachment

cc: Lee Buenconsejo-Lum
    Nancy Foster
    Mariana Gerschenson
    Scott Kuwada
    Kathy Matsumoto
August 11, 2022

Jerris R. Hedges, MD, MS, MMM
Professor & Dean
Barry & Virginia Weinman - Endowed Chair
651 Ilalo Street, MEB 2nd Floor
Honolulu, HI 96814

RE: Fallback Position for Dr. Naoto Ueno

Dean Hedges:

As requested, August 10, 2022 the Department of Medicine convened a Department Personnel Committee (DPC) consisting of 5 tenured professors (one from Surgery and another from Family Medicine, as we did not have 5 tenured Professors available on short notice) to review the request for Dr. Ueno to secure a fallback position as a tenured professor in the Department of Medicine and approved the action (see attachment). It was obvious to the DPC that Dr. Ueno is highly qualified to be a tenured faculty member in the Department of Medicine.

It is my understanding that should Dr. Ueno require a tenured position in the Department of Medicine that the funding will be provided through the Provost’s office as outlined in our email discussion on Aug 4, 2022.

We look forward to the successful recruitment of a new UHCC Director.

Sincerely,

Scott K. Kuwada, MD, AGAF, FACP
Professor and Interim Chair
Chief, Division of Gastroenterology

SKK/hmv
August 10, 2022

Dear Dr. Kuwada:

I write as designated chair of the ad hoc Department Personnel Committee to evaluate the potential tenurability of Dr. Naoto Ueno. The committee, consisting of myself, Drs. Tallquist (in absentia), Boisvert, Palafox, and Murayama, met on August 10 over Zoom to discuss the "fallback" tenure of Dr. Ueno, who is being considered for Directorship of the Cancer Center. I am pleased to report that the committee voted unanimously that Dr. Ueno is well qualified for tenure in the Dept. of Medicine if he steps down from his position in the Cancer Center. Dr. Ueno is presently a tenured Professor of Medicine at The University of Texas MD Anderson Cancer Center where he runs a clinic and research program for aggressive breast cancer. His fulfillment of the requirements for tenure in our department at the level of full professor are briefly summarized below:

1. Teaching - Active teacher of the range of medical trainees, multiple teaching awards, including the very prestigious UT Regents Award.

2. Clinical practice - Designs and directs multiple clinical protocols and a clinic devoted to rare and aggressive breast cancer. He has presented many Grand Rounds at his and other institutions.

3. Research - Almost 400 publications including many recent last author efforts suggesting continued active involvement in the projects. Multiple active grants and was PI of a recently concluded R01.

4. Leadership - Particularly strong mentorship of individuals, has organized many national and international conferences, and served on multiple administrative committees, often as chair.

5. Community service - Standing member of the Drug Discovery and Molecular Pharmacology (DMP) Study Section of NCI. He has developed strong collaborative efforts with many Japanese institutions.

In summary, Dr. Ueno is very well qualified for tenure at the University of Hawaii in the Department of Medicine, easily fulfilling all of our criteria. Moreover, it was the unanimous sense of the committee that he would raise the stature of the Cancer Center, bring a robust cadre of collaborators and connections in clinical trials, and importantly, improve the quality of breast cancer treatment in our State.

Sincerely,

Ralph V. Shohet, MD
Professor of Medicine
Kosasa Family Endowed Director of Cardiovascular Research
University of Hawaii
August 1, 2022

Naoto T Ueno, M.D., Ph.D.

MEMORANDUM OF APPOINTMENT, 2022 - 2023 Fiscal Year

Dear Dr Ueno:

The University of Texas System Board of Regents has authorized your appointment to the following position at The University of Texas MD Anderson Cancer Center subject to the following terms:

<table>
<thead>
<tr>
<th>Academic Appointment</th>
<th>Professor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tenure Status</td>
<td>Term Tenure</td>
</tr>
<tr>
<td>Department</td>
<td>BMO Department</td>
</tr>
<tr>
<td>Division</td>
<td>Cancer Medicine Division</td>
</tr>
<tr>
<td>Professional Component</td>
<td>$407,280</td>
</tr>
<tr>
<td>Period of Appointment</td>
<td>From 9/1/2022 to 8/31/2023</td>
</tr>
<tr>
<td>Administrative Appointment*</td>
<td>Executive Director, Inflammatory Breast Cancer Program</td>
</tr>
<tr>
<td>Administrative Supplement</td>
<td>$25,000</td>
</tr>
<tr>
<td>Award</td>
<td>Nylene Eckles Distinguished Professorship in Breast Cancer Research</td>
</tr>
<tr>
<td>Total Annual Salary</td>
<td>$432,280</td>
</tr>
</tbody>
</table>

*Administrative appointments and related salary components and benefits, if any, are without term and subject to termination at the pleasure of the President. Upon termination of your administrative appointment, related salary components and benefits will also end and your salary will revert to your base salary that is based upon your academic rank and experience.

This appointment is subject to all applicable state and federal laws, the Rules and Regulations of the Board of Regents of The University of Texas System, and all of MD Anderson Cancer Center's guidelines, policies (including without limitation the policies that govern intellectual property and the protection of confidential information), procedures, rules and regulations, as amended. This appointment and the salary indicated are subject to final approval of the FY23 budget by The UT System Board of Regents.

This appointment constitutes the fifth year of a tenured appointment for a seven year term as approved by The UT System Board of Regents and is subject to the availability of resources and other contingencies. Renewal of tenure is subject to peer review and approval by the President no later than the sixth year of this term of tenure.

The total salary, including administrative components, if any, is subject to deductions required by state and federal law and, if permitted by law, other deductions you may authorize.

This appointment and your employment with MD Anderson is subject to and contingent upon the following express conditions:

- Contemporaneous with this appointment, you must enter into a new or renewed agreement with the Physicians Referral Service (PRS), if applicable. As indicated in the PRS Bylaws you may not render professional services outside of your employment with MD Anderson and you must assign and pay over to MD Anderson any professional fees that you earn from outside professional services.
- You may not, without disclosure to and the prior written approval of MD Anderson, conduct research for or on behalf of another entity, receive research funding or support from an outside source, or operate a lab or research facility outside of MD Anderson.
- You must comply with the Rules and Regulations of The UT System Board of Regents that require that all research funds be deposited in MD Anderson approved accounts.
- You must comply with institutional conflict of interest and conflict of commitment policies, and in particular you must disclose in writing and receive prior approval for all outside employment, financial relationships, and compensated activities.

You will receive employee benefits and/or additional supplementation as may be authorized by applicable laws and by the PRS Bylaws.

Your Initials: [Blank]

MOA for: 100361
Your acceptance of this appointment indicates your agreement to comply with the terms as specified above. Please sign and accept this appointment via DocuSign. If we do not receive your signed acceptance within 30 days from the date of this memorandum, we will consider the appointment to be declined.

Sincerely yours,

Peter WT Pisters, M.D.
President

I accept this appointment.  

Date: 8/1/2022

(Signature)